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Abstract 
The importance of apoptosis as a means of homeostasis and maintaining genomic integrity, as 
well as the ability of cancer cells to escape this failsafe mechanism, has long been the subject of 
intense investigation. To investigate the possibility that prolactin might enable breast cancer cells 
to survive apoptotic insults, we stimulated T47-D and MCF-7 cells with ceramide (C2) and 
assessed the ability of prolactin to improve cell survival. Morphological studies and cell survival 
assays demonstrated a significant survival effect in T47-D cells exposed to prolactin. Because 
prolactin activates the Jak2-STAT5 pathway, we then proceeded to create a model in which the 
role of this pathway in apoptosis could be investigated. An initial attempt to inhibit 
dexamethasone-induced apoptosis in a human leukaemic cell line (CEM-C7) by establishing a 
stable clone expressing the prolactin receptor (for activating the JAK2-STAT5 pathway) was 
unsuccessful. Next, we established stable clones of breast cancer cells overexpressing STAT5b. 
Despite increased STAT5 signalling after prolactin stimulation, no enhancement of survival was 
demonstrated, implying that STAT5b is not responsible for survival following ceramide 
exposure. Surprisingly, increased STAT5 activation, following prolactin stimulation, actually 
increased cell death. 
The second half of this project involved investigation and characterization of the newly identified 
Met protein, which we showed to induce apoptosis in breast cancer cells as well as in other cell 
lines. Met is structurally related to SAF-B - which attaches to DNA at scaffold / matrix 
attachment regions and is thought to be involved in DNA transcription or mRNA processing. Met 
was shown to be confined to the nucleus, and partially co-localized with SAF-B, but not with 
splicing factor speckles. Signalling assays show that Met downregulates transcriptional activity 
within cells. 
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1 INTRODUCTION 
1.1 The Development of Cancer 
Cancer is a disease that involves multiple changes in the genome. The initial discovery of 
mutations within the genome associated with cancerous phenotypes led to the 
identification of oncogenes, whose presence conferred a dominant gain of function, and 
tumour suppressor genes, associated with recessive loss of function. Study of these genes 
has rapidly advanced our understanding of the nature of cancer, how it progresses and 
how it develops'. 
Accumulating evidence indicates that tumourigenesis is a multistep process in humans 
and reflects the genetic alterations that drive the transformation of normal human cells 
into malignant derivatives. Most cancers are diagnosed in the human population with an 
age-dependent incidence2. Analysis of various organ sites reveals lesions that may 
represent the intermediate steps through which cells have to evolve in the transformation 
from normality to a malignant phenotype3. This is further supported by increasing 
evidence showing that tumour cells invariably have mutated genomes, not just at one site, 
but multiple sites, from simple point mutations to massive disruptions such as 
chromosomal translocations4. The evidence in cultured cells is just as compelling. Rodent 
cells require at least two introduced genetic changes before they develop tumourigenic 
capability, and their human counterparts are even more resistant to transformation5. 
Transgenic tumour models also support the conclusion that tumourigenesis in mice 
requires multiple rate-limiting steps6. When considered together, these observations 
imply that for cancers to develop, each cell has to go through a series of genetic 
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alterations, which confer on the cells a growth or survival advantage until the final 
transformation of normal cells into cancer cells 3°7. 
In normal cells, regulatory pathways monitor the extra- and intra- cellular conditions in 
order to maintain cell proliferation and homeostasis. Thus in order for a cell to transform 
into a cancer cell, there are several obstacles to overcome before it can achieve 
immortality and ungoverned proliferation. There appear to be at least six essential 
alterations in cell physiology before this occurs: self-sufficiency in growth signals, 
insensitivity to growth-inhibitory signals, evasion of programmed cell death (apoptosis), 
limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasise. 
1__ ;2 Anontosis: Definition and Mechanisms 
The term `apoptosis' was first used in 1972 by Kerr et a19 to refer to the distinctive 
morphology of physiological cell death, and is interchangeably used with `programmed 
cell death'. Thus apoptosis results from the controlled activation of a death mechanism 
already encoded within the genome of every cell. This programme is usually directed and 
executed by the cell itself - an autodestruct mechanism that is aided by neighbouring 
cells only in the final stages when it is phagocytosed. 
Apoptosis was first described by its morphological characteristics, which comprise cell 
shrinkage, membrane blebbing, and nuclear fragmentation after chromatin condensation' 
11. This is followed by fragmentation into apoptotic bodies and eventual phagocytosis by 
surrounding cells12 
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The importance of apoptosis in the development of on organism has become increasingly 
apparent in recent years. This process is important early in embryonic development for 
the moulding of body parts - such as digit separation and cavity formation - and also the 
elimination of vestigial structuresi3. It is also important in tissue homoestasis, balancing 
cell division and attrition, and maintaining tissue mass. Damaged, diseased or genetically 
unstable cells are removed by apoptosis14. The controlled elimination of autoreactive 
lymphocytes is also mediated by apoptosis, the lack or disruption of which results in 
autoimmune diseases" 
Apoptosis is a programme, initiated and executed by cellular components under stringent 
control, requiring the coordinated activation of enzymes and the availability of adenosine 
triphosphate (ATP). In contrast, the other form of cell death - necrosis - does not require 
energy and is a result of the loss of the cell's ability to maintain ionic homeostasis. 
Apoptosis only involves one cell - the cell that is executing the programme - and does 
not lead to inflammation, destruction, or scarring and fibrosis of adjacent tissues. 
The apoptotic mechanism can be divided into two broad groups - sensors and effectors. 
The sensors monitor the extracellular and intracellular environment for conditions that 
determine whether a cell should live or die. Signals from these sensors regulate the latter 
group of components, which are responsible for effecting cell death if it is required. 
Extracellular death signals include Fas ligand (FasL), which signals via its binding to the 
Fas receptor16, and tumour necrosis factor(TNF)-a, which binds to the TNFR-1 
receptor 17,18 . Intracellular signals that can initiate apoptosis include DNA damage, 
4 
signalling imbalance provoked by oncogene action, survival factor insufficiency, and 
hypoxia12. Most cells also depend partly on cell-matrix and cell-cell adherence-based 
survival signals, the loss of which can elicit apoptosis (sometimes known as anoikis)19. 
Both soluble and immobilized survival signals probably reflect the needs of the tissue to 
maintain their cells in appropriate architectural configurations. 
Many of the apoptotic signals converge eventually on the mitochondria, which respond 
by releasing cytochrome c when stimulated by pro-apoptotic stimuli. This portion of the 
apoptotic pathway is influenced in part by the Bcl-2 family of proteins which have both 
pro-apoptotic (Bax, Bad, Bid, Bim) and anti-apoptotic (Bcl-2, Bcl-xL, Bcl-W) members 
20 whose actions determine the release of cytochrome c'21 
The final effectors of apoptosis comprise a group of intracellular proteases called 
caspases2. Two `initiator' caspases, -8 and -9, activated by death receptors such as 
Fas23'24 or cytochrome c25, i6 respectively, trigger the activation of a dozen or more 
effector caspases which are responsible for executing the apoptotic program27. 
1.2.1 Pathways for Apo tosis 
1.2.1.1 Caspases - the executors of apoptosis 
Caspases are cysteine proteases that specifically cleave after aspartic acid residues in the 
P1 position of substrates23, and are present as inactive proenzymes in the cytosol. 
Caspases are homologous in structure and usually synthesised as inactive zymogens with 
four distinct domains12. Activation of caspases requires proteolytic cleavage, usually by 
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other caspases, between domains with the removal of a prodomain and a linker region, 
and rearrangement of large and small subunits into an active tetrameric complex12. An 
additional mechanism of caspase activation involves the recruitment of adaptor proteins 
that allow procaspases to come into close proximity with each other and enables caspases 
to activate themselves in vivo29-32 
Caspases can be classified as `initiators' or `effectors', where initiator caspases are 
responsible for activating effector caspases, that are the ultimate effectors of apoptosis29. 
`Initiator' caspases (namely caspase 8 and 9) have long prodomains with structural motifs 
(eg death effector domain, DED, or caspase recruitment domain, CARD) that allow 
enzymes to associate with their activators 33,34 It is this binding of DEDs in the 
prodomains of caspases to DEDs on adaptor proteins, such as Fas-associated death 
domain (FADD), that results in activation of the caspase23,24. `Initiator' caspases are also 
distinguished by the fact that they are able to activate themselves as well as downstream 
caspases to generate active enzymes12. In contrast, `effector' caspases, namely caspase-3, 
-6, -7, and -14, all have short prodomains. 
Thus in the caspase cascade activation sequence, apoptotic signals arising extracellularly 
(e. g. tumour necrosis factor (TNF)-a) or intracellularly (e. g. p53 activation following 
deoxyribonucleic acid (DNA) damage), result in the activation of either caspase-8, 
caspase-9, or both. These in turn proceed to activate the effector caspases - principally 
caspase-3 - which are responsible for many of the morphological changes associated with 
the apoptotic process3s, 36 
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Knockout mice deficient in various caspases have been created and have clarified the 
roles each caspase plays in apoptosis. Functional caspase-3 is required for some typical 
hallmarks of apoptosis and is essential for the formation of apoptotic bodies, chromatin 
condensation and DNA fragmentation 37 39. Cells lacking caspase-8 do not apoptose in 
response to tumour necrosis factor (TNF) signaling, but are still susceptible to serum 
deprivation, chemotherapeutic drugs, y-irradiation and dexamethasone-induced 
killing40'41 Caspase-9 is essential for apoptosis induced by intracellular activators, 
especially those that cause DNA damage42. Moreover, caspase-9 deficient cells do not 
show activation of caspase-3, implying caspase-3 is downstream of caspase-9, thus they 
are resistant to dexamethasone and irradiation but retain sensitivity to TNF-a and CD-95 
induced cell death42.43. This sensitivity can be explained by the presence of caspase-8, the 
initiator caspase involved in death receptor signaling that can activate caspase-342 in 
caspase-9 deficient cells43. From all the evidence, it appears that different death- 
signalling pathways converge on downstream effector caspases, of which caspase-3 is 
regarded as a key executioner of apoptosis as activated by extracellular or intracellular 
stimuli44 
Activated caspases have two targets: regulatory proteins of apoptosis, whose breakdown 
enhances apoptotic activity in the cell, and structural and housekeeping proteins, the 
degradation of which results in cellular disintegration. Regulatory proteins targeted by 
caspases include p21-activated kinase (PAK), focal adhesion kinase (FAK), inositol-3- 
phosphate (PI-3) kinase, protein kinase B (PKB/Akt), anti-apoptotic members of the Bcl- 
2 family and members of the 1AP family. Structural components that are degraded by 
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caspases include nuclear lamins, actin, various regulatory proteins (e. g. fodrin, gelsolin, 
keratin), and proteins involved in DNA repair (e. g. poly-(-adenosine diphosphate-ribose) 
polymerase (PARP))45'46 (Fig. 1.1) 
In the mitochondrial pathway, most caspases are activated after the release of cytochrome 
c, but there is evidence to show that disrupting the action of caspases only delays the 
onset of apoptosis47. However, in other circumstances, loss of caspases results in a 
pathological increase in cell number39'42.43 Very little is known about mutations in 
caspases in cancers. 
1.2.1.2 The Death Receptor Pathway 
The death receptor pathway is triggered by `death receptors' (DR) such as Fas/CD95, 
tumour necrosis factor receptor (TNFR)-1, DR3, and TNF-related apoptosis-inducing 
ligand receptors (TRAIL-R) 1 (also called DR4) and 2 (also known as DR5)'7 49 (Fig 1.1). 
The receptors are characterized by the possession of a conserved extracellular cysteine 
rich domain, and the presence of a `death' domain within the cytoplasmic tail. 
These receptors initiate apoptosis in a similar fashion. This involves the binding of 
ligand, the formation of a trimeric or multimeric death-inducing signalling complex 
(DISC), and the recruitment of adaptor molecules. Each of the adaptor molecules binds 
procaspase-8, thus bringing the zymogens into close proximity with each other, initiating 
autoactivation and the release of activated caspase-8, which activates the caspase 
cascade. 
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Figure 1.1Role of caspases in apoptosis (based on Wallach et al 1997" and Ashkenazi et al 
1998°8). 
Initiator caspases -8 & -9 are activated by the death receptor pathway and the mitochondria/ 
pathway respectively. Both are capable of activating caspase-3, the main effector caspase for 
apoptosis. Caspase-3, apart from activating other caspases in the caspase cascade, also has 
specific targets. It cleaves inhibitor of caspase activated deoxyribonuclease (ICAD), and releases 
the inhibition on caspase activated deoxyribonuclease (CAD), allowing DNA degradation to 
begin. Caspase-3 also cleaves proteins involved in transcription (eIF-4GI) and DNA repair (DNA 
protein kinase), thus disrupting protein synthesis and DNA maintenance. These activities, as well 
as caspase-9 activation, can be inhibited by XIAP (red dots), a member of the inhibitors of 
apoptosis protein family. 
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All adaptor molecules are equipped with a death domain, allowing interaction with the 
death domain on the cytoplasmic tail of the death receptor. In addition, the adaptor 
molecules also possess a `death effector domain', by which these molecules can interact 
with procaspases or other adaptor proteins49,50 
As an example, TNF-a (Fig. 1.2) induces trimerization of its receptor (TNF-R1), resulting 
in recruitment of the signal transduction (adaptor) molecule TNF receptor-associated 
death domain (TRADD) through `death domains'. Recruitment of Fas associated death 
domain (FADD), another adaptor protein, by TRADD, in turn allows the recruitment of 
procaspase-8 to the signalling complex, and results in apoptosis through the activation of 
caspase-8, which initiates a protease cascade that cleaves cellular targets (including 
caspase-3)48. Thus, disruption of FADD will hinder caspase-8 activation, disrupting 
receptor-mediated cell death40. Surprisingly, this pathway is seldom altered in tumours, 
indeed it is often enhanced51. TRADD also recruits receptor-interacting protein (RIP) and 
TNF receptor-associated factor (TRAF-2), which result in activation of nuclear factor xB 
(NF-KB), and can suppress TNF-a-induced apoptosis52. This pathway itself can be 
blocked by TRAF-interacting proteins (TRIPs) which bind TRAF and block NF-KB 
activation 53 
Although TNF-R signalling was described in detail here, there are other members in this 
group, such as Fas, and TNF-related apoptosis inducing ligand (TRAIL) that signal in a 
similar fashion, involving the recruitment of death domains and culminating in the 
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Figure 1.2The TNF Receptor Family (based on Baker et al 199850, Wallach et al 199717 and 
Pimental-Muinos et a1199954). 
This family includes TNF-RI, CD95, Fas and TRAIL-RI/R2 (green). Activation by ligand (black 
circles) results information of a trimeric/multimeric complex. Adaptor molecules (red, orange, 
pink) are recruited in various stages, and this comprises the death inducing signalling complex 
(DISC), which is able thus to recruit procaspases (blue) and activate them. Regulators of this 
pathway include decoy receptors (DcR]/2) which are able to hind ligand, but lack a death 
domain and are unable to recruit adaptor molecules required for signal transduction. Another 
group of inhibitors are the FADD like ICE inhibitory protein (FLIP) family, which bind the DED 
domain of FADD and prevent recruitment of caspase-8. The TNF-RI also recruits TNF-R 
associated factors (TRAFs -6 members), which links the death receptor pathway to the NF-kB 
pathway, with ultimate inhibition of cytochrome c release. The action of TRAF. s can be inhibited 
by Traf interacting protein (TRIP) to block NF-kB activation. 
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1.2.1.3 The Mitochondria! Apoptotic Pathway 
Apoptosis can also be triggered from within the cell in response to various stressful 
events, such as withdrawal of growth factors or DNA damage following radiation, 
hypoxia, heat and drugs55. (Fig. 1.3) 
When this pathway is activated, mitochondria release cytochrome c and activate effector 
caspase-9. Unlike the Fas/CD95 pathway, this is often the target of oncogenic 
mutations51. Mitochondrial release of cytochrome c is partly modified by members of the 
Bcl-2 family, probably as a result of changes in permeability of the mitochondrial 
membrane. These changes could occur via a permeability transition pore (PTP), a 
proposed channel formed in response to necrotic or apoptotic signals. Several theories are 
still under intense investigation regarding the mechanism by which cytochrome c, along 
with other proteins such as apoptosis-inducing factor (AIF), second mitochondria-derived 
activator of caspase (Smac)56/ direct IAP-binding protein with low pI (DIABLO)57 (an 
inhibitor of the inhibitor of apoptosis protein family) and certain caspases, are released 
into the cytosol following activation of the mitochondria. 
The PTP appears to be a contact point between the outer and the inner mitochondrial 
membrane. From current evidence, the pore in the outer membrane appears to be under 
the control of voltage-dependent anion channel (VDAC) and possibly Bax (a member of 
the Bcl-2 family of proteins), while the inner membrane is under the influence of the 
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Figure 1.3The mitochondrial Apoptotic pathway, and the role of the Bcl-2 family in the 
induction or apoptosis (based on Gupta 2003, Cai et a11998w and Kroemer 19996). 
(Red lines: protective mechanisms, blue arrows: apoptotic pathways) Bcl-2 and Bcl-xL both 
prevent cytochrome c release from mitochondrion. When Bad dimerizes with either of them, Bax 
is released and initiates cytochrome c release. Truncated Bid (tBid)(formed by caspase-8 
processing of Bid) also activates Bax. Bcl-2 and Bcl-xL can prevent the formation of the 
apoptosome complex that comprises Apaf-1, cytochrome c and procaspase-9, which inhibits the 
downstream caspase cascade. Bad activity is regulated by phosphorylation by Akt/PKB, which 
initiates the sequestration of Bad by the 14-3-3 protein, thus inactivating it. Bax and Bak 
transcription are up-regulated in response to p53 activation. 
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Activated caspase-8 cleaves Bid, another member of the Bcl-2 family, which translocates 
to the nucleus and, in association with Bax, induces a conformational change and 
enhances opening of the PTP63. It is the opening of the PTP that is thought to be 
responsible for the release of cytochrome c into the cytoplasm64, where it binds to the 
Apoptotic protease activating factor (Apaf)-1/caspase-9 complex65. This complex 
formation results in the activation of caspase-9, which by activating caspases-3, -6 and -7, 
goes on to initiate the rest of the caspase cascade, resulting finally in cell death66 
Enforced expression of the pro-apoptotic members - Bax or Bak - results in increased 
mitochondrial membrane potential and release of cytochrome c, which can be blocked by 
overexpression of Bcl-267. 
Apart from the release of cytochrome c from the inter-membrane space of the 
mitochondria, apoptosis inducing factor (AIF) is also released. AIF, which also resides in 
the inter-membrane space of the mitochondria68 is a S7kDa protein. It was initially 
thought to be a protease, but has since been found to be homologous to NADPH- 
oxidoreductase69 and is thought to be responsible for the various nuclear changes that are 
characteristic of apoptosis, namely chromatin condensation, protein proteolysis and DNA 
fragmentation68. 
Another protein, Smac/DIABLO is released from the mitochondria following apoptotic 
stimuli. Smac/DIABLO is known to bind IAP proteins, and prevents their inhibition of 
caspase activities56 
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Ultimately, the final event of both pathways (i. e. TNF/TNFR-1 and activation of 
mitchondria) is activation of the caspase cascade that is responsible for digesting cellular 
contents. Cytosolic and nuclear proteins involved in DNA replication and repair, RNA 
splicing, cell division and cytoskeletal structure are digested, and their loss finally results 
in the morphological changes associated with apoptosis12. 
1.2.2 Regulators of Ap tosis 
Apoptosis being a gene-directed programme, it is not surprising that this pathway is 
safeguarded by many regulators and checks before it is allowed to proceed. Thus, there 
are many levels at which this programme may be aborted/prevented. A brief summary of 
the various proteins and pathways whose function it is to ensure that apoptosis occurs 
only when it is required, and not before, is outlined below. 
1.2.2.1 The Bcl-2 family ofproteins 
The first member of this family to be identified, Bcl-2, was discovered at the 
interchromosomal breakpoint of the t(14: 18), now known to be the distinguishing feature 
of follicular B cell lymphoma70'71. Oncogenes typically enhanced cell proliferation, 
however, in contrast, Bcl-2 exerted its effect by enhancing cell survival and defined a 
new group of oncogenes20,72,73 
The first pro-apoptotic member of the family to be identified was Bax - Bcl-2 associated 
protein X74. To date 17 members of the family have been identified and they can be 
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divided into 2 functional groups: those which promote apoptosis, such as Bax, Bad, Bid 
and those which suppress it, like Bcl-2 and Bcl-XOO. 75 
Mechanism ofAction 
Anti-apoptotic proteins, such as Bcl-2 and Bcl-xL reside on the outer mitochondrial 
membrane, where they are thought to prevent the release of cytochrome c (possibly by 
interacting with the voltage-dependent anion channel (VDAC))76. There is some evidence 
that Bcl-xL, and possibly Bcl-2, can bind apoptotic protease activating factor (Apaf) - 1, 
preventing the association of procaspase-9 with Apaf-l and cytochrome c, and hence, 
inhibits activation of caspase-97. 
The pro-apoptotic members, Bax, Bad and Bak, on reception of apoptotic signals, 
translocate to the mitochondria, where they initiate the release of cytochrome c, AIF and 
Smac/DIABLO78'79. In addition, Bad dimerizes with Bcl-xL, relieving its inhibitory effect 
on cytochrome c release80'81. Bad is itself regulated by Aktprotein kinase B (PKB), 
which phosphorylates Bad, allowing the protein 14-3-3 to bind and inactivate it82. 
Another member of the Bcl-2 family, Bid, is activated, by truncation to tBid, by caspase- 
883. tBid translocates to the mitochondrion where it stimulates Bax and Bad, and initiates 
cytochrome c release 84-86 (Fig 1.2). 
1.2.2.2 The inhibitor of apoptosis protein (IAP) family 
This family of proteins was first discovered in baculoviruses where they are responsible 
for suppressing the host apoptotic response to viral infection. Members of the IAP family 
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are characterised by a domain of -70 aminoacids named the baculoviral IAP repeat 
(BIR). Members can possess up to three tandem repeats of this sequence which appears 
to code for a zinc-binding fold87. The proteins are conserved between species, and are 
also found in humans, with all members possessing a BIR domain and the ability to 
suppress apoptosis, though the latter has still to be proven for many of them. 
There are six human IAPs - including c-IAP1, c-IAP2 and XIAP. The mechanism of 
action of these proteins is still under investigation, but they are known to be expressed in 
a wide variety of tissues, apart from XIAP, which has a restricted distribution88. 
Overexpression of XIAP, c-IAP1, c-IAP2 and other IAPs protects against apoptosis 
induced by various factors, including TNF, FasL, staurosporine, etoposide and growth 
factor withdrawal 88-91 . The three IAP members mentioned have been shown to 
bind and 
inhibit the activities of caspases 3,7 and 9, but not caspases 1,6,8 or 1092"94. Thus, these 
proteins are able to block both the death receptor pathway as well as the mitochondrial 
apoptotic pathway. Consistent with reports that IAPs bind to caspases is the observation 
that they do not affect the release of cytochrome c from mitochondria95'96, thus raising the 
question of whether IAP suppression of apoptosis is complete, or only delays the 
inevitable87. 
1.2.2.3 Serine/Threonine protein kinases and apoptosis 
Apoptosis can be regulated not only intrinsically, but also by extrinsic factors, such as 
growth factors, hormones, and cellular factors. In this regard, serine/threonine kinases 
have been implicated in the regulation of apoptosis. Kinases involved include the 
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mitogen-activated protein kinase (MAPK) family, cyclic AMP dependent protein kinase 
(PKA), protein kinase B (PKB/Akt) and protein kinase C (PKC)97. 
Mitogen-Activated protein kinases (MAPKs) 
The kinases in this family that are involved in apoptosis are the p42/44 extracellular 
signal-related kinases (ERK) 1 and 298, p38 MAPK99 and c-Jun N-terminal kinase 
(JNK)100 speccally. The latter two enzymes appear to be involved in inducing 
apoptosis, while the former appears to enhance survival. 
On growth factor withdrawal, both JNK and p38 MAPK are activated10', resulting in 
upregulation of Fas ligand production and release102, and subsequent activation of 
caspase-31°3 Other triggers of JNK activation are hypoxia, TRAIL receptor stimulation, 
nitric oxide and cellular stress104-106 
Concurrent with the activation of JNK/p38, inhibition of ERK signalling is also noted1°'. 
This is probably due, in part, to caspase-3 which has been shown to cleave Raf-1 (an 
upstream activator of ERK)107. In addition, ERK activation has also been proven to 
suppress apoptosis induced by hypoxia1°8, growth factor withdrawal109 and 
chemotherapeutic agents"O The actual mechanism for ERK inhibition of apoptosis is as 
yet undefined. However, possible candidate substrates include Bad", and caspase-9112 
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Protein Kinase A (PKA) 
The PKA enzyme is a complex entity, consisting of two catalytic subunits bound to 
regulatory subunits. There are three isoforms for the catalytic subunit, and four for the 
regulatory subunits. Regulatory subunits can be bound to PKA as either homo- or hetero- 
dimers113. Depending on the regulatory subunit in use (RI or RII), PKA is identified as 
type I or II respectively. PKA type I appears to be anti-apoptotic, and is thought to have a 
role in phosphorylating Bad' 14, whereas the role of type II PKA is still unclear. 
Protein kinase B (PKB) /Akt 
The importance of PKB/Akt in the suppression of apoptosis is no longer in dispute, and a 
large body of literature is now devoted to identifying and mapping out the signalling 
pathways involving this protein kinase, its regulation, and the role it plays in 
tumourigenesis'15. PKB/Akt is thought to be the major pathway by which trophic factors 
are able to inhibit apoptosis, via activation of the phosphoinositide-3 kinase (P13K), 
which is the upstream activator of PKB. The targets of this cascade are Bad, caspase-9, 
transcription factors of the Forkhead family and inhibitor of IKB (inhibitor of nuclear 
factor kappa-B) kinase (IKK). 
Phosphorylation of Bad allows it to bind 14-3-3 proteins and release Bcl-XL. 14-3-3- 
bound Bad is thus sequestered from the cytoplasm, unable to inhibit anti-apoptotic 
proteins further"-8211'. Another action of activated PKB is to phosphorylate caspase-965, 
thereby reducing its protease activity12. 
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The third substrate of PKB is IKK-a, which it phosphorylates and activates' 16 IKK-a 
inactivates IiB, and brings about the nuclear translocation and activation of nuclear 
factor-KB (NF-KB), thus upregulating the transcription of various survival factors117. The 
final substrate of PKB/Akt is the Forkhead transcription factor FKHRLI, which has been 
shown to induce the transcription of FasL and TNF-a'°2,118 119, and the proapoptotic Bcl-2 
family member, Bax12o, izi 
1.2.2.4 The tumour suppressor gene- p53 
p53, the first tumour suppressor gene to be linked to apoptosis, is found mutated in many 
cancer types and is often associated with an advanced disease stage and poor patient 
prognosis' 22. It is now known that p53 is a checkpoint protein involved in cell cycle arrest 
that is responsible for ensuring retention of genomic integrity following DNA damagesl 
Studies in p53 knockout mice show that endogenous p53 is involved in apoptosis: it is 
required for radiation induced apoptosis in the thymus but not for apoptosis induced by 
glucocorticoids or other stimulil23. '24This implies that p53 is involved in apoptosis 
resulting from DNA damage and can be stimulation- and tissue-specific. Other stimuli 
can also induce p53 to promote apoptosis, and mutations of both upstream and 
downstream components of the pathway can be found in human tumours122. 
The p53 protein has several functions: it can promote apoptosis, induce cell cycle arrest 
and senescence. Thus loss of p53 function could result in increased viability, 
chromosomal instability and increased cell lifespan. However, there is evidence to show 
that it is the apoptotic function of p53 that is crucial to tumour suppression. Disruption of 
20 
several p53 effectors (e. g. bax, apaf-1, casp-9) can promote oncogenic transformation and 
tumour development in mouse model systems' 25-127. Some tumour-derived p53 mutants 
remain capable of inducing cell cycle arrest but have lost their ability to induce apoptosis 
128,129 
Please see Fig. 1.4 for overview of Apoptosis and its regulation. 
1.3 The Disruption of Apoptosis in Cancer 
The ability of a tumour cell population to expand reflects not only the rate of 
proliferation, but can also depend on the rate of cell attrition, which can be changed as a 
result of decreased apoptosis or necrosis. Apoptosis appears to be a major source of cell 
death 130, and there is increasing evidence that resistance to programmed cell death is 
characteristic of most, if not all, cancers4s M, l31.132 That apoptosis may serve as a barrier 
to carcinogenesis was first suggested in 1972, when Kerr, Wyllie and Currie described 
massive apoptosis in cells populating rapidly growing, hormone-dependent tumours 
following withdrawal of the hormone9. 
The discovery that apoptosis was a gene-directed program had a significant impact on the 
understanding of tissue development and homeostasis, for it meant that cell number was 
regulated by factors that controlled proliferation and differentiation, as well as survival 
factors48,51133 More importantly, this genetic basis implied that cell death, like any other 
metabolic or developmental program, could be affected by mutation with resultant 
susceptibility or resistance to the process. 
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It is clear that the apoptotic mechanism exists in all cell types throughout the human 
body, requiring only activation to be initiated 134. Upon activation, apoptosis proceeds 
through distinct stages, ending in the disruption of cellular membranes, dissolution of 
cyto- and nucleo-skeletal structures, extrusion of the cytosol, degradation of 
chromosomes and breakup of the nucleus, all this occurring within a 30-120 minute 
period. All that remains is a shriveled cell body that is engulfed by neighbouring cells and 
disappears within 24 hours". 
Several signal transduction pathways promote cell survival when stimulated by growth 
and/or survival factors and may be important in controlling cell number. One such 
pathway is the PI-3 kinase pathway, which can be activated by Ras and downregulated by 
the PTEN tumour suppressor13s Many studies using either transgenic or knockout mice 
13 have shown that disruption of apoptosis is important in tumour development 
Identification of apoptotic triggers is important as it provides insight into the forces of 
tumour development and progression. In skin, excessive exposure to ultraviolet radiation 
induces apoptosis - which serves to remove heavily damaged cells. When p53 function is 
lost, these damaged cells survive, paving the way towards future tumour development142. 
Other apoptotic triggers are also important. As tumours increase in size, they outgrow 
their blood supply, encountering hypoxia, which can activate p53 and trigger 
apoptosis'43 A p53 defect allows the cells to survive this hypoxic stress and enables cell 
proliferation within the tumour14a With repeated divisions, telomeres within the cell 
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Figure 1.4 Summary of apoptotic (blue) and survival (red) pathways (based on Datta et at 
1999115, Mak & Yeh 2002139, Reed 1999140 and Reed 1999141). 
Apoptosis is induced in response to death receptor signalling, cytotoxic stress, such as serum 
deprivation, hypoxia and growth factor withdrawal, or DNA damage resulting from 
UV/radiation, heat, and drugs. All pathways activate either caspase 8 or caspase 9, and these in 
turn activate caspase 3, which is responsible for the morphological changes seen with apoptosis. 
At various stages of the apoptotic cascade, survival signals are able to intervene and inhibit 
apoptosis, and these factors include members of the Bcl-2 protein family, Akt/PKB and the IAP 
family. In addition, the death receptor pathway can be inhibited at the level of the death domain 
by FLIP or SODD. 
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telomere malfunction requires p53 to trigger apoptosis, in cells where there are p53 
mutations, they are able to survive this response despite being genomically unstable145 
Disruption of apoptosis may also be important in tumour metastasis, for which tumour 
cells require the ability to survive in the bloodstream and to invade a foreign tissue. 
Survival of epithelial cells in the bloodstream is normally prevented by their inability to 
survive in suspension, or the lack of appropriate tissue survival factors 
1. Thus, 
mutations that allow tumour cells to survive and attach to and invade different organs 
would facilitate the metastatic process. 
1.4 Anontosis in Breast Cancer Cells 
Cancer of the breast is the most common cancer affecting women in the United Kingdom 
(18%)147. Studies of cancerous breast epithelium shows that the rate of apoptosis is 
increased in ductal carcinoma in situ and invasive cancer148.149, however, compared to 
normal breast epithelium, this is still reduced relative to the rate ofproliferation'so 
As an indicator of prognosis, increased rates of apoptosis, contrary to expectation, are 
associated with worse prognosis and survival 149,151.152 Similarly, in cancers of higher 
grade, apoptosis is increased, but there is also a concomitant increase in the proliferative 
rate. 149 
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1.4.1 Mutations affecting Apoptosis in Breast Cancer Cells 
1.4.1.1 The Bcl-2 Oncogene 
Oncogenes are genes whose products stimulate cell cycle progression. In normal cells, 
the activation of oncogenes triggers a failsafe mechanism against malignant 
transformation by directly inducing apoptosis or `sensitizing' the cell to apoptotic stimuli. 
However, when this mechanism is overcome, cell cycle progression can proceed 
unchecked. 
Mutation of Bcl-2 has been observed in at least 80% of breast tumours153 and, 
surprisingly, was associated with better prognosis in Bcl-2 positive patients'53 In 
addition, there was a positive association between Bcl-2 status and hormone receptor 
positivity and low histologic gradel54 . 
Bcl-2 appears to modulate cell division, and its loss is associated with increased tumour 
grade and proliferation, associated with high apoptotic and necrotic rates within 
tumours' 55. The presence of Bcl-2 does confer a survival advantage against apoptosis. 
MCF-7 breast cancer cells, positive for epidermal receptor 2 (HER-2), are more resistant 
to apoptosis and exhibit an upregulation of Bcl-2 and Bcl-xL expressionl56. Moreover, 
the ligand heregulin, which activates HER-3 and HER-4 receptors and downregulates 
Bcl-2 expression, can induce apoptosis in certain breast cancer cell lines157. Thus, aside 
from the influence of Bcl-2 on cell cycle progression, its increased expression in breast 
cancer cells can suppress apoptosis induced by a number of factors, and is associated 
lsa with the increased expression of proteins involved in metastatic spread 
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1.4.1.2 The c-Myc oncogene 
In normal cells, ectopic c-myc expression drives proliferation and prevents cell cycle 
arrest upon serum withdrawal, yet there is no accumulation of cell number as there is a 
corresponding loss of cells due to apoptosis'59. Survival factors, such as IGF-1, can 
suppress c-myc induced cell death without affecting c-myc-induced proliferation160. 
Likewise, c-Myc cooperates with Bcl-2 to transform cells161,162 because Bcl-2 allows c- 
myc-induced proliferation to proceed without apoptosis. 
1.4.1.3 The p53 tumour suppressor gene 
Loss of p53 function in vivo results in acceleration of the rate of tumourigenesis induced 
by mitogenic oncogenes, which is associated with decreased apoptosis in situ 
t63"16s G 
Myc induces apoptosis in a p53-dependent manner'66"167 and cells overexpressing c-Myc 
are more sensitive to various apoptotic stimuli such as serum-deprivation, hypoxia, Fas 
and TNF-a132. Another target of oncogene-induced sensitization is the mitochondrion, 
where c-Myc enhances cytochrome c release from mitochondria and cytochrome c is 
itself sufficient to sensitize cells to diverse agents '68'169. Oncogenes can facilitate 
cytochrome c release independent of p53169, though p53 is capable of inducing Bax and 
proteins that can affect mitochondrial functionl'o, l'1 Thus, p53 may be responsible for 
the sensitization to, as well as the active induction of, cell death in oncogene-expressing 
cells and mutations in the p53 gene would facilitate oncogenesis by allowing cells to 
evade oncogene-induced apoptosis. 
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The role of p53 in breast tumourigenesis is well documented. Mutations involving p53 
are fairly common172, with one study estimating a mutation rate of 20-40%173. Indeed, in 
BRCA1-associated tumours, 90% are associated either with mutations in p53, or exhibit 
increased expression of p53 protein174. In vitro studies involving the T47-D cultured 
human breast carcinoma cell line have shown that expression of wild-type p53 protein 
was able to inhibit proliferation 175 (T47-D cells possess a mutation in the p53 gene 17). In 
addition, Patel et al. showed that there was a strong correlation between overexpresion of 
p53 and breast tumour aggressiveness in patients with node-negative disease' 
1.4.1.4 The PTEN tumour suppressor gene 
The PTEN (phosphatase and tensin homolog deleted on chromosome 10) gene encodes a 
55kDa enzyme that possesses phosphatase activity178,179 Mutation or loss of PTEN has 
been implicated in a large number of cancers, including breast cancer18°. Despite this 
finding, PTEN does not appear to have a dominant role in the majority of breast cancers. 
Germline mutations are rare in breast cancer (6% of cancers)181, while loss of 
heterozygosity at the PTEN locus is the most frequent lesion observed182 In breast cancer 
cells, overexpression of PTEN can induce apoptosis, and cell cycle arrest183. Clinically, 
decreased expression of PTEN has been associated with a more advanced stage of breast 
cancer179. The PTEN enzyme has been shown to negatively control the P13-kinase 
survival pathway by dephosphorylating phosphatidylinositol-3,4,5 triphosphatetg'"tss, 
thus preventing activation of PKB/Aktlls 
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1.4.1.5 Death receptors in breast cancer 
The TNF-receptor family in the form of Fas (or CD95) is widely expressed in normal 
breast epithelia. FasL was found to be markedly higher in breast malignancies compared 
to normal epithelium and benign breast lesions'86 . 
Moreover, there was a correlation 
between FasL and lymph node status, while Fas expression correlated with smaller 
tumour size and negative node status, which was consistent with another study that 
showed patients with Fas-positive tumours had longer disease-free survival when 
compared to Fas-negative patients'g'. In contrast, Fas expression was very low in several 
different breast tumour cell lines' 86 
1_5 Methods for the Detection of Apoptosis 
As investigation into the field of apoptosis increased over the last ten years, the number 
of methods of detecting apoptosis has increased in parallel. Most methods employ 
techniques that exploit characteristics that are unique to the dying cell. 
Evidence acquired over the last decade shows that the apoptotic mechanism is highly 
conserved, which has made it possible to devise methods for detecting the products at 
various stages in order to differentiate apoptotic cells. Methods for detecting apoptotic 
cells can be divided into the following categories: surface morphology and composition, 
nuclear events and DNA cleavage, cell dissolution, cytoplasmic biochemical activation 
events, and mitochondrial function and integrity'88. 
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1.5.1.1 Surface Morphological and Biochemical Changes 
The classical features of apoptosis, best observed under electron microscopy, can be 
detected with light microscopy with the help of dyes e. g. haematoxylin, or propidium 
iodide26°la9, l9o The first signs of apoptotic cell death are the condensation of nuclear 
material, with the accumulation of densely staining chromatin at the periphery of the 
nucleus. This is accompanied by cell shrinkage. Cell surface blebbing then occurs and the 
cell detaches itself from its neighbors. The nuclear outline becomes much folded before 
the nucleus disintegrates, dispersing the nuclear fragments throughout the cytoplasm. 
Eventually the cell fragments, resulting in the formation of several discrete membrane- 
bound apoptotic bodies. These bodies are then phagocytosed by surrounding cells. 
Apoptotic bodies are thus a common hallmark of apoptosis and can be found either 
extracellularly or inside other cells following phagocytosis. Apoptotic bodies can be 
diverse in appearance, but tend to be round or oval, and contain varying amounts of 
condensed chromatin. Their size varies considerably9"1°, 191 
Externalization of phosphatidylserine (PS) and phosphatidylethanolamine is another 
hallmark change to the cell surface during apoptosis192"194. Annexin V, which binds to 
these molecules, is a good marker for this process and can be detected using either flow 
cytometry or fluorescent microscopy 195" These phospholipids are normally found on 
the inner layer of the plasma membrane bilayer as well as other membranes. The reason 
why PS appears on the outer membrane is not clear but it has been shown to occur quite 
early, just after segmentation of nuclei. It has also been found that not all cells exhibit this 
1 phenomenon97, l9s 199 , and that caspase inhibition can prevent its occurrence. 
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When interpreting Annexin-labeling results, care has to be exercised because towards the 
terminal stages of apoptosis, or during necrosis when the plasma membrane is leaky, 
Annexin can diffuse inside the cell and interact with intracellular PS. 
Permeability of the plasma membrane is another difference between necrotic and 
apoptotic cells which can be exploited by the use of large molecular weight DNA binding 
dyes, e. g. propidium iodide (PI), which are unable to enter intact cells without 
permeabilization, and thus are unable to label apoptotic cells until the final lytic stage. 
Conversely, smaller dyes that can attach to DNA can label both apoptotic and normal 
cells. By the use of flow cytometry, apoptotic cells can be distinguished from necrotic 
cells as those that show internal labeling with a small dye (e. g. DAPI, Hoechst 33342) 
without taking up PI198,200 
1.5.1.2 Nuclear changes and DNA changes 
It was observed at an early stage that nonmitotic cells entering apoptosis exhibited 
characteristic changes in nuclear shape and organization. This change is probably the 
most accurate indicator of apoptosis, though it does not have to be present for apoptosis 
to occur. Cells that have been enucleated may still be able to initiate and execute the 
apoptotic program, which indicates that the effector mechanism for apoptosis lies in the 
cytoplasm201. Despite this, nuclear changes provide an early and relatively unequivocal 
landmark of apoptosis in nucleated cells, which occurs just after surface blebbing 
begins2°2. 
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Another characteristic of apoptosis is the loss of DNA integrity where DNA 
fragmentation occurs with cleavage of DNA between nucleosomes. DNA fragmentation 
has been exploited by the addition of enzymes that are capable of adding labeled 
nucleotides to the 3'-OH ends of single-stranded DNA203'204. The labeled nucleotides can 
then be detected by immunological methods. Such assays were originally called TUNEL 
(terminal deoxynucleotidyl transferase mediated UTP nick end labeling) but may also be 
called ISEL (in situ end-labeling technique). 
When nuclei from apoptotic cells are extracted and analyzed by gel electrophoresis, a 
distinctive internucleosomal `ladder' of DNA fragments is usually apparent. This remains 
one of the most widely used methods for the detection of apoptosis, but requires 
extraction of DNA from a large number of cells. Moreover, apoptosis in these cells must 
be fairly synchronous for analysis, and this may not always be possible. Another problem 
with this and other DNA based methods involving electrophoresis is that spatial 
information as well as quantification of apoptosis is lost. 
1.5.1.3 Other Biochemical Changes 
Recent discoveries regarding the many steps in the apoptotic program include caspase 
activation and the cleavage of specific caspase substrates. By incorporating these specific 
substrates into cells and detecting the cleaved product, new assays have been developed. 
Other biochemical changes that occur in apoptosis which may be used as a marker 
include transglutamine activation, the expression of certain surface and intracellular 
antigens, changes in mitochondrial activity, and cytochrome c release. 
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1.6 Aims of Proiect 
1) Previous studies have provided some evidence for a protective role of prolactin in 
breast cancer cells, so one aim of this project was to investigate in greater detail the role 
of prolactin, and in particular its ability to activate the Jak-STAT pathway, as a survival 
factor for breast cancer cells. 
2) Initial studies with Met (a SAF-B related protein) suggested that its expression had 
profound changes on gene expression in cultured breast cancer cells. A second aim of this 
project was therefore to test the hypothesis that this protein might induce apoptosis in 
breast cancer cells. 
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2 Materials and Methods 
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Recombinant human prolactin was kindly provided by V. Goffin of INSERM, Paris. The 
freeze-dried powder was dissolved in 1.5M Tris (pH 8.0) and the concentration 
determined by the Micro Protein Determination kit (Sigma). A stock solution of 
500gg/ml was made, and stored in aliquots at -80°C. As concentration of a protein does 
not necessarily reflect the biological potency of the hormone, bioactivity was confirmed 
using the Nb2 Prolactin Bioassay (see Section 2.3). Unless stated otherwise, this was 
used in all assays requiring prolactin. 
All cell lines, unless stated otherwise, were obtained from the European Collection of 
Cell Cultures (ECACC, Porton Down). The HeLa cell line, a human cervical carcinoma 
cell line, was a kind gift from Dr. Craig McArdle (URCN, Bristol), and the SF cell line, a 
primary human fibroblast cell line, was kindly given by Dr. Andrew Morgan (University 
of Bristol). 
2_1 Micro Protein Determination 
The Sigma Micro Protein Determination kit (p. 225) was based on the Biuret and Lowry 
methods for determining protein concentration, with modifications to improve the 
sensitivity and stability of the reagents. A sample of the protein solution was mixed with 
the Biuret reagent and later with the Folin and Ciocalteu's phenol reagent. The colour 
formed was read at 570nm and protein concentration determined from a calibration curve. 
The Protein Standard solution provided was diluted 1: 100 using 0.85% (w/v) NaCl 
solution. This gave a protein concentration of 100mg/dL, and from this protein solutions 
of 0,25,50 and 75 mg/dL were obtained by diluting with the appropriate amount of 
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0.85% NaCI solution. 40µ1 of each protein solution, as well as the test solution, was 
pipetted into 0.5m1 Eppendorf tubes. 440µ1 of Biuret agent was added to each tube, 
mixed well and incubated at room temperature for 10 minutes. 20µl of Folin and 
Ciocalteu's phenol reagent was added to each tube, mixed well and incubated at room 
temperature for 30 minutes. 200µ1 of each solution was then transferred to a microtitre 
plate and absorption at 750nm determined using a microplate reader (Dynex Revelation). 
2_2 Cell Culture 
All adherent cell lines were maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 2mM L-glutamine, 10% fetal calf serum, incubated in a 
humidified 5% CO2 atmosphere at 37°C. The CEM-C7 cell line, and its sub-clones, as 
well as the Nb2 lymphoma cell line, were maintained in RPMI 1640 medium 
supplemented with 2mM L-glutamine and 10% fetal calf serum. Experiments were 
performed on cells in serum free medium (SFM): Ham's nutrient DMEM/F12 1: 1 mix 
without phenol red supplemented with sodium bicarbonate (1.2 mg/ml), 0.1% (w/v) 
bovine serum albumin (BSA) and apo-transferrin (10 pg/ml). 
2_3 Nb2 Prolactin Bioassay 
The bioactivity of prolactin was assayed using Nb2 rat lymphoma cells. 5x104 cells were 
plated in lml in each well of a 24 well plate in serum free medium and incubated for 24 
hours. Following this, varying concentrations of prolactin (final concentration ranging 
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from IOng/ml to IOµg/ml) were added to the wells and the cells incubated for a further 4- 
5 days. Cells were then counted using a Coulter Counter (p. 221). 
2.4 Cell Counting using the Coulter Counter 
On the day of counting, the medium was aspirated, and the cells gently washed with PBS. 
l00µ1 of trypsin was added to each well and cells were incubated at 37°C for 5 minutes 
before 9O00 of serum-containing medium was added to the wells. After resuspension, 
the cells were separated gently using a 21 G needle, and 0.2m1 of the cell suspension was 
added to 19.8m1 of PBS for counting in the Coulter counter. Cell density in 0.5m1 PBS 
was then assessed by the Coulter Counter. Each suspension was counted in triplicate and 
the average count taken in order to calculate cell concentration of the original suspension 
solution (by multiplying cell count obtained by 40). 
2.5 Induction of Anontosis 
Apoptosis in breast cancer cells was induced using the ceramide C2 analogue. Cells were 
seeded onto six well plates (3x105 per well) in complete medium, incubated for 48-72 
hours, and the medium changed to SFM for 24 hours prior to treatment. Cells were dosed 
with ceramide with or without prolactin and incubated for 24 hours before being collected 
for analysis of apoptosis. 
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2.5.1 Assessment of Apoptosis by Light Microscopy 
Cells (2.5x104 per well) were plated into 8-well Labtek Chamber slides in 500µ1 of 
medium and incubated overnight. After washing with Dulbecco's PBS (phosphate 
buffered saline) and starving for 24 hours in serum free medium (SFM), cells were 
exposed to ceramide in the presence or absence of prolactin for 24 hours before they were 
fixed and stained. For fixation, cells were first washed twice in PBS and air-dried. This 
was followed by dipping in acetone for 5 minutes. Slides were then air-dried and placed 
in the freezer for storage until they were stained. Staining was carried out by washing the 
slide with water, then dipping each slide 4-5 times in haemotoxylin, and rinsing with 
water before dipping 4-5 times in eosin. Slides were then dipped in 70% ethanol followed 
by 100% ethanol to fix the stains and then air-dried. Coverslips were fixed onto the slides 
with glue and allowed to dry before viewing under the light microscope. In order to 
assess the apoptotic index, a total of at least 1000 cells were counted, in at least three 
separate fields per well. Cells that exhibited nuclear shrinkage, chromatin condensation 
and also fragmented nuclei were all counted as apoptotic. 
2.5.2 Assessment of Apoptosis using FACS Flow Analysis 
After induction of apoptosis, cells (seeded in 6-well plates as previously stated) were 
collected as follows: the supernatant was aspirated and centrifuged (2000 rpm, 5 minutes) 
to collect floating cells. Attached cells were then washed with 0.5m1 PBS, which was 
collected and centrifuged to collect unattached cells. 200µl of trypsin-EDTA was then 
added to each well and incubated at 37°C for 5 minutes. A further 800µ1 of complete 
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medium was then added to the well, and cells transferred to a 1.5m1 Eppendorf tube. 
These cells were centrifuged at 2000 rpm for 5 minutes and the supernatant discarded. 
2.5.2.1 Analysis of cell cycle profile by flow cytometry 
This experiment relies on the ability of propidium iodide to bind DNA. The amount of 
propidium iodide bound is proportional to the amount of DNA, thus providing a measure 
of the quantity of DNA present in each cell. 
For analysis of cell cycle profiles, the pelleted cells were fixed in 70% ethanol for at least 
24 hours prior to analysis by flow cytometry. The fixed cells were re-pelleted (2000 rpm, 
5 min) and washed with PBS. The washed cells were then resuspended in Krishnan's 
reagent (p. 220) and incubated at 4°C in the dark for at least 30 min prior to analysis on a 
FACSCalibur flow cytometer (Becton Dickinson) (See Fig. 2.1). 
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Figure 2.1 Diagrams showing a 
typical dot plot (top) and histogram 
(bottom) obtained during FACS 
analysis of the cell cycle profile. 
Cells in G1 contain the normal 
quantity of DNA, while cells in G2, 
representing cells that have completed 
DNA replication, possess double this 
amount. Cells in S phase represent 
cells that are in the midst of 
replicating their DNA, in the synthesis 
phase, while cells in preGi contain 
less than the normal quantity of DNA 




2.5.2.2 Analysis ofapoptotic index using Annexin- V 
Another method of assessing whether cells have initiated the apoptotic pathway is to 
measure the expression of phosphotidylserine on the outer leaflet of the cell membrane. 
This phospholipid is found naturally on the inner leaflets of all cell membranes, but only 
appears on the outer leaflet when apoptosis is induced. This change occurs quite early in 
the apoptotic process. Annexin-V is a protein with a high affinity for phosphatidylserine 
in the presence of calcium, and when coupled to FITC, enables the detection of 
phophatidylserine on the cell surface by flow cytometry or fluorescent microscopy. 
Annexin-V can diffuse through leaky membranes in necrotic cells or cells undergoing 
late apoptosis, so propidium iodide is added simultaneously to identify the latter group of 
cells. Cells exhibiting only the annexin-FITC complex on their surface are assumed to be 
in early apoptosis (Figure 2.2). 
For detection of apoptotic cells using Annexin-V, cells (3x105 per well) were seeded in 6- 
well plates and transferred to SFM 24 hours prior to treatment. Cells were then incubated 
with various concentrations of ceramide, with or without prolactin at 37°C for 24 hours 
before collection for analysis. Floating cells were collected and added to cells obtained by 
trypsinization as previously described. The combined cells were pelleted (2000rpm, 5 
min), washed with binding buffer (ApoAlert® Annexin-V-FITC kit, p. 225), and stained 
with Annexin-V and propidium iodide as described in the manufacturer's manual. The 
labeled cells were taken up in the buffer provided to a final volume of 0.5ml. 1x104 cells 
were counted and the proportion of apoptotic, necrotic and live cells determined 
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Figure 2.2 Figure to demonstrating the various populations that appear following Annexin- 
V and propidium iodide staining. 
RI is the population of live cells that excluded both stains. R2 is the cell population that exhibits 
dual staining, and is consistent with cells in necrosis or late apoptosis. Region R3 represents cells 
with Annexin-V staining alone, consistent with early apoptosis. 
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All FACS data were analysed using the CeliQuest software package (p. 221). 
2.6 Assessment of Cell Survival 
Cell survival was assessed by three independent methods - cell number, metabolic 
activity of cells (XTT metabolism), and colony formation. 
2.6.1 Cell Survival Assays - Cell Counting 
Cells (5x104 per well) were seeded in a 24-well plate and incubated overnight. After 
being washed twice with Dulbecco's PBS the cells were starved in SFM for 24 hours. 
Cells were pretreated with or without prolactin for 30 minutes prior to exposure to 
ceramide in SFM and incubated for the time specified, after which fetal calf serum was 
added to a final concentration of 10% (v/v). Following this, cells were incubated for 
another 4-5 days before being trypsinised and counted using a Coulter counter (Sect 2.4). 
2.6.2 Cell Survival Assay - Cell Proliferation Kit II (XTT) 
The Cell Proliferation Kit II (XTT) (p. 225) was used to ascertain the viability of cells 
after treatment with ceramide. XTT (sodium 3'-[l-(phenylaminocarbonyl)-3,4- 
tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic acid hydrate) is a yellow 
tetrazolium salt. It is cleaved into a soluble orange formazan dye by mitochondrial 
dehydrogenases, found only in metabolically active cells, and the optical density is then 
spectrophotometrically quantified by spectrophometrical absorbance using a scanning 
multiwell spectrophotometer. The proportion of cleaved XTT is directly proportional to 
the number of viable cells left in the population. 
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The components of the kit are a XTT labeling reagent and an electron coupling reagent. 
Both components are stored in working aliquots at -20°C. To assay one 96-well plate, 
5m1 of XTT labeling reagent is mixed with 0.1 ml electron coupling reagent and aliquots 
(50µ1) added to each well. 
Cells (1x105 per well) were seeded into a 96-well plate, in 10011 of medium, and 
incubated overnight. They were washed once with Dulbecco's PBS before being starved 
in l00µ1 of SFM for 24 hours. Following serum starvation, cells were pre-incubated with 
prolactin before the addition of ceramide. Cells were exposed to ceramide for 24-48hrs 
prior to the addition of fetal calf serum to the final concentration of 10% (v/v). (The time 
of incubation for each of the cell lines was determined by morphological analysis; MCF-7 
cells required 24 hours before developing the morphological characteristics of apoptosis, 
whilst T47-D cells required a further 24 hours before taking on the apoptotic 
characteristics. ) Cells were then incubated for a further 4-5 days before 50µl of XTT 
labeling mixture was added to each well. Cells were incubated with the labeling mixture 
for 18hrs before the spectrophometrical absorbance was measured using a microplate 
reader at 450nm. 
2.6.3 Cell Survival Cloning Assay 
T47-D cells (1x106 per well) were seeded into T25 flasks and incubated overnight. The 
cells were then washed twice with SFM and incubated in SFM for a further 24 hours. 
After incubation in the presence or absence of prolactin for 30mins, cells were exposed to 
varying concentrations of ceramide for 24 hours in the continued presence of prolactin 
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before they were trypsinized and set in agarose gels. Agarose gels were set up by first 
laying down a base layer of a 0.6% gel consisting of 1 volume of 1.2% solution of a low 
gelling agarose and 1 volume of 2x DMEM (p. 221), total volume 2.5 ml per 60mm petri 
dish. This was allowed to gel at room temperature before being incubated at 37°C in 5% 
CO2 while the top gel layer was prepared. The top layer consisted of a 0.35% gel 
prepared by mixing 4.5 volumes of 2xDMEM, 4.5 volumes of 0.7% agarose solution and 
1 volume of cells. For each plate, approximately 250 cells were plated. Plates were 
incubated for 10-14 days before being assessed for colony formation. Prior to staining, 
Neutral red solution (p. 221) was diluted 1 in 25 with PBS and 500µ1 of the final solution 
was added to the gels and incubated for at least 30 minutes prior to counting colonies 
consisting of four or more cells under a dissecting microscope. 
2_7 Growth Assays 
Cells (5x104 per well) were seeded in 24-well plates in complete medium and left to 
attach overnight. They were then washed twice with Dulbecco's PBS and transferred to 
SFM with or without prolactin before being incubated at 37°C in 5% CO2 for 4-5 days. 
Cells were then harvested and counted on a Coulter counter as previously described (Sect 
2.4). 
2.8 Measurement of Cell Proliferation using Thvmidine Incorporation 
Cells were seeded into 96-well plates in 100µl DMEM supplemented with 1% serum 
(that had been charcoal stripped, p. 216) and incubated overnight. The cells were then 
exposed to prolactin for 18 hours before the addition of [3H] thymidine (5OnCi/ml) for 6 
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hours. Medium was then discarded and 100µl of trypsin-EDTA added to each well. The 
cells were incubated at 37°C for 30 minutes before being frozen at 20°C for at least 3 
hours before harvesting. Cells were thawed before they were harvested and the 
radioactivity captured onto filter mats using a cell harvester (TOMTEC Harvester). Next, 
the filter mat was impregnated with wax enriched with a radio-scintallant and allowed to 
dry. Radioactivity was then determined in a Wallac MicroBeta Trilux 1450 liquid 
scintillation and luminescence counter to assess [3H]thymidine incorporation (software - 
1450 MicroBeta Windows Workstation, Version 3.2). 
2.9 Preparation of olasmid DNA 
2.9.1 Miniprep plasmid DNA preparation 
Plasmid minipreps were prepared using a QIAprep Miniprep Kit (p. 225). The bacteria 
were lysed under alkaline conditions, neutralized, and the lysate cleared of cell debris and 
genomic DNA using a filter. The plasmid DNA was then adsorbed onto the QlAprep 
membrane under high salt conditions, and released from the filter using a low salt buffer. 
E. coli bacteria transformed with the desired plasmid DNA were inoculated into 
antibiotic-treated LB and incubated for 18-20 hours at 37°C with gentle shaking 
(300rpm). Bacteria were then pelleted by centrifugation at 3000rpm for 15min at 4°C. 
The pellet was resuspended in 250µ1 of buffer P1, which contains RNase A, before 
addition of 250µ1 buffer P2 (lysis buffer). The solution was then mixed and incubated at 
room temperature for 5 min before being neutralized with 3501LI of buffer P3. The 
resulting cloudy solution was centrifuged for 10 min at 13,000rpm. 
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The supernatant was transferred to a QlAprep spin column and centrifuged at 13,000 for 
lmin. The membrane was washed using buffers PB and PE, which were added to the 
column and centrifuged at 13,000 for 1 min. The DNA was then eluted into a clean 
Eppendorf tube using 50µl of EB buffer amd stored at -20°C until required. 
2.9.2 Midi- or Maxi-prep plasmid DNA preparation 
Plasmid DNA was extracted from E. coil cultures using the HiSpeed Plasmid Purification 
Kit (p. 225). Briefly, transformed E. coli containing the desired plasmid DNA were 
inoculated into 150-250 ml of antibiotic-treated LB medium and incubated at 37°C for 
12-16 hours with gentle shaking (37°C, 300rpm). The bacterial cultures were collected by 
centrifugation (3000rpm, 4°C, 30 minutes) and the supernatant removed completely. The 
bacterial pellet was suspended in buffer P1, and an equal volume of buffer P2 added. The 
solutions were gently mixed by inversion before being incubated at room temperature for 
5 minutes. Chilled buffer P3 was then added to the mixture, mixed by inversion, and then 
poured into the prepared QIAfilter Cartridge and incubated at room temperature for 10 
minutes. 
A HiSpeed tip was prepared by the addition of buffer QBT. The bacterial lysate was 
passed through the QlAfilter cartridge by inserting the plunger and filtered onto the 
equilibrated HiSpeed tip. After the lysate had passed through the HiSpeed tip by gravity, 
the tip was washed with buffer QC. The DNA immobilized on the tip was eluted using 
buffer QF, and precipitated by adding isopropanol and incubating for 5 minutes at room 
temperature. A QlAprecipitator was attached to the nozzle of a 20m1 syringe and the 
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DNA solution emptied into the barrel. The plunger was inserted and the mixture filtered 
through the QlAprecipitator. The collected DNA was finally eluted into a clean 
Eppendorf tube with TE buffer and DNA concentration determined by 
spectrophotometry. 
2.10 Snectronhotometric Determination of DNA concentration 
This was performed using the GeneQuant II. The machine was first programmed to 
measure the concentration of dsDNA, at a dilution factor of 71. The cuvette was filled 
with 7Oµ1 of Elgastat water, which was used as the reference point. 10 of the plasmid 
preparation was then added, pipetted gently to mix, and the dsDNA concentration read at 
260A. 
2.11 Horizontal Aearose Gel Electrophoresis 
Plasmid DNA was isolated by agarose gel electrophoresis. A1% TAE gel was formed by 
dissolving SeaKem Agarose (0.5mg) in 1xTAE buffer (50m1) (p. 223). Ethidium bromide 
was incorporated into the gel by the addition of lµl ethidium bromide solution (10mg/ml) 
for every 10ml of the agarose gel. The cooled gel mixture was poured into a horizontal 
electrophoretic gel tank, the comb inserted, and allowed to set at room temperature for 
30-60 minutes. Sufficient 1xTAE buffer was used to cover the gel, before DNA samples 
were loaded. DNA samples for analysis were prepared by the addition of 2.5pl of loading 
buffer to 10µl of each sample. 
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Depending on the molecular weight of the DNA plasmid, the markers (either VII or VIII, 
p. 226) were also loaded onto the gel. Samples were electrophoresed at a constant voltage 
of 50V for 1-2 hours. 
DNA separated in this manner was visualized using a UV transilluminator and 
photographed. Gel blocks of desired DNA products could be cut out at the same time and 
plasmid DNA purified using the QlAquickTM Gel Extraction Kit (p. 225). 
2.12 Purification of DNA from Agarose Gels 
DNA was extracted from TAE gels using the Gel Extraction Kit. The DNA band of 
interest was excised from the gel using a sharp, clean scapel. The gel sample was 
weighed and placed in a 1.5m1 Eppendorf tube. 3 volumes of Buffer QG were added for 1 
volume of gel (100mg - 100µl). The tube was incubated at 50°C for 10min or until the 
gel dissolved. Following gel dissolution, the colour of the solution has to be compared 
with that of Buffer QG. If the colour is orange or purple, 3M sodium acetate can be added 
to alter the pH, as the QlAquick membrane works best at pH<7.5. Next, I gel volume of 
isopropanol was added to the mixture and mixed. The solution was then applied to the 
QlAquick spin column, centrifuged at 13,000rpm for lmin and the flow-through 
discarded. Next 0.5ml Buffer QG was added to the column, centrifuged as before, and the 
flow-through discarded. The column was then washed with 0.75m1 of Buffer PE by 
centrifugation as before. The QlAquick column was then placed over a clean Eppendorf 
tube and the DNA eluted into it with 501l EB by centrifugation. The eluted DNA was 
then stored at -20°C until required. 
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2.13 Restriction Enzyme Digests 
Restriction enzyme digests of plasmid DNA were performed to analyse DNA products as 
well as to isolate plasmid DNA of interest for subsequent reactions. A typical digestion 
would be performed at 37°C for 4-18hrs and would consist of the following components: 
x µl of DNA (containing 5-101tg plasmid DNA) 
5 µl restriction enzyme A 
5 µl restriction enzyme B 
5 µl appropriate restriction enzyme 1 Ox buffer 
+y µl nuclease free water (to bring final reaction volume to 50µl). 
Analytical digests were performed on a smaller scale and were typically as follows 
x µl of DNA (containing 1-21tg plasmid DNA) 
1 µ1 restriction enzyme A 
1 µl appropriate restriction enzyme l Ox buffer 
+y µl nuclease free water (to bring final reaction volume to 10µl). 
2.14 Ligation Reaction 
Following enzymatic digests to create free ends, insert DNA can be ligated to linearized 
vector DNA to form a circular plasmid. 1µl of T4 DNA Ligase (Roche) was added to 
reaction mixtures that contained 1 i1 of T4 DNA Ligase IN buffer, and various ratios of 
vector to insert DNA. The final reaction volume was IOµ1 and any shortfall was made up 
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with nuclease free water. Vector to insert ratios of 1: 1,1: 3, and 1: 6 were used, and the 
mass of DNA required for each reaction was calculated as follows: 
ng of vector x kb size of insert x molar ratio of 
insert 
= ng of insert 
kb size of vector vector 
Ligation reactions were incubated at 14°C overnight, and products of the reaction were 
separated and isolated by horizontal agarose gel electrophoresis. 
2.15 Transformation of competent E. coli with plasmid DNA 
Commercially available competent cells were used for the transformation (Top10, p. 225). 
2µl of the DNA plasmid was incubated with 50µl of competent cells on ice for 30 min. 
The cells were then shocked in a 42°C water bath for 30s, re-incubated on ice for 1 min 
before 2501t1 of LB was added. The cells were incubated at 37°C for 1 hour, then plated 
onto antibiotic-treated LB agar plates using an ethanol-flamed glass rod, and incubated at 
37°C overnight. Plates were examined the next day for colony formation and colonies 
were picked at random and inoculated into antibiotic-treated LB of various volumes as 
required for mini-, midi-, or maxi- DNA preparations. 
2.15.1 Storage of Transformed E. coli 
0.85ml of the clones of transformed E. coli incubated in LB(p. 220) overnight was added 
to 0.15m1 of sterile glycerol, and the solution pipetted to ensure thorough mixing before 
storing at -80°C. 
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2.16 Methods used in the Transfection of Cells 
The various cell lines used were transfected with a variety of methods. The T-47D, MCF- 
7, COS-7, HepG2, SF and Ros cell lines were all transfected using the Fugene6 
transfection reagent. Hela cells were transfected using Lipofectamine Plus, and the CEM- 
C7 cells were transfected by electroporation. 
2.16.1 Transfection of Cells using the FuGENE 6 Transfection Reagent (Roche) 
The FuGENE 6 reagent is a lipid based transfection reagent that complexes with and 
transports the DNA into the cell during transfection. Adherent cells are plated one day 
before transfection, aiming for a confluency of 50-80% on the day of transfection. 
Depending on the size of the plate to be transfected, varying amounts of DNA and 
FuGENE 6 reagent were used to transfect the cells according to the manufacturer's 
protocol. 
Transfection reactions were performed according to the manufacturer's protocol. Briefly, 
FuGENE 6 reagent was equilibrated to room temperature before use. SFM, enough to 
bring the total volume of the mixture to 1001l per transfection sample, was added to a 
small sterile Eppendorf tube. Next, FuGENE 6 was added directly into the SFM and the 
contents mixed by gentle tapping. DNA solution was then added to the prediluted 
FuGENE 6 reagent and the solution mixed again. The contents were incubated at room 
temperatre for 15-45 minutes to allow Fugene6 to complex with the DNA. 
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The transfection mix was added dropwise to each dish and swirled around to ensure 
thorough mixing. Cells were returned to the incubator for 24-48 hours depending on the 
assay performed. 
2.16.2 Transfection of cells by Lipofectamine Plus 
Lipofectamine Plus (p. 226) was used to transfect HeLa cells, as this method provided a 
higher rate of transfection ('80%) compared to other methods. HeLa cells were plated in 
6-well plates the day before transfection so that they were -40-50% confluent on the day 
of transfection. The transfection mix was constituted in serum free DMEM (SFDMEM, 
p. 222). The DNA was first added to SFDMEM (100µ1 per well to be transfected), 
followed by the Plus reagent. This solution was mixed by tapping and then incubated for 
15-20 minutes at room temperature. Lipofectamine reagent was then added to SFDMEM 
(1001il for every well to be transfected), and this was mixed with the pre-incubated DNA- 
Plus mixture for another 15-30 minutes. The transfection mixture was then added to each 
well (200µl of mixture per well), and the cells incubated at 37°C, 5% CO2 until the cells 
were required. 
2-16.3 Transfection of Cells by Electroporation 
CEM-C7 cells were prepared for electroporation by washing twice in PBS, before being 
resuspended to a fmal concentration of 10x106 cells per ml in PBS. 50Oµl of the cell 
suspension was then electroporated with 40µg of DNA plasmid in a 0.4cm cuvette 
(BioRad), using a BioRad Gene Pulsar II. Cells were electroporated using 1050µF and 
300V, the time constant ranged from 11.6-12.7ms. Cells were immediately transferred to 
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complete medium and allowed to recover for 48 hours before being placed in RPMI-1640 
medium containing selection antibiotic (G418) at 800µg/ml. Cells were kept in this 
medium for 2 weeks before being transferred to maintenance medium (RPMI-1640 with 
350pg/ml G418). 
2.17 Methods for Clonal Selection 
2.17.1 Clonal selection by serial dilution 
Clones of CEM-C7, MCF-7 and T47-D cells were obtained by limiting dilution. Parent 
cultures were harvested by the usual method and diluted to a final concentration of one 
cell per ml of complete medium. Cells were then seeded in to a 96-well plate at 200pl per 
well, so that on average there would be one cell every five wells. Cultures were left to 
grow over two to three weeks at 37°C in 5% CO2. Colonies detected after this period 
were transferred to T25 flasks for subsequent analysis. 
2.17.2 Clonal selection by colony formation in aga ose gels 
The CEM-C7, MCF-7 and T-47D cell lines were also cloned by plating in low gelling 
agarose gels using a method similar to that described in Section 2.5.3. A feeder layer of 
human fibroblasts (5x104 cells/dish) was initially seeded onto 60mm dishes and allowed 
to attach. The base gel consists of a 0.6% agarose gel, and is formed by mixing equal 
volumes of 2xDMEM (2xRPMI for CEM-C7 cells) (p. 221) and a 1.2% agarose gel 
solution. This mix is allowed to set at room temperature and then incubated with 5%CO2 
at 37°C till required. 
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Cells to be cloned are collected by trypsinization where necessary, and diluted down to a 
concentration of 400 cells per ml. The upper 0.3% gel is then formed by mixing 1 volume 
of cell suspension with 4.5 volumes of 2xDMEM (or 2xRPMI for CEM-C7 cells) and 4.5 
volumes of a 0.6% agarose gel solution. This gel was allowed to set at room temperature 
before the dishes were placed in a humidified chamber and incubated at 37°C in 5%CO2 
for 10-14 days. Colonies that developed were transferred to T25 in medium containing 
G418 before subsequent analysis. 
2.18 Protein Extraction and Western Blottin 
Cells were washed twice with PBS and resuspended in SLB supplemented with aprotinin 
(12.5pg/ml), leupeptin (12.5gg/ml), PMSF (1mM) and pepstatin A(lOpg/ml). The cell 
lysate was kept on ice for 10 minutes, with occasional vortexing to break up the DNA. 
The lysate was then centrifuged at 13,000rpm for 10 minutes at 4°C to pellet the genomic 
DNA. 40µl of crude cell extract was added to an equal volume of loading buffer 
(containing 5% 2-mercaptoethanol) (p. 221) and heated to 95°C for 5 minutes before 
being cooled to room temperature and loaded onto a vertical polyacrylamide gel (4% 
stacking gel and 8% separation gel) containing SDS (p. 222). 
Where appropriate, immunoprecipitation was performed on the crude lysate. In this case, 
750µl of crude lysate was incubated with primary antibody for 2 hours at 4°C with gentle 
rocking. Protein-A agarose beads were washed three times in ice cold SLB (p. 222) and 
suspended to a final volume of l000, and suspended beads (90pl) added to the mix and 
incubated for a further 1 hour at 4°C with mixing. The antibody-agarose-A bead 
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complexes were collected by centrifugation and washed 3 times in SLB (6000 rpm, 1 
minute, 4°C) and the supernatant removed. Loading buffer (containing 5% 2- 
mercaptoethanol) was added to the protein-A agarose-antibody pellet and the mixture 
heated to 95°C for 5 minutes. The mixture was centrifuged briefly to pellet the agarose 
beads, and the supernatant loaded onto the acrylamide gel as above. 
Electrophoresis was performed at 55V overnight with molecular weight markers (p. 226) 
run alongside samples. 
Separated proteins were transferred to a nitrocellulose membrane by using a semidry 
transfer blotter (BioRad) at 15V for 30 minutes. The nitrocellulose membrane was then 
incubated in a blocking solution (5% milk in TBS-Tween, p. 223) for 60 minutes at room 
temperature on a shaker. The membrane was washed twice with TBS-Tween before 
incubation with the primary antibody for at least one hour at room temperature on a 
shaker. Excess antibody was removed by washing the membrane in TBS-Tween for 30 
min at room temperature on a shaker, the buffer being changed every 5 minutes. The 
membrane was incubated with the secondary antibody for 1 hour and washed again 
before incubation with the horseradish peroxidase substrate in the ECL (Enhanced 
Chemiluminescence) Kit (p. 225), and then exposed to photographic film for 1-10 mins. 
The following antibody combinations were used (primary antibody; secondary antibody): 
Flag-Pr1R: anti-Flag M2 antibody (Sigma, 1: 1000 dilution); sheep anti-mouse, HRP- 
linked (1: 10,000 dilution). 
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STATS: anti-STATS, C-17 (Santa Cruz, 1: 2000 dilution); goat anti-rabbit, HRP-linked 
(1: 10,000 dilution). 
HA-STAT5b: anti-HA - mouse monoclonal (Sigma, 1: 3000 dilution); sheep anti-mouse, 
HRP-linked (1: 10,000 dilution). 
HA-Het, or Met-HA: rabbit HA-probe (Santa Cruz, 1: 1000 dilution); goat anti-rabbit, 
HRP-linked (1: 10,000 dilution) 
2.19 Lacto2enic Hormone Response Element (LURE) Reporter Assay 
Reporter gene assays are widely used to determine the transcriptional activity of cells. A 
reporter assay consists of a reporter gene linked to a promoter that is transfected into the 
cells. In the LHRE reporter assay, a luciferase gene is linked to 6 tandem copies of the 
STAT5 response element. The addition of prolactin to responsive cells results in the 
formation of STAT5 homodimers that bind to the STAT5 response element. This 
activates transcription of the luciferase gene with resultant expression of the luciferase 
enzyme. This enzyme catalyzes a reaction involving D-Luciferin and ATP in the presence 
of oxygen and Mge+resulting in light emission. Luciferase activity was quantified using a 
Dynex luminometer. 
Cells (1 xl 05 per well) were seeded into 24-well plates and incubated overnight before 
being transfected with the LH E reporter gene together with other plasmids as specified, 
using the Fugene 6 reagent as previously described. The cells were incubated overnight, 
and then transferred to SFM for 6 hours before the addition of prolactin. After incubation 
for a further 18 hours, cells were lysed in 65µl of lysis buffer A (p. 221). 20µl of the lysate 
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was added to 100µl of luciferase assay reagent (p. 220) (20 min, room temperature) and 
luciferase activity assessed immediately using a Dynex luminometer. The amount of light 
emitted was integrated over 12s (10011 assay buffer injected per sample, time to read 
10s). 
2.20 ERE-Tk-Luc Reporter Assay 
To assess transcriptional activity of the oestrogen receptor, cells were seeded into 48-well 
plates and incubated overnight. The cells were then transfected with ERE-Tk-Luc and 
various plasmids using FuGENE 6 and incubated overnight. The cells were then serum 
starved in SFM for at least 6 hours before the addition of 10-8M oestrogen (final 
concentration) for 18 hours. The cells were lysed and luciferase activity measured using 
the Dynex luminometer as above. 
2.21 ß-Galalactosidase Reporter Assa 
The ß-galactosidase enzyme is commonly used as a reporter molecule for many assay 
systems, primarily to assess transfection efficiency of mammalian cells. The ß- 
galactosidase enzyme encoded by the plasmid is constitutively active (under the control 
of a SV-40 promoter) so that assessing its activity provides a measure of transfection 
efficiency. 
Cells (3x104 per well) were seeded into a 48-well plate and incubated overnight before 
being transfected with a plasmid encoding a constitutively active ß-galactosidase enzyme 
(pSV-ßgal 60ng). The cells were then incubated overnight and serum starved for a further 
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24 hours before lysis in 65µl of lysis buffer A (p. 221). 3011 of the lysate was added to 
170µl of chlorophenol red-ß-D-galactopyranoside (CRPG) reagent (p. 219) and incubated 
at 37°C for sufficient time for the colour chage to develop. The colour intensity was then 
measured at 570nm using the RLX ß-microplate reader (Dynex Technologies). 
2.22 Cellular localisation Studies 
Cells were grown on 22x22mm cover slips to -50% confluency before transfection with 
various plasmids (as indicated in each experiment) and incubated for 24-48 hours to 
allow for protein expression. The cells were then washed with PBS (pH 7.4) and fixed in 
2% PFA in PBS (p. 218) for 20min at room temperature. The cells were then washed with 
PBS before permeabilization with 0.1% Triton X/PBS for 5 mins before being washed 
again in PBS. Non-specific protein binding was blocked by treating cells with 1% (w/v) 
BSA/PBS for 20mins before incubation overnight with primary antibody at 4°C (see 
experiments for antibody and dilutions). The cells were next washed 3 times with 
1 %BSA/PBS before incubation with secondary antibody for 1-1.5 hrs at room 
temperature in the dark. Following this, coverslips were washed three times in PBS 
before they were mounted onto glass slides (BDH) using DAKO fluorescent mounting 
medium. Slides were stored in the dark at 4°C until confocal microscopy. 
2.22.1 Confocal microscopy 
Confocal images were obtained using a Leica TCS SP scanning laser microscope 
equipped with a Kr/Ar laser using a 63x oil immersion objective. EYFP was detected 
using a filter set with excitation filter of 51Onm and an emission filter of 530nm. Cy3 was 
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visualized with a filter set with an excitation filter of 568nm and an emission filter of 
590nm. All images were processed with Leica software for 2D analysis. 
2.23 Genomic DNA Extraction 
High molecular weight DNA was extracted from cultured cells using the following 
method. 
A maximum of 5x106 cells were collected and washed with PBS. Cells were centrifuged 
at 1000 rpm for 5 min and the supernatant discarded. 700µl of Lysis Buffer B was added, 
and the cell pellet re-suspended. 35 µl of proteinase K (10mg/ml) was added to the cell 
suspension and the mixture placed in a heating block set at 55°C for a minimum of 4 hrs. 
Next, an equal volume (-750 µl) of phenol was added to the mixture, mixed thoroughly 
by inversion, and then centrifuged at 13,000rpm for 15 min. The aqueous phase was 
removed carefully and an equal amount of phenol / chloroform / indoleacetic acid added 
and the mixture centrifuged for 15 min at 13,000 rpm. Next, 70 µl of 3M NaAc (pH 5.2) 
and 3 volumes of absolute ethanol (at room temperature) was added to the extracted 
aqueous phase. The mixture was again centrifuged at 13,000 rpm for 15 min at 4°C. The 
pellet obtained was washed in 70% ethanol and re-centrifuged. Finally, the pellet was re- 
suspended in 100-500µl of TE to dissolve the DNA. 
2.24 RNA Extraction 
RNA extraction from cultured cells was performed using the RNeasy Mini Kit (p. 225) 
according to the manufacturer's instructions. The cells are first collected by gentle 
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trypsinization using 0.25% trypsin EDTA. Approximately 7x106 cells were then lysed in 
60011 buffer RLT (containing IOld of 2-mercaptoethanol per ml of RLT) and the sample 
homogenized using a 21 gauge needle and lml syringe. 6O011 of 70% ethanol was then 
added to the homogenized sample and mixed thoroughly by inversion. The lysate was 
then added to the mini-column which was centrifuged at 13,000rpm for 15s. The 
remainder of the lysate was added to the column, which was centrifuged as before. 
Next, 7001il of buffer RWl was added to the column, which was centrifuged as before 
and subjected to two washes using buffer RPE. Finally, RNA was eluted with two 501L 
aliquots of nuclease-free water. The extracted RNA was then either used immediately or 
stored at -80°C until required. 
2.25 Poly(A+) RNA Isolation 
mRNA was isolated using the PolyATract Isolation System IV (p. 225), which utilizes 
biotinylated oligodT bound to streptavidin-linked magnetic beads as a means of 
separating mRNA from total RNA. The mRNA was extracted according to 
manufacturer's protocol as follows. 
The volume of total RNA was brought up to S0011 using nuclease-free water, and heated 
at 65°C for 10 minutes. Following this, 3p. 1 of biotinylated oligodTs and 131l of 20xSSC 
(sodium chloride, sodium citrate buffer, as supplied) buffer was added to the RNA 
solution, which was allowed to cool to room temperature. 
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Magnetic beads were resuspended in the storage buffer and then collected by using the 
paramagnetic stand (Promega). The storage buffer was carefully removed and the beads 
washed 3 times using 3O0µ1 0.5xSSC per wash, each time collecting the beads on the 
magnetic stand. After the final wash, the beads were re-suspended in l0011 of 0.5xSSC 
buffer. 
The entire RNA solution was then added to the magnetic bead suspension and mixed by 
inversion. The mix was incubated at room temperature for 10 min, inverting the tube to 
mix the contents at regular intervals. The beads were then washed 4 times using 300µl of 
0.1 xSSC buffer. Following. the final wash, the beads were resuspended in 100µl of 
nuclease-free water. The beads were mixed, then collected on the magnetic stand, and the 
supernatant fraction containing mRNA removed and collected in an RNase free tube. The 
beads were resuspended in another 1001tl of nuclease-free water and additional mRNA 
collected. The mRNA was then aliquoted and stored at -80°C. 
2.26 Polymerase Chain Reaction 
The PCR amplification cycle consists of a number of steps: denaturation at 95°C, which 
causes the intertwined DNA strands to separate, annealing at 55°C, to allow the primers 
to anneal to the template of interest, and finally the extension phase, usually at 72°C 
(optimal temperature for Taq polymerase function) where Taq synthesises the 
complementary strand of DNA template. The recommended times for denaturation are 
between 15s-2min, annealing for 30-60s and extension times are usually 1-2 minutes. 
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After completion of the amplification cycles, the DNA synthesized can be analysed or 
used as required. 
The following is a typical reaction mix for PCR: 
Vol Final concentration 
IOx Buffer 5111 lx 
MgC12 (50mM) 2.5 µl 1.5mM 
dnTP mix (20mM) 0.5 Eil 0.2mM each 
Primer 1 (50pmoles) I t1 1µM 
Primer 2 (50pmoles) 1 µl 1 µM 
Taq pol 0.2 pl 0.025u/0 
Template DNA x µl 
dH20 to bring total reaction volume to 50µl 
Depending on the number of samples to be processed, a master mix is made and the 
sample DNA added to each reaction mix. The final DNA concentration in the mix should 
not exceed lOng/ml. Reactions were carried in thin-walled 0.5m1 tubes. For each PCR 
reaction performed. The conditions were optimized for each primer pair, so amounts and 
concentrations of each component added may vary from the standard protocol (indicated 
with each specific experiment performed). All components of the PCR reaction were 
obtained from Gibco-BRL, except for the primers (Invitrogen). 
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When using RNA (or mRNA) as a substrate, a combined reverse transcription-PCR (RT- 
PCR) assay was performed using the Access RT-PCR kit from Promega. 
A typical reaction mix consists of the following: 
Volume Final concentration 
Nuclease-free water (to final volume of 501t) Xjil 
AMVITJI 5x reaction buffer 10µ1 lx 
dNTP mix (10mM each dNTP) lµl 0.2mM 
5'primer 50pmol 11M 
3'primer 50pmol 1 µM 
25mM MgSO4 2µd 1mM 
AMY reverse transcriptase (5u/µ1) 11t1 0.1u/µ1 
ifi DNA Polymerase (5u/µ1) I ld 0. lu/µl 
RNA template Y. 1 
The RT-PCR reaction is started by the addition of the RNA template. All components 
were added into thin-walled 0.5m1 reaction tubes on ice. The tubes were then placed in a 
TECHINE thermocycler and the RT-PCR programme initiated. 
All RT-PCR reactions were optimized by using [Mg21 between 1mM and 3mM for each 
primer/template reaction. In addition, several reactions were performed at various 
annealing temperatures in order to identify the best annealing temperature for each primer 
pair. 
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2.27 LIl Uridine Incorporation as a measure of RNA transcription 
2.27.1 [3H] Uridine incorporation to assess total RNA synthesis 
To measure uridine incorporation into total RNA, cells were plated in 96 well plates and 
incubated overnight. They were then transfected with the plasmid of interest and 
incubated for 48 hrs. Following this, tritiated uridine (1 ELCi) was added to the wells for 
lhr before cells were lysed and the radioactivity transferred to Filter Mat A (Wallac) as 
follows. The medium was discarded and 100µl of trypsin-EDTA added to each well. The 
cells were incubated at 37°C for 30 minutes before being frozen at -20°C for at least 3 
hours before harvesting as previously described for thymidine incorporation. To measure 
[3H]uridine incorporation into poly(A) RNA, cells were plated into 60mm dishes and 
incubated overnight. They were transfected on the following day with the plasmid of 
interest and incubated for 48 hrs. [3H]uridine (20 µCi) was then added to each dish, and 
incubated at 37°C, 5%CO2 for 1 hr. Next, the cells were collected by trypsinization, and 
RNA extracted in the manner described previously. From the resulting RNA solutions, an 
aliquot was removed, to provide a measure of the total radioactivity of the RNA solution. 
The remaining solution was then subjected to mRNA extraction as described previously. 
Each mRNA sample was then placed into 6m1 polyethylene vials (Packard Biosciences) 
and 3mls of scintillant (Optiphase `HISAFE' 3 liquid Scintillation Cocktail, Perkin 
Elmer, p. 218) added to each sample before the radioactivity was measured in the 1400 
DSA Liquid Scintillation Counter (Wallac). Analysis was performed using 1400 DSA 
version 2.5 (software, Wallac). 
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3 Does Prolactin Protect Breast Cancer Cells against Apoptosis? 
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Early studies designed to block the release of pituitary prolactin failed to show a 
convincing therapeutic effect in the treatment of human breast cancer20$'206 although 
recent studies have returned to the possibility that prolactin may play a role in breast 
cancer207.. 08. Prolactin does have an established role in murine mammary 
tumourigenesis20` , 210, however. In humans, we know that not only are breast cancer cells 
able to synthesize their own prolactin211-213 but breast cancer tissue has been shown to 
have higher levels of prolactin receptors compared to normal breast tissue214. Moreover, 
the prolactin receptor can be activated by other lactogenic hormones, such as growth 
hormone (GH)215 which may account in part for the lack of efficacy reported for agents 
such as bromocriptine. Thus it appears that the time has come for a re-evaluation of the 
role of prolactin in breast tuomourigenesis2'6-218. Many cancer therapies rely on the 
induction of apoptosis and cell death to bring about a reduction in tumour bulk. Evidence 
suggesting that use of a prolactin antagonist could inhibit growth of breast cancer cells by 
inducing apoptosis219 prompted us to investigate this effect in greater detail. Two cell 
lines were used to investigate the possible effects of prolactin on survival from apoptosis. 
The MCF-7 and T47-D immortalized cell lines were derived from patients with 
disseminated breast cancer. It is known that T47-D cells express a high level of prolactin 
receptors, while MCF-7 cells express fewer receptors on the cell surface 0.221. 
3_1 RESULTS 
3,1,. 1_ Induction of Apoptosis using Ceramide 
In order to provide a system for identifying the anti-apoptotic effects of prolactin (Prl), 
initial studies were designed to assess the induction of apoptosis in T47-D cells by the C2 
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ceramide analogue, N-acetyl-U-sphingosine (C2), which had been shown previously to 
induce apoptosis in breast cancer cells222,223. 
3.1.1.1 Quanlification of'Apoplosis by Light Microscopy 
First, we used morphological analysis by light microscopy to assess the induction of 
apoptosis. T47-D cells (25x104 per well) were seeded into 8-well Labtek chamber slides 
in complete medium and incubated overnight before being transferred to serum free 
medium for 24 hours prior to treatment with ceramide. Ceramide was added at the 
concentrations shown, and cells were incubated for a further 24 hours. The medium was 
aspirated and slides washed with phosphate-buffered saline (PBS) before cells were fixed 
with 100% acetone. The slide was stained with haemotoxylin and eosin (H&E) and a 
cover slip mounted to aid viewing under the microscope. The extent of apoptosis was 
assessed by counting 1000 cells in three separate fields in the same well, at the same time 
determining the proportion of apoptotic cells. Fig. 3.1 shows a dose response of the effect 
of ceramide on T47-D cells. From this graph, it can be seen that apoptosis rises from -5% 
in untreated cells to -13% in T47-D cells treated with 30pM ceramide. The rate of 
apoptosis appeared to plateau after 20µM and this concentration was used for most 
studies. Over the course of these studies, the effectiveness of ceramide varied somewhat 










Figure 3.1 Morphological assessment of apoptosis in T47-D cells exposed to ceramide. 
Cells in 8-well Labtek chamber slides were incubated with ceramide in serum free medium for 24 
hours before being fixed with acetone and stained with H&E for assessment under the light 
microscope. 
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T47-D cells were then treated with a single dose of ceramide (20µM) in the presence or 
absence of prolactin (200ng/ml) after being starved for 24 hours in serum-free medium. 
Following the addition of ceramide, cells were incubated for a fiuther 24 hours before the 
slides were washed, fixed and stained for assessment by light microscopy. As seen in Fig. 
3.2, there is a clear increase in the number of apoptotic cells to 13%±5 (SD) in cells 
treated with ceramide, which decreases to 4%±2 (SD) (p<0.05) in the presence of 
prolactin. The results shown are the mean of three experiments. 
Although these experiments seemed to demonstrate a clear protective effect of prolactin, 
there were several inherent difficulties in assessing apoptosis by this method. In 
particular, reproducibility proved extremely difficult to achieve and it could be argued 
that assessment by this method is subjective. Therefore we decided to investigate the use 
of other methods for assessing apoptosis. 
3.1.1.2 Quantification ofApoptosis by Analysis of the Cell Cycle Profile 
The cell cycle profile of a given cell population allows the observer to assess how various 
treatments are able to affect population dynamics, as well as allowing the identification of 
`pre-G1'cells that are undergoing apoptosis. 
As an initial experiment, a dose response to ceramide was performed in T47-D cells 
(Fig. 3.3a), which were then subjected to cell cycle analysis. Surprisingly, there did not 
appear to be any significant increase in the pre-GI population after ceramide treatment 











Figure 3.2 Morphological assessment of apoptosis in T47-13 cells exposed to ceramide in the 
presence of prolactin. 
I17-L) cells were treated with 201LAI ceramide in the absence or presence of prolactin 
(200ng ml). Cells were incubated with ceramide. / r 24 hours hefnre being. fixed and stained. The 
figure is the mean of 3 separate experiments (error bars indicate standard deviation, *pO. 0-5) 
each peº formed in triplicate. 
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From this experiment, it would appear that DNA degradation is minimal in these cells. 
When cells were assessed morphologically, there were obvious signs of apoptosis 
present, but this was not reflected in the cell cycle profile. Ceramide did appear to arrest 
cells in the G2 phase of the cell cycle, however (Fig. 3.3b). The proportion of cells in the 
G2 phase increased from 14% in controls to 24% following treatment with ceramide. 
Thus we decided to investigate another method of assessing apoptosis. 
3.1.1.3 Quantification ofApoptosis by Annexin- VBinding 
As shown in Fig. 3.4, when T47-D cells were incubated with different concentrations of 
ceramide for 24 hours, there was a clear decrease in the fraction of live cells (80.6% to 
51.2%) and a corresponding increase in the number of necrotic cells (5.5% to 23.3%). 
The fraction of apoptotic cells, however, showed minimal change (1.3% to 2.7%). 
On the basis of this experiment, we were interested to assess whether prolactin would 
reverse the increase in the `necrotic'cell population following ceramide treatment after 
pre-incubation with 250ngIml prolactin. Therefore, T47-D cells were treated without or 



















Figure 3.3 PreGt (a) and G2 (b) populations of T47-D cells after exposure to ceramide as 
assessed by Cell Cycle Profile analysis. 
Cells were serum slarred for 24 hours hefbre Irealment with ceramide. Cells were then incuhaled 
for a further 24 hours before they were collected by trvpsinization, washed and fixed with 70% 
ethanol, and stained with propidium iodide for analysis of the cell cycle profile on the flow 
cylomeler. 
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Figure -3.4 Annexin-V staining to assess apoptosis in T47-D cells exposed to ceramide. 
T47-D cells were deprived of serum für 24 hours hcfore exposure to ceramide. The cells were 
collected and stained with Annexin-V and pmpidium iodide to identify live, necrotic and 
apoptotic populations. 
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Figure 3.5 Use of annexin staining to assess possible protective effect of prolactin on 
ceramide-induced cytotoxicity in T47-D cells. 
Cells were treated with serum free medium alone (Ctrl), 200ng ml prolactin (Pr! ), 50jAf 
ceramide (C'? ), and 501zM ceramidc: with 200ng ml prolactin (('2 ' J'rl) and incubated . 
fin- 48 
hours. 7 hey were then collected by trypsinization, washed and stained with Annexin-V and 
propidium iodide 
. 
for analysisof the extent of uhoptosiS by flow cytomeirV. Me results vhown 
represent the mean oj'3 experiments (error bars indicate standard deviations). 
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3.1.2 Ability of Prolactin to Preserve the Proliferative Capacity of Breast Cancer Cells 
Exposed to Ceramide 
In the experiments described above, difficulty was experienced in demonstrating a 
classical apoptotic response in breast cancer cells. As an alternative approach to assessing 
the survival effect of prolactin, we decided to assess the clonogenicity of cells following 
the addition of ceramide as the cytotoxic agent. Initially, we used an indirect assay of 
clonogenicity by measuring cell proliferation after exposure to ceramide. Owing to the 
change in approach, we decided to include MCF-7 cells in the investigation as a separate 
control population, as -they have prolactin receptors, but fewer than T47-D cells(-8000 
sites and -26,000 sites per cell respectively)22°. 
3.1.2. / Quantification of Cell Survival using a Growth Assay 
For this study, cells were seeded into 24-well plates and left overnight to attach. They 
were then placed in serum-free medium for 24 hours before the addition of ceramide 
(40µM ceramide to MCF-7 cells and 50µM ceramide to T47-D cells) in the presence or 
absence of prolactin (200ng/ml). The cells were incubated further (MCF-7 cells for 24 
hours and T47-D cells for 48 hours) before fetal calf serum (10% v/v) was added to the 
wells. The cells were then allowed to proliferate for 4-5 days before being collected by 
gentle trypsinization for counting on the Coulter counter. 
In MCF-7 cells (Fig. 3.6a), the cell count fell from 45+16x104(SD) to 16+11x104(SD) 
after treatment with ceramide. After treatment with both prolactin and ceramide, there 
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Figure 3.6 Use of cell counting to assess the effect of prolactin on survival of (a) MCF-7 and 
(b) "I'47-D cells. 
MCI, '-7 and 147-/) cells were treated in serum free medium alone ((.. 'trl), with 200ng, tnl prolactin 
(Prl), 4OjjA'f ceramide in MCF-7 cells and 50p Af ceramide in T47-I) cells (C? ), or both ceramide 
and prolactin (C2+prl), MCI -7 cells were incubated , 
for 24 hours and T47 -D cells for 48 hours 
he/irre 10% (r. r) fetal calf serum was added. The cells were then incuhaied, / r a_Jiiriher 5 dues 
hefbre they were collected by t? psinizatiun and counted using a Coulter Counter. Figures 
represent the mean of three independent experiments (error bars indicate standard deviations, 
*: p -- 0.5). 
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was no significant protective effect of prolactin, the cell count being 17±7x104(SD). 
These data represent the mean of three separate experiments in the MCF-7 cell line. 
In T47-D cells (Fig. 3.6b), the number of cells fell from 10±4x104(SD) to 5±2x104(SDM) 
in cells after treatment with ceramide, but increased again to 7±2x104(SD) after treatment 
with ceramide plus prolactin (p<0.5). These data represent the mean of three separate 
experiments in the T47-D cell line, and show what appears to be a strong protective effect 
of prolactin. It was also observed that prolactin alone did not induce any significant 
proliferation in either cell population and confirms observations made by Vonderhaar that 
fetal calf serum inhibits prolactin-indiced proliferation 224. 
3.1.2.2 Quantification of Cell Survival using the X77' Cell Proliferation Kit 11 
For this assay, we seeded 5x104 cells in complete medium and allowed them to attach in 
96-well plates. They were then washed gently with Dulbecco's phosphate buffered saline 
before they were serum-starved for 24 hours. Following this, ceramide. (40µM to MCF-7 
cells, and 50µM to T47-D cells) was added in the, absence or presence of prolactin 
(200ng/ml) and cells were incubated for 24 hours (MCF-7 cells) or 48 hours (T47-D 
cells). The XTT was then added to the wells and incubated for a further 18 hours before 
the optical density was read at 450nm using a microplate reader. Fig. 3.7a shows the mean 
result from three experiments in MCF-7 cells. The addition of ceramide decreased the 
optical density from 2.0±0.4(SD) to 0.6+0.1(SD). The addition of prolactin did not give a 
significant increase in the optical density measured (0.7+0.3(SD)). Fig. 3.7b shows the 
mean data from four separate- experiments with T47-D cells. The optical density 
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Figure 3.7 Use of the X1T assay to assess the effect of prolactin on survival of (a) MCF-7 
and (b) T47-D cells. 
Cells were serum svurved for 24 hours before treatment with: serum free medium only (Girl), 
200ng. ml prolactin (Prl), ceramide (('2) (401, M it, MC'F-7,501AI in 7'47-D cells), or both 
ceramide and prolactin ((72 ' Prl). MCF-7 cells were incubated fier 24 hours, and T47-D cells for 
48 hours, before fetal calf serum was added to a final concentration of 10% (v v). ('e//. v were 
incubated for a further 5 days before the addition of. '7T and the optical densiNi' read 18 hours 
later. (*. -p --0.03). The above figures are the mean of 4 experiments, each performed with 6 
replicates. 
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decreased from 0.8±0.2(SD) in control cells to 0.3±0.1(SD) when cells were exposed to 
ceramide. The addition of prolactin resulted in a significant (p<0.05) increase in the 
optical density to 0.4+0.1(SD). 
3.1.2.3 Assessment of Cell Survival by a ClonogenicAssay 
The `gold standard' for measuring cell survival is to assess clonogenicity. Thus the ability 
of T47-D cells to form colonies in agar gels following cytotoxic insult by ceramide was 
assessed. Fig. 3.8 shows a dose response curve to ceramide using this assay in T47-D 
cells, and on this basis a concentration of 20µM was chosen for subsequent experiments. 
To determine whether prolactin could exert a protective effect in this assay, 1.5x106 cells 
were seeded into a T25 flask and allowed to attach. The cells were then serum-starved for 
24 hours before they were incubated in the absence or presence of 250ng/ml of prolactin 
for an hour. Ceramide (20µM) was then added in the continued presence of prolactin and 
cells were incubated for a further 24 hours. Following this, all the cells, including 
floaters, were collected by trypsinization and 250 cells were plated onto 60mm dishes in 
agarose gels and incubated for 14 days. Three replicates for each treatment condition 
were plated. The gels were then stained with 0.05% Neutral Red Solution for 1 hour 
before the number of colonies was counted using a dissecting microscope. A typical 
experiment is shown in Fig. 3.9. When results of 3 experiments were combined, treatment 
with ceramide resulted in a small decrease in the number of colonies formed (from 
183±63(SD) to 160±63(SD)), but there was no protective effect when cells were treated 









Figure 3.8 T47-D Clonogenic survival assay of T47-D cells exposed to ceramide. 
T47-D cells were seeded into T25 flasks and serum starved for 24 hours. The cells were then 
exposed to various concentrations of ceramide 24 hours before being collected by gentle 
trypsinization and seeded onto agarose gels at a concentration of 500 cells per gel. The gels were 
then incubated for 14 days before they were stained with neutral red solution and the number of 
colonies counted. 
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Figure 3.9 Use of clonogenic survival assay to assess the effect of prolactin on survival of 
T47-D cells. 
T47-D cells were seeded into 725 flasks and starved of serum for 24 hours. The cells were then 
treated without or with 250ng%ml prolactin. for 1 hour before addition of 201AI eeramide for 24 
hours. The cells were then trypsinized and seeded into agarose gels and incubated for 14 days. 
The gels were then stained with neutral red and the number of colonies counted. The figure 
represents a typical experiment. This experiment was performed 3 limes in triplicate. 
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experiments, it is difficult to draw any firm conclusions about the effects of ceramide or 
prolactin on clonogenicity of T47-D cells. 
3_2 DISCUSSION 
The sphingomyelin (SM) pathway is part of the stress response system linking diverse 
environmental stresses (UV, heat shock, oxidative stress and ionizing radiation) to 
cellular effector pathways 225,226. The second messenger in this system is ceramide, 
generated by hydrolysis of SM through SM-specific phospholipases C termed 
2 n. Sphingomyelinases (Smases) or by de novo synthesis 
Ceramide generation occurs early and is not dependent on caspase activation229-131. Use 
of exogenous ceramide (either analogs or neutra1222,232.233) or Smase elevates intracellular 
ceramide levels and results in apoptosis22s, z26 
Extracellular agents and insults (such as TNF, Fas ligands and chemotherapeutic agents) 
can activate sphingomyelinsases, which act on membrane sphingomyelin resulting in the 
release of ceramide225. Inducers of ceramide generation include 1,25-dihydroxyvitamin 
D3, TNF-a, endotoxin, interferon-gamma, interleukin-1 (IL-1), FasL, dexamethasone, 
ionizing radiation, chemotherapeutic agents, heat and nerve growth factor (NGF)234. 
Breast cancer is the most common cancer affecting women in the world today, making up 
18% of all cancers detected in women. In the UK, it is the commonest cause of death in 
women in the 40-50 age groups. The incidence of breast cancer increases from the onset 
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of puberty, peaks just before the menopause and then declines thereafter 5. There also 
exists a distinct geographical distribution, where incidence rates in the West are greater 
than in the Far East235 
All breast cancers arise from the epithelial cells of the terminal duct lobular unit and are 
classified according to histological appearance. There are seven categories: mucoid, 
papillary, classical lobular, tubular, cribiform, medullary and NOS (not otherwise 
specified)236. As with all cancers, the aggressiveness of the cancer is classified into 
grades, which refer to the degree of differentiation of the cells, and stages - which refer 
to the tumour size, number, presence of spread, whether it affects only lymph nodes or 
has metastasized to other organs236 
Prolactin is a pleiotrophic neuroendocrine polypeptide hormone with many actions, the 
mechanisms of which are still poorly understood237. It is synthesized as a 23kD peptide 
by lactotrophs in the anterior pituitary gland and upon secretion into the blood stream acts 
as an endocrine factor on its target organs. It is best known for its actions on the 
mammary gland, being critical for its proper development and maturation238, i39. Whilst its 
mitogenic effect has long been accepted, it has only recently become known that 
prolactin may have a survival effect on certain cell types240, and possibly in breast cancer 
cells too219. Recent studies have shown that the hormone may be locally produced in 
tissues (breast epithelial cells and decidual cells of the bone or brain) outside the pituitary 
gland237. The best-characterized action of prolactin is on the mammary gland where it 
stimulates DNA synthesis, epithelial cell proliferation, and the promotion of milk 
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production241'242In other mammalian cell lines, STATS has been implicated in 
tumourigenesis 243,244 as well as cell survival245, za6 
The role of prolactin in breast cancer has always been controversial, but recent evidence 
has shown that it may play a more significant role than was previously believed. Thus, 
for example, prolactin antagonists have been shown to inhibit proliferation in breast 
cancer cells247. One recent report suggests that this inhibition may actually be due, in 
part, to the induction of apoptosis by prolactin antagonists219. 
Using morphological analysis, we found that in T47-D cells there was a clear protective 
effect of prolactin. In these cells (Fig. 3.2), the number of apoptotic cells detected 
decreased after treatment with prolactin (13%±5 (SD) to 4%±2 (SD), p value<0.05). 
Several problems were encountered in using morphological analysis as a method for 
quantifying apoptosis, however. First, there was some difficulty in identifying the 
apoptotic cells in ceramide-treated wells, apart from those cells at an advanced stage of 
apoptosis. The gradual change from viable to apoptotic status made it difficult to identify 
apoptotic cells with confidence, making assessment somewhat subjective, except where 
cells displayed the classical features of very densely staining nucleus with a very little 
cytoplasm. Moreover, if only apoptotic bodies were left, it was difficult to know if they 
arose from a single cell or from several. 
Second, the loss of cells during washing prior to fixation added to the problem as the 
cells that were lost were likely to be cells that were least viable. This may have led to a 
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bias during assessment under the microscope when only viable cells were seen and 
resulted in a contradictory decrease in the amount of apoptosis detected as the ceramide 
concentration increased. It would have been interesting to have collected these `floaters' 
and analysed them by fixing and staining with H&E to assess their morphology. 
Due to these difficulties, we investigated the possibility of using other methods to assess 
apoptosis. Cell cycle analysis of T47-D cells after treatment with ceramide did not result 
in an increase in the preGi population. Cells were arrested in the G2 phase, however, 
which has been reported previously when T47-D cells were exposed to various 
chemotherapeutic drugs248. 
When assessing the cell cycle profile to estimate the degree of apoptosis that occurs in a 
given cell population, there is the assumption that the cells undergo DNA degradation 
resulting in a decrease in the DNA content of the cell. One possible explanation for a lack 
of change in the pre-GI population in breast cancer cells could be that either ceramide- 
induced apoptosis did not result in DNA degradation or laddering during apoptosis, as 
has been observed by other groups with MCF-7 cells249'zso. 
Use of annexin-V binding to determine the extent of apoptosis in breast cancer cells was 
also rather unsatisfactory. While the number of viable cells was clearly decreased, the 
apoptotic population (cells stained only with annexin-V-FITC) remained consistently 
small, with the majority of non-viable cells being stained both by annexin and propidium 
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iodide. Measurement of live and dead cell populations did not show any protective effect 
of prolactin on apoptosis / cell death. 
The method of Annexin-V staining relies on the expression of phosphatidylserine on the 
outer leaflet of the cell membrane early in the apoptotic process, but with maintenance of 
cell membrane integrity, which is responsible for excluding propidium iodide from the 
cells. In breast cancer cells, either phosphatidylserine exposure does not occur early 
during apoptosis, or cell membrane integrity is lost early in the apoptotic process as very 
few cells were labeled with Annexin alone, and the majority of non-viable cells were 
labelled with both Annexin and propidium iodide. This double staining implies that the 
cells were necrotic or in late apoptosis. 
It is possible that trypsin-EDTA may have affected membrane integrity, allowing 
diffusion of propidium iodide into the cell, so resulting in the large fraction of apparently 
necrotic cells detected. Identification of optimal conditions for each experiment was the 
main obstacle in obtaining consisting results. It was necessary to use various doses of 
ceramide ranging from 20µM to 70µW during the course of these studies in an attempt to 
obtain consistent results. Finally, as can be seen in figure 3.5, when all the cell 
populations were added together, they fail to make up 100% of the cell population. This 
was because a significant proportion of the propidium iodide stain appeared to detect cell 
debris, and this population could not be excluded from the total cell count. 
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Thus, we were unable to detect clear evidence of apoptosis either by cell cycle analysis or 
by Annexin staining, two methods currently in use to assess the extent of apoptosis. This 
suggests that T47-D and MCF-7 cells may have an inherent inability to undergo DNA 
laddering or typical apoptosis. There is increasing evidence to show that different forms 
of apoptosis or programmed cell death exist251-2s3 Development of the `classical' features 
of apoptosis requires the participation of specific caspases as well as other enzymes83'249 
T47-D cells have a mutated form of the p53 gene' 75; 254 , which may account 
for their 
inability to undergo classical apoptosis. High levels of an oncoprotein MDM-2, a 
negative regulator of p53, have been found in both MCF-7 and T47-D cells lines248. 
MDM-2 functions by binding p53 and antagonizes its transcriptional activity, as well as 
promoting the degradation and nuclear export of the p53 protein248, and thus may 
contribute to the resistance to undergo apoptosis in these cell lines. A literature search 
revealed very few studies of apoptosis in T47-D cells, although detection of apoptosis in 
these cells by morphological analysis and flow cytometry using diverse apoptotic agents 
has been reported255-257 The extent of apoptosis induced in T47-D cells ranged from 
14%258, to 43%2ss This large increase detected using Annexin-V in the latter study, was 
in response to progesterone treatment. We did not wish to complicate our study by using 
a hormone to induce apoptosis, as there may be other pathways activated by progesterone 
which could interact with prolactin. Regarding the efficacy of a prolactin antagonist219 in 
inducing apoptosis, the authors reported a 3-to-15 fold induction of apoptosis in the cells 
by the antagonist, which was dose-dependent. Overall, there is agreement with our 
observations that the T47-D cell line is relatively resistant to apoptosis induced by a 
. variety of agents2sa, 
i59,2M 
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In addition to ceramide, we tried a variety of other cytotoxic/apoptotic agents (gamma 
irradiation, progesterone, taxol etc., results not shown), however, we were unable to 
detect any change in the preGi population or any increase in Annexin-V binding. 
As an alternative approach, we attempted to assess prolactin effects on clonogenic cells. 
First we used an indirect method of determining numbers of clonogenic cells by allowing 
cells to proliferate. After a period of proliferation, the number of T47-D cells was 
reduced from 10±4x104(SD) in controls to 5±2x104(SD) in cells after treatment with 
ceramide, but increased again to 7±2x104(SD) in cells treated with ceramide and 
prolactin (p<0.5) (Fig. 3.6b). 
These results show a clear protective effect of prolactin in T47-D cells. A potential 
criticism of these experiments could be that prolactin is simply stimulating proliferation. 
This seems unlikely, however, because there was no proliferative effect of prolactin in 
this experiment (10±4x104(SD) for control cells, versus 10±2x104(SD) for cells treated 
with prolactin). 
Similar results were obtained with the XTT assay (Fig. 3.7b), where there was an 
increase in optical density from 0.3±0.1(SD) in T47-D cells treated with ceramide alone 
to 0.4+0.1(SD) (p<0.05) when cells were treated with both ceramide and prolactin. 
Again, this indicates a protective effect conferred by the addition of prolactin. 
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Next, we assessed clonogenicity of T47-D cells directly by their ability to form colonies. 
Taking the mean of 4 separate experiments there was no clear protective effect of 
prolactin on the clonogenicity of T47-D cells (Fig. 3.9). Again, the extremely variable 
response to ceramide resulted in a much smaller effect of ceramide in these experiments 
than we predicted from the initial dose response (Fig. 3.8), making it difficult to assess 
any protective effect of prolactin. The apparent lack of protection by prolactin in this 
assay could result from the distance separating cells when they are suspended in agarose 
gels. We have recently found (Michael Norman, unpublished results) that the 
proliferative response to prolactin is strongly dependent on cell density. Thus, as 
clonogenic assays (Figs. 3.6 and 3.7) abolish cell-to-cell contact, this could account for 
the lack of survival benefit by the presence of prolactin. 
Should prolactin be confirmed as a survival factor, the implications could be far-reaching. 
Most breast tumours are capable of synthesizing and secreting prolactin211,261, and the 
prolactin receptor is found on most breast cancer cells 161-16'. Thus prolactin signalling 
may provide a mechanism for these cells to evade the apoptotic process. Conversely, 
antagonizing prolactin receptors in tumour cells, whilst simultaneously exposing the 
cancer to radio- or chemo-therapy, could increase the effciency of subsequent tumour 
kill, and thus increase the effectiveness of curent therapies. 
The results obtained by morphological assessment and the cell survival assays appear to 
confirm our hypothesis that prolactin can act as a survival factor in breast cancer cells. 
Other assays (cell cycle analysis, Annexin-V staining and colony formation in agarose 
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gels), however, do not support this hypothesis. A likely explanation for this discrepancy 
would be that the parameters under investigation in each assay were different, and 
ceramide could have distinct effects in each. The most obvious discrepancy lies between 
the morphological and growth studies (which show a protective effect of prolactin) and 
the Annexin-V staining (which does not show any protective effect by prolactin). It is 
possible that the `necrotic' population identified in the latter assay (Fig. 3.5) included 
cells which were still viable, and would have been able to recover subsequently had the 
assay been allowed to proceed for longer. 
Our difficulty in identifying `classical' signs of apoptosis such as Annexin staining in 
T47-D cells is not in keeping with available data, though there are very few papers 
regarding apoptosis in T47-D cells. Evidence from these publications255'258 suggests that 
T47-D cells can undergo apoptosis when treated with certain agents. It seems more 
likely, however, that differences in T47-D cells or other reagents (e. g. fetal calf serum or 
plastics) used in each laboratory will underlie variations in each response. 
One possible reason for the discrepancy in results between the cell survival assays and 
the clonogenic assay is that in the former, cells are more likely to remain in contact with 
each other. Thus it is possible that signalling initiated by prolactin is protective, but only 
under certain circumstances, perhaps requiring the presence of cell-to-cell interactions to 
be effective. Most of the results in this study only document small increases in cell 
survival. 
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4 Attempt to Create a Model for Dissecting the Contribution of the 
Jak2-STAT5 pathway to Apoptosis 
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Having obtained some evidence to support the hypothesis that prolactin enables breast 
cancer cells to survive the apoptotic insult of ceramide, we wished to investigate the 
signalling pathways underlying this mechanism. One of the major pathways activated by 
the prolactin receptor is the Jak2-STAT5 pathwa}2M. 
Based on previous work showing that it was possible to inhibit the apoptotic pathway 
when STAT5 is activated by a variety of cytokines246 65"268, we postulated that activation 
of the Jak-STAT pathway mediates the ability of prolactin to confer protection against 
apoptosis in breast cancer cells. 
The results in Chapter 3 showed that the amount of apoptosis detectable in breast cancer 
cells is both small and variable. Hence, due to the difficulties encountered in analyzing 
this pathway in breast cancer cells, we decided to create a model of apoptosis in an 
established cell line that could be used more easily to investigate the role of the Jak- 
STAT pathway. 
The CCRF-CEM cell line was established from a patient with acute lymphoblastic 
leukaemia. The CEM-C7 sub-clone of these cells could provide a useful test system for 
the analysis of apoptosis because these cells are particularly sensitive to glucocorticoid- 
induced apoptosis269, the extent of which is much greater than that detectable in breast 
cancer cells. Because no receptor capable of activating the Jak-STAT pathway has been 
identified in these cells, we decided to create clones stably expressing the prolactin 
receptor. 
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One advantage of transfecting CEM-C7 cells with the prolactin receptor would be that 
transfection of mutated receptors could be performed in the future for further dissection 
of the signalling pathways involved in any anti-apoptotic effects mediated by the 
receptor 
4.1 Results 
4.1.1 The Presence of Jak2 in CEM-C7 cells 
In order for the transfected prolactin receptor to be effective in activating signalling in 
CEM-C7 cells, the components of the Jak-STAT pathway have to be present. To confirm 
that Jak2 is expressed in CEM-C7 cells, 5x106 cells were lysed, and crude extract 
immunoprecipitated with anti-Jak2 antibody (New England Biolabs). After 
electrophoresis using a 12% acrylamide gel, a Western blot (Fig. 4.1) showed that Jak2 (- 
130 kDa) is indeed present in CEM-C7 cells. 
4.1.2 The Presence of STAT5 in CEM-C7 cells 
Evidence for expression of STAT5 in CEM-C7 cells has been obtained previously 
(personal communication by E. Brad Thompson). To confirm this finding, 3x106 cells 
were lysed and a cell extract was electrophoresed using a 12% acrylamide gel. As shown 
in Fig. 4.2, Western blotting with anti-STAT5 (C-17, Santa Cruz) confirmed the presence 




Figure 4.1 Expression of Jak2 tyrosine kinase in CEM-C7 cells. 
5x106 x cells were lysed and the crude extract immunoprecipitated with anti-Jak2 antibody (New 
England Biolabs). Western blotting was performed on immunoprecipitated extract using anti- 
Jak2 antibody. 
Crude 
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Figure 4.2 Expression of STATS in CEM-C7 cells. 
3x106 x cells were lysed and crude extract electrophoresed and transferred to nitrocellulose. The 
membrane was probed with anti-STAT5b (C-I7 antibody, Sigma) as the primary antibody and 
anti-rabbit IgG as the secondary antibody. 
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4.1 
.3 Construction of the pCMV-Fla Pr1R plasmid 
A plasmid encoding the full-length human prolactin receptor, tagged with a Flag epitope 
on the N -terminus, was available at the start of this study (constructed by Dr. Hayley 
Whittington). This sequence was present in a pAdlox vector which lacks a selection 
marker. The cDNA was therefore first transferred to a vector with an appropriate 
selection cassette. (See Fig. 4.3) 
4.1.3.1 Isolation of Flag-Pr/R from Plag-Pr1R pAdlox 
The Flag-Pr1R pAdlox plasmid (10µg) was digested with Sall (50units, at 37°C for 3 
hours), and dephosphorylated to prevent re-ligation. The linearized DNA was digested 
with EcoRI (50units, at 37°C for 3 hours), and the resultant Flag-Pr1R cDNA fragment 
isolated. 
4.1.3.2 Creation ofpCMV vector 
The EGFP sequence was removed from the pEGFP-Nl plasmid (Invitrogen, Netherlands) 
by a 2-stage restriction digest. 10µg of pEGFP-Nl was digested with Smal (50 units, at 
25°C for 2.5 hrs) and then with NotI (50 units, at 37°C for 2.5 hrs). Blunt ends were 
created (10 units Klenow enzyme, 151il Klenow buffer, Ild 10mM dNTPs and 33µl 
digested vector DNA, incubated together at 25°C for 1 hour). The resultant DNA was 
purified and re-ligated (10 units T4 ligase, 14°C overnight). 
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4.1.3.3 Insertion of FlagPrlR into pCMVplasmid 
The pCMV vector was linearized by XhoI (10units) and EcoRI (10units) digests and 
ligated to the F1agPr1R using T4 ligase. The resultant plasmid was isolated under UV 
visualization after agarose gel electrophoresis and purified by gel extraction. 
Competent E. coli cells were transformed using the new pCMV-FlagPrlR plasmid and 
mini preps made from the resultant colonies. DNA was extracted for an analytic 
restriction digest (using Dra I) to select colonies with the desired plasmid inserted in the 
correct orientation (Fig. 4.4a, lane 2,5,10,11, and 13). Positive plasmids would exhibit 4 
separate bands while plasmids containing the insert in the wrong orientation would only 
exhibit 2 bands. The positive plasmids were then subjected to another restriction digest 
(using Bgl II) to confirm that the cDNA was orientated correctly (Fig. 4.4b). Plasmids 
with correctly oriented inserts would only have a single Bg1II restriction digest site. 
4.1.4 Western Blot of HEK 293 cells Transfected with pCMV-FlagPrlR 
Prior to using pCMV-FlagPrlR to transfect CEM-C7 cells, Hek 293 cells were transfected 
to ensure that the FLAG epitope could be detected on an expressed protein of the 
appropriate size. 3x106 cells were transfected with pCMV-F1agPr1R (51Lg) using FuGENE 
6, and incubated for 48 hours to allow for protein expression. The transfected cells were 
lysed and the crude extract electrophoresed before analysis by Western blotting. As 
shown in Fig. 4.5 the anti-Flag M2 monoclonal antibody (Sigma) detected a protein of 




Figure 4.4 Selection of transformed E. coli containing correctly oriented Flag-PrIR plasmid. 
(a) Selection of E. coli colonies containing plasmids with the Flag-Pr1R in the correct orientation. 
Colonies of E. coli were chosen at random and mini preps of DNA made. The resultant plasmids 
obtained were subjected to diagnostic digest by Dra 1. 
(b) Confirmatory diagnostic digest ofplasmids, previously identified by Dra 1, using Bgl II. 
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4.1.5 The ability of pCMV-F1agPrlR to activate signalling 
To confirm that pCMV-FlagPrlR was able to activate STATS, 3x104 COST cells were 
plated onto 24 well plates and incubated overnight. Each well was then transfected using 
Fugene 6 with STAT5b (SOng), LHRE reporter (250ng) and one of the following: empty 
pCMV vector (100ng), pCMV-FlagPrlR (100ng), original vector containing the Flag- 
tagged receptor pAdlox-FlagPrIR (100ng), or wild type PrIR (100ng). The cells were 
incubated overnight and then serum starved for at least 6 hours before the addition of 
growth hormone (250ng/ml) for a further 18 hours. Cells were then lysed in 100µ1 of Cell 
Lysis Buffer (Promega), subjected to a freeze-thaw cycle and 501il of the lysate analysed 
in a luminometer (Dynex Revelation) for luciferase activity. 
Fig. 4.6 shows that whilst the re-constructed plasmid pCMV-FlagPrlR does activate 
signalling in response to prolactin stimulation, its activity is much less than that of the 
original pAdlox plasmid. One point to note is the very much higher baseline activity 
(-3000 RLU) of the both the pAdlox and the wild-type plasmids compared to pCMV- 
FlagPr1R (-50 RLU). This could be due to an inadvertent mutation introduced into the 
sequence, resulting in decreased expression. 
COS-7 cells (5x106 in 60mm dishes) were transfected with either 2µg of pCMV-F1agPr1R 
or pAdloxFlagPrlR. Following a 24 hour incubation, the cells were lysed and the crude 
extract electrophoresed. Fig. 4.7 shows that the expression of pCMV-FlagPrlR is 
markedly lower than that of pAdloxFlagPrlR, providing an explanation for the 




Figure 4.5 Detection of pCMV-FlagPrlR expression in HEK293 cells. 
3x106 cells were lysed. The crude extract was electrophoresed and transferred to a nitrocellulose 
membrane which was probed with anti-FlagM2 antibody (Sigma) as the primary antibody and 










Figure 4.6 Signalling activity of the prolactin receptor expressed by different plasmids in 
COS-7 cells. 
COS-7 cells were transfected with the LHRF, reporter and either p(. MV (control plasmid), 
pCMV-rlagPruR(TP) (test plasmid), pAdlox-FlagPrlR (original Flag-tagged receptor) or wt- 
PrIR (wild type Pr1R plasmid). the cells were serum-starved for 6hrs hefore exposure to 250ng 
growth hormone (GH) or vehicle for 18 hours. This experiment was performed using the human 
growth hormone (GH) as an alternative since prolactin was not available at the time. 
101 
pCMV pCMV-FP pAdlox FP wt PrIR 
Ctrl pAdloxFP pCMV-FP 
-90kDa -o. 
490 ow-1111M 
Figure 4.7 Expression of pCMV-FlagPrlR and pAdlox-FlagPrlR plasmids in COS-7 cells. 
COS- 7 cells were transfected with either pCMV-F1agPrIR or pAdlox-FlagPrlR. The cells were 
lysed and crude extracts were electrophoresed. Western blotting was performed using the anti- 
FlagM2 antibody. 
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In view of the discrepancy in both the signalling ability and protein expression of the 
pCMV-FlagPrlR plasmid compared to the pAdlox- FlagPrlR plasmid, it was decided that 
co-transfection of the original pAdlox-FlagPrlR with a vector containing a selection 
cassette was preferable to using the pCMV-FlagPrlR plasmid. The pcDNA3 (Invitrogen) 
commercial vector was chosen for this purpose as it contains a G418 resistance cassette. 
4.1.6 Cloning of CEM-C7 cells 
With time in culture, CEM-C7 dexamethasone-resistant cells accumulate270. The 
explanation for this instability is that, having only one functional allele coding for the 
glucocorticoid receptor, CEM-C7 cells resistant to dexametliasone accumulate rapidly as 
a result of spontaneous mutations in the remaining allele271. Thus, it was imperative to 
select clones sensitive to both dexamethasone, which induces apoptosis, and G418, - 
which would be used to select positive clones. Fig. 4.8 (top) shows an initial experiment 
to determine the G418 sensitivity of uncloned cells. 
4.1.6.1 Selection of CEM-C7 clones sensitive to dexamethasone 
To select glucocorticoid sensitive clones, CEM-C7 cells were cloned by serial dilution 
and the clones recovered were tested for dexamethasone sensitivity. Fig. 4.8 (middle) 
shows the response of the various clones to incubation with dexamethasone (1µM) for 48 
hours. Cell viability was analysed using the XTT assay. 
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4.1.6.2 Sensitivity of CL'M-C7 clones to G418 
The CEM-C7 clones obtained by serial dilution were then tested for G418 sensitivity. 
Fig. 4.8(bottom) shows the effect of exposure to G418 for 72 hours on cell viability, 
analysed by the XTT assay. 
Clones: 21D, 31E, 42G, 59E and 112B were selected for further study as they were 
sensitive to both dexamethasone and G418. 
4.1.6.3 Transfection of CEM-C7.21D cells with pEGFP-N1 
The CEM-C7 cell line is difficult to transfect, though most success has been achieved 
using electroporation272'273. In initial experiments designed to establish conditions for 
effective transfection of CEM cells, a commercial vector expressing the enhanced green 
fluorescent protein (EGFP), pEGFP-Nl (Clontech), was used. Cells were electroporated 
with varying amounts of DNA (15-451. Lg) at 10501F and 300V. Using this protocol and 
40µg of DNA, we were able to transfect about 2% of clone 21D, with the EGFP plasmid 
(Fig. 4.9) as detected by fluorescent microscopy. With the other concentrations of DNA 
used (10,20 and 30µg), however, no fluorescent cells were detected. The other clones 
(31E, 42G, 59E and 112B) selected for sensitivity to dexamethasone and G418 were also 
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Figure 4.9 Transfection of CEM-C7 clones with EGFP-N1 by electroporation. 
6x106 CEM-C7 cells were electroporated with varying concentrations of EGFP-NI plasmid. The 
cells were incubated for 48 hours post transfection to allow for protein expression and the cells 
screened by fluorescent microscopy. The figure shows results obtained with clone 211) 
transfected with 40, ug of DNA. 
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4.1.7 Attempt to isolate CEM-C7 cells stably expressing the Prolactin Receptor 
CEM-C7.21D cells were initially electroporated with 40µg of pAdlox-FlagPrIR and 
pcDNA3.1 (80µg DNA in total), but no viable cells were obtained from this transfection. 
Since the concentration of DNA may have been toxic for the cells, CEM-C7.21D cells 
were next electroporated with 20µg of pAdlox-FlagPr1R and 20µg of pcDNA3.1 
(1050µF, 300V) (401tg of DNA in total). Cells were transferred immediately to RPMI- 
1640 medium that had previously been placed in a T25 flask, and incubated at 37°C in 
5% CO2. 
Following electroporation, cells were allowed to recover over 48 hours before they were 
placed in medium containing G418 (800µg/ml) to begin the selection process. This 
selection condition was maintained for 2 weeks, aller which the concentration of G418 
was decreased to 400pg/ml. Once cell numbers had recovered sufficiently, clones were 
obtained by serial dilution and then re-cloned in agarose gels. 
4.1.8 Attempt to Detect Fla tagged Prolactin Receptor in CEM-C7 cells 
4.1.8.1 Detection of FlagPrlR by Western Blotting 
A total of 25 clones were isolated after G418 selection. To test for PrIR expression, 5x106 
cells were collected from each clone and lysed. Mouse monoclonal anti-Flag M2 
antibody (Sigma) was used for immunoprecipitation and precipitates were 
electrophoresed on an SDS-Page gel. Separated proteins were then transferred to an 
Immobilon membrane by semi-dry transfer and the membrane probed using anti-Flag M2 
as the primary antibody and an anti-mouse antibody conjugated with horseradish 
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peroxidase (Amersham Pharmacia) as the secondary antibody. Fig. 4.10 shows a Western 
blot of the various clones obtained, none of which expressed a detectable Flag-tagged 
protein. 
Our inability to detect Flag-tagged protein could have been due to failure of protein 
expression, or failure to stably incorporate the prolactin receptor cDNA into genomic 
DNA. We decided to investigate this further by performing a PCR reaction on genomic 
DNA extracted from the clones to screen for incorporation of the Pr1R cDNA. 
4.1.8.2 Detection of Flag-PrIR by Polymerase Chain Reaction 
Genomic DNA from 5x106 cells of each clonal population was extracted. Then Ing of 
dsDNA was used as a template for a PCR reaction with primers specific for the prolactin 
receptor. Primers were complementary to different exons, so minimizing the risk of 
amplifying sequences from the CEM-C7 prolactin receptor gene. 
The primers used were: 
Forward: CTGTGGATTAAATGGTCTCC 
Reverse: TGCAGGTCACCATGCTATA 
The forward primer is complementary to a sequence in exon 8 and the reverse primer 
corresponds to a sequence in exon 10. 
The PCR reaction consisted of an initial dissociation period (94°C, 2 min), 40 cycles of 
dissociation (94°C, 30s), annealing (62°C, 1 min), and extension (68°C, 1 min), and a 
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final extension period (68°C, 7 min). Positive clones should allow amplification of a 
360bp fragment, and Fig. 4.11 shows that a number of clones (1,3 and 6) had 
incorporated the Flag-tagged prolactin receptor cDNA into their genome. 
4.1.8.3 Detection of'Flag-PrIR by STAT5 activation 
As we were unable to detect the Flag-PrIR by Western blotting, while PCR demonstrated 
that the Flag-tagged Pr1R cDNA had incorporated into the genomic DNA, we decided to 
test for Pr1R expression by detection of STAT5 activation. 
CEM-C7 clones (1x106) were serum starved for 24 hours, and then exposed to 250ng/ml 
prolactin for 30 min. The cells were then lysed and the crude extract subjected to 
electrophoresis. A Western blot was performed using the anti-STAT5b (C-17) antibody 
(Sigma). Fig. 4.12 shows that no activation of the STATS protein by prolactin could be 
detected (usually detected by a band shift as a result of phosphorylation of the STATS 
protein, thus activated STATS runs at a higher molecular weight compared to inactive 
STAT5), showing that despite incorporation of the Flag-Pr1R cDNA into the genome of 
the CEM-C7 cells, it was not being expressed at a sufficiently high level for detection of 
activation of signalling pathways. Unfortunately, clones 4 and 5 had a very poor STATS 
yield, hence the faint bands detected in the blot. 
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Figure 4.10 Attempt to Detect Flag-PrIR in CEM-C7 clones. 
89 Ctrl 
3x106 cells from each stable CEM-C7 clone were lysed and crude extracts immunoprecipitated 
with the anti-FlagM2 antibody (Sigma). Western blot was performed with anti-FlagM2 antibody 
(Sigma). The control lane contains crude extract from COS-7 cells transfected with pAdlox- 
FlagPrlR. 
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Figure 4.11 Detection of prolactin receptor cDNA in CEM-C7 clones by polymerase chain 
reaction. 
Genomic DNA was extracted from CEM-C7 clones and subjected to polymerase chain reaction. 
The PCR products were electrophoresed on an agarose gel and three clones (1,3 and 6) positive 
for the prolactin receptor were identified (Positive control (+ve) was the product from PCR of 






Figure 4.12 Attempt to detect presence of Flag-tagged PrlR by activation of the STAT5 
protein. 
CEM-C7 cells have no known receptor for the activation of STAT5, thus any activation detected 
can be attributed to a stably incorporated Flag-Pr1R. Clones (3x106) were serum starved for 24 
hours prior to treatment without or with 250ng/ml Prl for 30 min. The cells were then lysed and 




The biological activities of prolactin are manifested through a specific membrane 
receptor - the prolactin receptor (PRLR). The PRLR is part of the cytokine 
haematopoietic superfamily of receptors, which includes the growth hormone (GH), 
erythropoietin and IL-2 receptors274. Members of this family are single membrane 
spanning receptors organized into three domains: an extracellular ligand binding domain, 
a hydrophobic transmembrane domain and an intracellular signaling domain containing a 
proline rich motif 17. 
Different forms of the receptor exist. A long (90kDa) and a short (40kDa) form - each 
generated by differential splicing of a single gene, differing only in the length of the 
cytoplasmic domain 275. The intermediate form is a deletion mutant of the long form 
which in the rat lacks 198 amino acids in its cytoplasmic region. This is the form found in 
rat Nb2 lymphoma cells and is the most responsive to prolactin276. There is also evidence 
for the presence of this form in some human breast cancers211. Both the long and 
intermediate forms transduce a differentiation signal as measured by induction of milk 
protein expression277, and all three promote mitosis278'279. 
4: 2.1 Signalling Pathways for Prolactin 
When prolactin associates with its receptor, it induces sequential receptor dimerization 
with the active complex involving one prolactin molecule bound to two receptor 
molecules237'264'M, resulting in a cascade of intracellular events. In mammary epithelial 
cells, prolactin has been shown to activate several signaling pathways (Jak-STAT 
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pathway281, Ras-MAP pathway282, PI-3 kinase pathway, PKC pathway237 and the FAK- 
paxillin pathway283) which are likely to contribute to the different responses e. g. 
proliferation, apoptosis or differentiation. 
4.2.2 The JAK/STAT Pathway 
The prolactin receptor does not have its own kinase activity and thus has to recruit other 
kinases in order to transduce intracellular signals. Jak2, a member of the Janus family of 
kinases, is constitutively associated with the prolactin receptor and undergoes 
phosphorylation when prolactin binds 284 . The Jak2 
kinase is transphosphorylated and 
activated as a result of receptor dimerization285. Once activated, Jak2 then phosphorylates 
tyrosine residues of the PRLR cytoplasmic domain286. The phosphorylated tyrosine 
residues serve as docking sites for the -SH2 domains of STAT5 proteins, bringing 
STAT5 protein into close proximity with Jak2. STAT5 is then activated by 
phosphorylation by Jak2, released from the receptor, undergoing homodimerization 
before translocation to the nucleus where STAT5 dimers regulate transcription of their 
target genes287 (Fig. 4.13). Two isoforms of STATS have been identified, STAT-5a and 
STAT-5b288. In mouse models, STAT-5a is required for full lobuloalveolar 
development289. 
We wished to investigate further the possible role of the Jak2/STAT5 pathway in survival 
signalling that had been studied in the previous chapter using breast cancer cells. The 
small and variable amount of apoptosis detectable in these cells led us to consider 
investigating this effect in another cell line where apoptosis could be more readily 
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induced and detected. The CEM-C7 cell line was selected because these cells apoptose 
readily when exposed to dexamethasone. We first confirmed that the components of the 
Jak2/STATS pathway were present in these cells (Figs. 4.1 & 4.2). Then, to provide a 
means for activating the Jak2/STATS pathway in these cells, we proceeded to create 
clones stably expressing the prolactin receptor. 
For these studies, a plasmid containing the Flag-tagged prolactin receptor and a selection 
cassette was first created (Fig. 4.3). Luciferase reporter assays showed that while the 
newly constructed plasmid did respond to prolactin stimulation, it appeared to have 
decreased signalling ability (Fig. 4.6), and to be expressed at much lower levels 
compared to the original pAdlox-FlagPrlR plasmid (Fig. 4.7), even though the Flag- 
tagged receptor was detectable on a Western blot. 
Disappointingly, the pCMV-FlagPrIR plasmid created did not appear to be expressed as 
efficiently as the original pAdlox-FlagPrlR plasmid. When transfected into HEK-293 
cells, the protein is detectable by its Flag-tag on western blots, and runs at the correct 
molecular weight (Fig. 4.5). The pCMV-FlagPrlR, pAdlox-F1agPrlR, and the wild type 
Pr1R all contain the CMV promoter driving transcription, thus transcription rates of these 
plasmids in the COS-7 cells should be similar. It may be, therefore, that a mutation which 







Figure 4.13 The JAK/STAT Signalling Pathway activated by the prolactin receptor (based 
on Bole-Feysot et al 1998237). 
Binding ofprolactin induces dimerization of the receptors. Constitutively associated Jak2 kinases 
are activated and induce tyrosine phosphorylation of tyrosine residues on the cytoplasmic tail of 
the receptor, which act as a docking site for STAT5 protein via the SH2 domains. STA T5 then 
undergoes transphosphorylation by JAK2 and activated STA75 is released into the cytoplasm. 
Activated STAT5 homodimerizes, translocates to the nucleus where it binds DNA and regulates 
target gene trasneription29. 
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We decided that it was more prudent to avoid the possibility of using a receptor that 
might not signal efficiently. Instead, CEM-C7 cells were co-transfected with the original 
pAdlox vector expressing the Flag-tagged PrIR and a commercial vector - pcDNA3 
(Invitrogen) - which included a selection cassette. 
Lymphoid cells are notoriously difficult to transfect. Probably the most efficient method 
of transfecting these cells is by electroporation and several groups have succeeded in 
transfecting CEM-C7 cells by this method 273,291 . Other methods 
have been used with 
lymphoid cells, such as antibody-linked polyethyleneimine, which has been successfully 
used in Jurkat cells292'293. We tested this method of transfection using a commercial kit 
(ExGen500) that has become available recently, but with little success (data not shown). 
Other means of transfection, such as Fugene6, were also unsuccessful. 
Successful transfection of the CEM-C7 cells was achieved, at low efficiency, using 
electroporation. Of the G418 sensitive clones tested, clear evidence of transfection was 
obtained with only one clone (CEM-C7.2 1D) (Fig. 4.9), and all subsequent transfections 
were performed with this clone of CEM-C7 cells. 
Two separate attempts were made at transfecting the CEM-C7.21D cells with Flag- 
tagged prolactin receptor, but we were unable to isolate a single clone in which the Flag- 
tagged protein was detectable on Western blotting. We also attempted to detect cell 
surface expression using the anti-FlagM2 antibody linked to fluoroscein isothiocynate 
(FITC) (Sigma), but again no clones were detected using this antibody (data not shown). 
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Evidence from PCR analysis (Fig. 4.11) showed that 12 clones had incorporated the 
plasmid into their genome, even though the protein did not appear to be expressed, which 
was consistent with the failure to activate STAT5 by prolactin (Fig. 4.12). It is possible 
that receptor number on the cell surface was too low for the Flag-signal to be detected, 
though this should still have resulted in STAT5 activation. 
Failure to detect expression of the Flag-tagged receptor could result from defects in 
transcription of cDNA into mRNA, translation of the mRNA into the desired protein, or 
expression of the protein at the cell surface. The CEM-C7 cell line is an immortalized cell 
line and in the course of its development may have lost certain functions that are present 
in normal lymphoid cells. Alternatively, it is conceivable that some factor(s) could be 
present in these cells that block transcription of the gene or destabilize the mRNA. At the 
level of transcription, the cDNA could have been incorporated into a region of the 
genome that was `silent', and thus be unable to recruit the DNA transcription machinery. 
Another possibility is that by some mischance, all the plasmids that incorporated stably 
into the host genome were not intact or complete (e. g. linearization of the plasmid could 
have resulted in cleavage of the cDNA sequence), and thus when transcribed, did not give 
rise to an intact protein. 
Another possible explanation for the failure to detect Flag-tagged prolactin receptor could 
be that there was insufficient Jak2 in CEM-C7 cells. Lodish et a129° showed that surface 
expression of the erythropoietin receptor (EpoR) depends on the presence of Jak2. As the 
prolactin receptor is closely related to the EpoR, the extent to which it is expressed on the 
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cell surface may also be dependent on the amount of Jak2, and if other cytokine receptors 
had sequestered all the available Jak2, this may have affected surface expression of the 
transfected prolactin receptor. If the time had been available, we would have attempted to 
co-transfect cells with Jak2 cDNA, together with pAdloxFP and pcDNA3, to determine 
whether this would enhance expression of the prolactin receptor. 
Activation of STATs has been observed in many tumours295"297, and activation of the 
Jak/STAT pathway has been shown to promote survival pathways268'298. Moreover it has 
been shown that oncogenic activation of STAT, (e. g c-Src or Abl) is sufficient to induce 
cells to undergo transformation29', 300. The creation of a cell line where apoptosis could 
have been inhibited by activation of the Jak/STAT pathway would have been a very 
useful model to investigate the role of interactions between signalling pathways and other 
factors involved in deciding whether cells survive apoptotic insults. 
Unfortunately, it appears that either (a) by chance, none of those stable cell lines that 
incorporated cDNA did so in a manner that allowed protein expression, or (b) CEM-C7 
cells possess some property that prevents expression of the prolactin receptor. If (a) is 
true, it should be possible to derive a clone stably expressing the PRLR by continuing the 
study. However, due to time constraints, we did not feel that it would be profitable to 
continue these studies. 
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5 Creation of Stable Breast Cancer Cell Lines Overexpressing STAT5 
119 
5_1 Overexnression of STATS in T47-D and MCF-7 breast cancer cell lines 
Two closely related transcription factors, STAT5a and STAT5b, mediate signalling by 
the prolactin receptor. Both are actively involved in organ development and maturation; 
functions which have been definitively demonstrated by gene knockout studies301. 
STAT5a-knockout mice exhibit defective development of the mammary gland, and 
impaired lactation when the mice are pregnant302. The phenotype displayed is similar to 
that of prolactin receptor knockouts -303. Mice that are STAT5b -/- display a phenotype 
similar to that induced by a defective growth hormone receptor304. Mice lacking both 
STAT5a and STATSb are infertile, and also have defective immune functions305 
A role for STATS in cell cycle progression and survival has begun to emerge, and a 
number of target genes have been identified, including cyclin-dependent kinases (cdks), 
G1 cyclins, and cdk inhibitors306'307. Several studies have provided strong evidence that 
STAT5 is involved in anti-apoptotic signalling in haematopoietic celIS246 '268,308, and 
STAT5 has also been shown to induce Bcl-XL and Bcl-2 proteins, both of which are anti- 
apoptotic268,309"312. Likewise, constitutive STAT activation has been documented in many 
malignancies, mostly as a consequence of upstream oncogene activation - e. g. STATS in 
lymphoproliferative disorders activated by BCR"Ab1243'313 and STATs 1,3, and 5 are 
activated in mammary / lung tumours314,315 
Based on the above findings, we hypothesized that activation of STAT5 by the prolactin 
receptor could also be involved in anti-apoptotic signalling in breast cancer cells. To test 
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this hypothesis, we decided to overexpress STAT5a and STAT5b in breast cancer cells to 
determine whether or not the survival effect of prölactin could be enhanced. 
5_2 RESULTS 
5.2.1 Transient Overexpression of STAT5b in T47-D and MCF-7 Breast Cancer Cells 
This experiment was performed to ensure that endogenous STATS is not already present 
in sufficient quantity to provide a maximal signal in T47-D or MCF-7 cells. Thus 3x104 
cells (per well) were plated out in 48-well plates and incubated overnight. The cells were 
transfected with LHRE reporter (200ng) and either 200ng pcDNA (empty plasmid for 
control) or 200ng STAT5b expression vector using FuGENE 6. The cells were incubated 
for 24 hours to allow for gene expression, and serum starved for 6 hours before the 
addition of 2SOng/ml prolactin for a further 18 hours. Luciferase activity in cell lysates 
was then measured using a Dynex luminometer. 
From Fig. 5.1, it can be seen that overexpression of STATSb in T47-D cells results in a 
marked increase in activation of the LHRE STAT5 reporter gene (from 130±9(SD) to 
790±118(SD) arbitrary units, p value<0.05) in the presence of prolactin. In MCF-7 cells, 
there was also a clear increase (from 216±27(SD) to 749±39(SD), p<0.05), though less 
than that seen with T47-D cells. Interestingly, in the MCF-7 cells, the basal activity 
(216±27(SD) without prolactin stimulation) of the LHRE reporter is very much higher 
than that observed in the T47-D cells (130+9(SD)). 
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5.2.2 Creation of Breast Cancer Cell Lines Stably Overexpressing STAT5 
Since transient transfection with STAT5 increased the signalling activity of the LHRE 
reporter, we decided to create breast cancer cell lines stably overexpressing either 
STAT5a or STAT5b to assess the effect of increased levels of activated STATS on 
proliferation and survival in response to prolactin. We initially transfected the breast 
cancer cells with the HA-STAT5b plasmid as we have had previous experience working 
with this construct, and have detected it on Western blotting both in crude extracts and by 
immunoprecipitation. 
T47-D and MCF-7 cells (5x105) were plated onto 6-well plates and incubated overnight. 
The cells were co-transfected with 1µg HA-tagged STATSb plasmid and 1µg pcDNA3.1 
plasmid, which provided the selection marker, using Fugene 6 as the transfection agent. 
The cells were incubated for 48 hours to allow for gene expression before the medium 
was replaced with medium supplemented with G418 (1200gg/ml) to select transfected 
cells that had stably incorporated the pcDNA3.1 plasmid. The cells were maintained in 
this medium for 2 weeks, when the G418 concentration was decreased to 400pg/ml. 
Following the selection of resistant cells by G418, STAT5b-transfected cells were 
serially diluted and seeded into 96-well plates to obtain monoclonal populations of cells. 
Cells were incubated for 2 weeks and colonies transferred to T25 flasks, with 400pg/m1 
G418 to provide a selection pressure. A total of 13 colonies were derived from the MCF- 
7 line and 9 colonies from the T47-D line. 
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Figure 5.1 Enhanced activation of a STATS reporter by prolactin in T-47D and MCF-7 cells 
transiently overexpressing STATSb. 
T-47D or MCF-7 cells were co-lransfected with LHRE reporter plasmid (200ng) and either 
pcDNA3.1 (control vector, 200ng) or S1AT5b plasmid (200ng). 24 hours post transfection, cells 




5.2.3 Detection of Transfected STAT5b in Breast Cancer Cells by Western Blotting 
In order to detect the presence of the HA tag linked to STAT5b in colonies that 'had 
stably incorporated STAT5 cDNA, 5x106 cells from each clone were collected and lysed 
in 5O00 SLB. 400 of the crude lysate was denatured with 2xSSB and electrophoresed 
on an 8% SDS-PAGE gel. The rest of the lysate was immunoprecipitated with an anti- 
HA mouse monoclonal antibody (Sigma) (1: 1000) and immunoprecipitated proteins 
electrophoresed on an 8% SDS-PAGE gel. 
The separated proteins were semi-dry transferred to Immobilon-P membrane and the 
presence of immuno-precipitated HA-STAT5b detected using anti-STAT5b antibody C- 
17 (Santa Cruz) at a dilution of 1: 2000. Goat anti-mouse antibody at a dilution of 
1: 10,000 was used as a secondary antibody. The blot was developed using the enhanced 
chemiluminescence (ECL) kit from Amersham. Using this method, two clones expressing 
the HA tag were detected - one T47-D clone, designated T47-D. st5bl, and one MCF-7 
clone, designated MCF-7. st5bI (see Fig. 5.2). Comparing the two clones, there appears to 
be a greater expression of STAT5b in the T47-D clone, T. st5bl, compared to the MCF-7 
clone, M. st5bl. 
5.2.4 Effect of Stable STAT5b Expression on Signalling Activity 
To determine whether stable incorporation of STAT5b increased prolactin signalling 
activity via the STAT5 pathway, activation of transiently expressed LITRE reporter in 
- response to prolactin was assessed. 
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Each clone was seeded in a 24-well plate (5x104 cells in I ml) and incubated overnight. 
Cells were transfected with 200ng of LHRE reporter using Fugene 6 and incubated 
overnight. The cells were then serum-starved for at least 6 hours before treatment with or 
without 250ng/ml prolactin for 18 hours. The cells were then lysed and luciferase activity 
measured using the Dynex luminometer. 
As shown in Fig. 5.3, both clones with stably incorporated STAT5b cDNA show 
increased activation of the LHRE STAT5 reporter gene compared to the untransfected 
parent cell lines. In the parent T47-D cells, luciferase activity increased from 5±3(SD) to 
14±3(SD) (p<0.05). In clone T. st5bl, luciferase activity increased from 6±3(SD) to 
314±71(SD) (p< 0.05). 
In the MCF-7 untransfected parent line, there was only a very small increase in luciferase 
activity when cells were stimulated with prolactin (from 552+113(SD) to 680+56(SD), 
not significant), which was not unexpected due to the low level of prolactin receptor 
expressed by these cells. The MCF-7 clone stably expressing STAT5b (M. st5bl), on the 
other hand, showed a small increase in luciferase activity when stimulated with prolactin 
(423±64(SD) to 743+168(SD), p<0.05)), though this effect was largely due to a decrease 
in basal activity. Again, it should be noted that, compared to T47-D cells, the basal level 






Figure 5.2 Detection of HA-STATSb in T47-D and MCF-7 clones by Western blotting. 
5x106 cells from each clone were lysed, and the crude extract was immunoprecipitated with the 
anti-HA antibody, and the proteins separated by electrophoresis. This blot was then probed with 
anti-STAT5b antibody (C-17, Sigma). Positive (f ve) and negative (-ve) controls are crude 
















Figure 5.3 Effect of stable overexpression of STATSb on the ability of prolactin to activate 
the LHRE reporter. 
Parental 1.7-D and MCI -7 cells, together with clones urerexpressing SJA15h, were seeded in 
complete medium and incubated overnight. Me cells were then tran. sfected with the LHRIs 
reporter and incubated for 24 hours before being serum starved for 6 hours. Finally, cells were 
incubated in the absence or presence of 250ng prolac tin for afurther 18 
hours. The results shown 
are from a typical experiment, which gave similar results on four separate occasions. 
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5.2.5 Effect of STAT5b Overexpression on the Proliferative Response to Prolactin 
5.2.5.1 Proliferative response to Prolactin Measured Using Cell Counting 
MCF-7 and T47-D cells (lml at 5x104 cells per ml) were seeded in 24-well plates. The 
cells were incubated overnight before they were washed and serum starved in SFM for 24 
hours before exposure to 250ng/ml of prolactin. After incubation for 4-5 days, cell 
number was determined by cell counting (Coulter Counter). 
Fig. 5.4 shows that while there is a modest increase in proliferation rate in the 
untransfected parent T47-D cells [(43±19(SD)x104 to 50±2(SD)xl04) cells per well], 
prolactin actually inhibits proliferation of the T. st5b1 clone. As expected, there is 
minimal effect of prolactin on the proliferative rate of MCF-7 cells, which may reflect the 
lower number of prolactin receptors in these cells. Neither was there any proliferative 
effect of prolactin on the M. st5b1 clone. This experiment was performed 4 times and a 
typical set of results is shown. From the graph, it can be seen that while the parent T47-D 
cell line exhibits a mild proliferative effect in response to prolactin, neither the 
untransfected MCF-7 parent line or either of the STATSb clones showed any increase in 
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Figure 5.4 Proliferation of clones stably expressing STAT5b as assessed by cell counting. 
Cells from the S1: 415b clones and both untransfecled T47-D and M('F-7 parent lines were serum 
starved for 24 hrs before exposure to Ong or 250ng of prolactin fr 5 days. ('ells were then 
harvested and counted on the Coulter Counter to assess proliferation. This figure is a typical 
experiment, which was performed on 4 separate occasions. 
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5.2.5.2 Proliferative response to Prolactin Measured by [3H]-Thymidine Incorporation. 
As an alternative measure of proliferative responses, thymidine incorporation was 
measured. 1x105 cells were seeded in l00µl in each well of a 96-well plate in 1%CSS and 
incubated overnight. The cells were then exposed to 250ng/ml prolactin for 18 hours 
before 12.5nCi of [3H]thymidine (in 20µl of 1 %CSS) was added to each well. The cells 
were incubated for a further 6 hours before the medium was discarded and l00µ1 of 
trypsin-EDTA added to each well for 30 minutes at 37°C. The plates were frozen at - 
20°C for at least 3 hours before harvesting of cells onto a filter mat. Activity was 
measured using a ß-microplate reader (Wallac software). 
Fig. 5.5 shows that prolactin increases [3H] thymidine incorporation in the untransfected 
T47-D cells by -36% (from 11190+850(SD) to 16640+1330(SD) p<0.05). In agreement 
with results obtained with cell counting, (Fig. 5.4) prolactin did not result in a significant 
increase in thymidine incorporation in the T. st5bl clone. Again, no response was 
detected in the MCF-7 parent line, or in its derivative, M. st5bl. 
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Figure 5.5 Effect of overexpressed STAT5b on 13HI thymidine incorporation in response to 
prolactin stimulation. 
T47-D, MC: F-7, T. st5bI and M. st5bI cells were seeded in I%C ASS and incubated overnight. Ihey 
were then exposed to Ong or 250ng of prolactin for I8hrs he/ore the addition of 13H/ thymidine. 
Thymidine incorporation was allowed to continue for 6 hours, after which cells were lvsed, 
harvested and the radioactivity measured on a ß-microplate reader. This experiment was 
performed 3 times and the figure shows the results from a typical experiment. 
131 
T-47D T. st5bl MCF-7 M. st5bl 
5.2.6 Does STAT5b Protect Breast Cancer cells against Apoptosis? 
5.2.6.1 Survival Assay of STAT5b Clones assessed by Cell Counting. 
MCF-7 or T47-D cells and their clones (5x104 per ml) were seeded into 24-well plates 
and incubated overnight. The cells were gently washed with SFM and then serum starved 
in SFM for 24 hours. After incubation in the presence or absence of 250ng/ml prolactin 
for 1 hour, cells were incubated with 40µM ceramide for 24 hours before FCS (10% v/v) 
was added. The cells were then allowed to proliferate for 4-5 days before being harvested 
by gentle trypsinization and cell number assessed using the Coulter Counter. 
From Fig. 5.6, it can be seen that the presence of overexpressed STAT5b in either the 
T47-D or the MCF-7 cell lines does not confer a survival advantage in ceramide-induced 
cytotoxicity. In fact, contrary to expectations, there appears to be a survival disadvantage, 
in the T47-D STATSb overexpressing clone, T. St5bl. In the untransfected T47-D parent 
cells, treatment with ceramide decreases the cell population (from 78±2(SD)xl04 to 
17+1(SD)x104, -21% of the untreated population) while in the STAT5b clone, the cell 
number decreases from 67+7(SD)x104 to 7+1(SD)x104 (-10% of the untreated 
population), a greater loss in cell number than that in the untransfected cells (p<0.005). 
Moreover, in the STAT5b over-expressing cells exposed to both ceramide and prolactin, 
the cell number decreases further to 5+1(SD)x104 (-8% of the untreated population). 
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Figure 5.6 Effect of prolactin on survival of STATSb expressing clones following ceramide 
exposure, assessed by cell counting. 
T-47D, MCF-7, T. st5bl or M. s(5bl cells were serum starved for 24 hrs before exposure to the 
absence or presence of 250ngýml prolactin for I hr. The cells were then exposed to OpM or 3O M 
ceramide for 24 hrs prior to being 'rescued' by IO%FCS (vv 1). The cells were allowed to 
proliferate for 4-5 days before they were trypsinized and the cell number counted by the Coulter 
counter. This experiment was performed 3 times, and the results shown are from a typical 
experiment. 
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5.2.7 Survival Assay of STAT5b Clones assessed by XTT assay 
1x104 MCF-7 or T47-D cells were plated into 96-well plates and incubated overnight. 
The cells were washed with SFM, and serum starved in SFM for a further 24 hours. Next, 
the cells were incubated in the absence or presence of 250ng prolactin for 1 hour before 
the addition of 40µM ceramide (Sigma). After 24 hours, FCS (10% v/v) was added to 
each well and the cells incubated for an additional 4 days. XTT was added and incubated 
with the cells for 4-8 hours before the colour density (570nm) was measured on a Dynex 
microplate reader. 
As shown in Fig. 5.7, neither MCF-7 cells nor the corresponding clone overexpressing 
STAT5 (M. st5bl) display a response to prolactin treatment. Fig. 5.7 also shows that in 
T47-D cells ceramide decreases the absorption at 470nm to -30% of the control. As with 
the previous assay, ceramide exposure decreases the absorption at 470nm in the STAT5b 
clone further, to -11% of control cells (p<0.05). Again, a greater decrease than that 
recorded for the untransfected parent cells. The presence of prolactin, as before, does not 
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Figure 5.7 Effect of prolactin on survival of STAT5b expressing clones following ceramide 
exposure, assessed by XTT assay. 
T47-D, MCP 7 and their STAT5b clones were plated into 96-well plates and the cells incubated 
overnight. The cells were serum-starved for 24 hours before exposure to Ong ml or 250ng ml 
prolactin jor I hour. The cells were then incubated in 0µM or 40pMfor 24hrs and then 'rescued' 
with lO%FCS (v, v). The cells were allowed to proliferate for 4-5 days before the addition off/7 
and the absorption at 470nm recorded. This was performed 3 times, and the figure shown 
represents a typical experiment. In each case, parental cells in the absence of ceramide are 
arbitrarily set at the value of 1. 
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5.2 
.8 
The Effect of Over-Expressed STAT5b on the Cell Cycle Profile of Breast Cancer 
Cells 
5.2.8.1 Does prolactin induce cell cycle arrest of clones over-expressing STAT5b? 
Given the results of the survival assays, we wondered whether prolactin stimulation of 
cells over-expressing STAT5b could induce cell differentiation and hence cell cycle 
arrest in GI. Flow cytometry was therefore used to assess any such effect. 
3x105 cells (T47-D, MCF-7 and their STAT5b clones) were each seeded into 6-well 
plates. The cells were serum starved for 24 hours prior to exposure to vehicle or 
250ng/ml prolactin for a further 48 hours. The cells were then collected, stained with 
propidium iodide, and the cell cycle analysed by flow cytometry. 
Fig. 5.8 shows that serum starvation induces a greater GI arrest in the T. st5bl clone, with 
80±0.4% (SD) of the cells in G1, compared to 60+2% (SD) of the parent T47-D cells 
(p<0.0001). The presence of prolactin does not alter this change. In the MCF-7 cells and 
the M. st5b1 clone, there is no cell cycle arrest, and prolactin does not alter the cell cycle 
dynamics. 
5.2.9 Attempts to Create Stable Breast Cancer Cell Lines Overexpressing STAT5a 
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Figure 5.8 Effect of prolactin on the cell cycle profile of STATSb overexpressing breast 
cancer clones assessed by flow cytometry. 
7.17-D, MCF-7, T. st5b I and M. st5bI cells were plated onto 6-well plates. The cells were serum 
starved for 24 hours and then exposed to the absence or presence of 250ng ml prolactin for a 
further 24 hours before they were analysed by flow cytometry. 
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T47-D and MCF-7 cells were co-transfected with 1µg HA-STATSa and 1µg pcDNA3 
plasmids as previously described. The cells were then incubated for 48 hours before they 
were exposed to G418 (1200µg/ml) for 2 weeks to select stably transfected cells. Cells 
surviving the selection process were then cloned in agarose gels. We had previously 
created STAT5b stable clones by serial dilution and it was evident that cloning by serial 
dilution was quite a harsh treatment, resulting in very few clones. Thus for the STATSa 
clones, we used a gentler cloning procedure, providing nutrients with a fibroblast feeder 
layer. 
Despite numerous attempts at agarose get cloning, we were unable to obtain any clones 
from the STATSa-transfected cell population. Observations showed that colonies were 
present, detectable at the microscopic level. However, after reaching a certain size, the 
colonies all failed to develop further and we were unable to obtain clones of breast cancer 
cells stably over-expressing STAT5a. 
5.2.10 Detection of STAT5a expression by Western blotting 
Concurrent to our attempts to create stable cell lines over-expressing the STAT5a protein, 
we performed transient transfections using the STAT5a and STATSb plasmids in COS-7 
cells to optimize detection of the proteins in stable clones. 
COS-7 cells (5x106) were seeded into 90mm dishes and incubated overnight. The cells 
were transfected with 5µg of HA-STAT5a using Fugend and then incubated for 24 hours 
before protein extraction. Crude extracts of the cells were denatured and electrophoresed 
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in an SDS-Page gel. Western blot analysis was performed using anti-HA antibody (clone 
H7). HA-tagged STAT5b-transfected COS-7 cell extracts were used as a positive control 
for both the HA-tag as well as protein expression. 
As shown in Fig. 5.9, a faint protein band running at a slightly higher molecular weight 
than STAT5b was detectable in the crude extracts of cells transfected with the HA- 
STAT5a plasmid. This is consistent with the documented size of the STAT5a protein 
(94kDa), compared to the 92kDa molecular weight of STAT5b316 Expression of the 
STAT5a protein was considerably weaker, however. Thus, although the two plasmids are 
similar constructs and under the control of the same promoter (CMV), for an unknown 
reason STAT5a expression appeared to be at a much lower level, providing a possible 
explanation for the difficulty in identifying cells stably expressing the protein. 
Unfortunately, due to lack of time it was not possible to pursue these studies further. 
5.3 Discussion 
While STAT5 has been shown to be a growth signal transducer in haematopoietic cells306 
and a survival signal transducer in red cell progenitors where it activates the transduction 
of Bcl-xL294, whether it plays a similar role in the survival of mammary cancer cells has 





Figure 5.9 Expression of HA-STAT5a and HA-STAT5b in COS-7 cells, assessed by Western 
blotting. 
COS-7 cells were transfected with either HA-STAT5a or HA-STAT5b plasmids. Crude extracts 
were prepared and electrophoresed. Western blotting was performed using the anti-HA antibody 
(H7 clone). 
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The purpose of the work described in this chapter was to determine whether enhancement 
of the prolactin signalling response could increase the protective effect of prolactin 
against apoptosis. In T47-D cells co-transfected with empty plasmid (pcDNA) and the 
LURE reporter, exposure to prolactin results in a small increase in luciferase activity. 
Overexpression of STAT5b together with exposure to prolactin causes this activity to 
increase at least 6-fold. From the results shown in Fig. 5.1, we can conclude that in the 
untransfected parent cell lines, levels of endogenous STATS are a limiting factor for 
activation of a STAT5 reporter. This increased activation therefore provided an 
opportunity to investigate the role of STATS in prolactin responses of breast cancer cells. 
Based on studies in other cell types, we hypothesised that STATS is involved in the 
survival pathway of breast cancer cells. Increasing endogenous levels of STAT5 might 
therefore be expected to increase signalling along this pathway following prolactin 
stimulation,, and the creation of stable breast cancer cell lines which over-express STATS 
should help to determine whether or not the STAT5 pathway is involved in anti-apoptotic 
signalling in these cells. 
Western blotting (Fig. 5.2) identified clones expressing HA-STAT5b, and LHRE reporter 
assays confirmed that STAT5b signalling was enhanced compared to that of 
untransfected parental T47-D cells (Fig. 5.3). 
Our original hypothesis was that overexpression of STATSb would either enhance 
responsiveness of cells to prolactin (if those responses were mediated by STAT5b), or be 
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without effect (if signalling pathways other than STATS were involved). Contrary to our 
expectations, the results obtained were not immediately compatible with either of these 
hypotheses. Figures 5.4 and 5.5 show that while there is a modest increase in 
proliferation in the untransfected parent T47-D cells, this is not reflected in the T47-D 
clone overexpressing STATSb. In fact, the results suggest that the level of STAT5b is not 
the determining factor in the proliferation of T47-D cells, and instead, its overexpression 
may actually inhibit the proliferative response to prolactin. As expected from earlier 
studies221283, there is a minimal effect of prolactin on the proliferative rate of MCF-7 
cells whether or not they overexpress STAT5b, presumably a reflection of the lower 
number of prolactin receptors in these cells221. 
Survival assays, whether assessed by cell counting or by the XTT assay, also suggest 
that, far from conferring protection from ceramide-induced apoptosis, over-expression of 
STAT5b actually results in increased susceptibility to ceramide-induced cytotoxicity in 
T47-D cells (Figs. 5.6 and 5.7). In MCF-7 cells prolactin has no significant effect on 
ceramide-induced cytotoxicity whether or not STATSb is overexpressed. 
Thus, contrary to our expectations, stable over-expression of STAT5b in these breast 
cancer cell lines did not enhance the proliferative or survival effects of prolactin. Instead, 
when all the data on proliferation and rate of apoptosis in T. st5b1 are considered, it 
would appear that by overexpressing STAT5b we have inadvertently created a cell line 
that could potentially be more susceptible to apoptosis. This goes against the 
conventional view that STATSb stimulation results in proliferation 318,319. Logically, it 
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should be presumed until proven otherwise that endogenous STATSb stimulation, in 
itself, will still result in proliferation of the cell population, however, it would be 
interesting to investigate how overexpressing STATSb alters the dynamics of cell 
metabolism, triggering cell cycle arrest and increasing susceptibility to apoptosis. Perhaps 
the most likely explanation for this would be that STAT5a mediates the proliferative and 
protective effects of prolactin in breast cancer cells and overexpression of STAT5b 
`squelches' the effects of STAT5a. Although STATSb appears to be expressed at a higher 
level than STAT5a in T47-D cells288, evidence from `knock-out' animals provides strong 
os evidence for a critical role of STAT5a, but not STAT5b, in mammary development3,32o 
Another possible explanation could be that over-expressed STAT5b induces 
differentiation of the T47-D cells under conditions of stress (i. e. serum starvation) so that 
the apparent increase in cell death when prolactin is added to survival assays could be 
explained by the accumulation of cells in GI as they differentiate. Cell cycle analysis of 
the clones following serum starvation (Fig. 5.8) does indeed show the accumulation of 
cells in G1, but this effect is not enhanced by prolactin, making it unlikely that STAT5b 
is promoting differentiation. There are several possibilities to consider regarding this 
unexpected response. One possibility is that STAT5b is not involved in the proliferative 
or survival pathways in T47-D cells, or if it is involved, it does not have a dominant role 
in these cells. Another possibility is that even though the basal level of STAT5 signalling 
has been increased in the STATSb clones, it is the signalling cascade downstream of this 
which is the limiting factor, and the increased STATS signalling is unable to elicit any 
further response. However, neither of these possibilities would explain why over- 
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expressed STAT5b actually reversed the expected responses. It is possible that increased 
expression of STAT5b interferes with cellular function and diminishes the ability of cells 
to withstand stress (e. g. when exposed to ceramide or deprived of serum). 
It was unfortunate that we were unable to isolate any breast cancer clones stably 
overexpressing STATSa. Since over expressed STAT5b does not appear to affect the 
ability of breast cancer cells to survive apoptosis, this indicates the possibility that 
STAT5a could be responsible for this effect, which was also suggested in a recent 
paper321. However, in view of the poor expression of the STAT5a plasmid as shown on 
Western blotting and the lack of time, we were unable to perform further studies to create 
stable STAT5a cell lines. 
In the MCF-7 cell line and its STAT5b clone, M. st5bl, the lack of prolactin response 
could be explained by the low level of expressed STAT5b (Fig. 5.2) which did not lead to 
a clear increase in STAT5b signalling (Fig. 5.3). There are several other possibilities to 
consider regarding the lack of response in MCF-7 cells. One possibility is that STAT5b is 
not involved in the proliferative or survival pathways in MCF-7 cells and its 
overexpression interferes with the functioning of whichever protein is responsible. 
Another possible reason, which would account for the high basal activity of STAT 
activation in these cells (Figs. 5.1 and 5.3), is that in this cell line STATS is constitutively 
active. This possibility is supported by a recent study showing that both T-47D and MCF- 
7 cell lines have constitutively active STAT5b322. If this is the case, it might explain why 
the cells did not exhibit any response to further STAT5b expression, as the level of 
144 
STAT5b may already be sufficient for maximal response in these cells. Another more 
interesting possibility would be that the expression of endogenous prolactin by the cells 
themselves 323,324 may be sufficient for maximal protection against apoptosis. This would 
also account for the failure to increase STAT5b response to prolactin stimulation. Thus in 
hindsight, it would have been interesting to measure the level of endogenous prolactin 
production in these two cell lines whilst they were in serum free conditions, in order to 
prove or disprove whether they were able to synthesis bioactive hormone despite serum 
starvation. Moreover, this could be further investigated by using neutralizing antibodies 
to prolactin to assess if this affected the cell cycle profile and apoptotic response in the 
MCF-7 cell lines. 
Finally, it is possible that the two STAT5b overexpressing clones are not `typical'. As 
only one stable clone was isolated from each breast cancer cell line, it would have been 
difficult to make any definitive conclusions from the results obtained because mutant or 
variant clones could have been inadvertently selected. 
In conclusion, over-expressing STAT5b does not appear to confer a survival advantage in 
breast cancer cells. In fact, overexpression of STAT5b seems to diminish responsiveness 
to prolactin. More work needs to be done to confirm this fording, however, as well as to 
assess what changes are induced by increased STAT5 signalling. 
145 
6 Induction of Apoptosis in Breast Cancer Cells by Met, a protein 
closely related to Het/SAF-B 
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6_1 Introduction 
The Met gene, identified by Dr. Shane Colley, bears a strong similarity to Het I(Heat- 
shock protein 27-Ere-Tata binding protein), also called SAF-B (Scaffold Attachment- 
Factor B) or HAP Q nRNP Al -associated protein), which was discovered independently 
by three groups32s-327. Over a region of 863 amino acids, Met shares 35% identity with 
Het/SAF-B. Like, SAF-B, Met has a SAF Box, an RNA binding domain and a 
glutamine/arginine rich region in the carboxyl terminus (Figs 6.1 and 6.2). SAF-B was 
first identified as one of four novel nuclear proteins that bind to the scaffold/matrix 
attachment regions (S/MARs) of DNA. S/MARs are thought to be responsible for linking 
chromatin to the nuclear matrix scaffold, and may be important for transcription of 
DNA 328. SAF-B is known to bind RNA polymerase 11 and is involved in alternative 
splicing of pre-mRNA326. Independently, Oesterreich et al. showed that expression of Het 
resulted in decreased transcription from the hsp-27 promoter325 and also caused down- 
regulation of transcription by the oestrogen receptor329. In addition, a third group used 
yeast two-hybrid screening to isolate a cDNA encoding a protein of 917 amino acids 
which associated with hnRNP Al (heterogeneous nuclear ribonucleoprotein Al) and had 
a sequence identical to Het/SAF-B. In the latter study, this protein was found to co- 
localize with heat shock factor-1 (HSF-1) following exposure to 42°C for 1 hour327. 
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MuMET 22 IT ELRVIDLRSELKRRNLDINGVKTVLVSRLKQAI 
HuMET 22 ITDLRVIDLKSELKRRNLDITGVKTVLISRLKQAI 
HET 31 LSDLRVIDLRADVRKRNVDSSGNKSVLMERLKKAI gi: 2828536 
SAF-A 8 VKKLKVSELKEELKKRRLSDKGLKAELMERLQAAL gi: 6226894 
AcinusL 72 LQALRVTDLKAALEQRGLAKSGQKSALVKRLKGAL gi: 5931959 
PIAS 11 VMSLRVSELQVLLGYAGRNKi-IGRKHELLTKALHLL gi: 3643105 
Ku70 571 LGKLTVPTLKDICKAHGLKSGPKKQELLDALIRHL gi: 3241858 
DEK 149 LKKFRNAMLKSICEVLDLERSGVNSELVKRILNFL gi: 544150 
PARP 2 SARLRVADVRAELQRRGLDVSGTKPALVRRLDAAI g1: 2959360 
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Figure 6.1 Met SAF Box and RNA binding domains. 
A) Mouse and human MET SAF Boxes aligned with corresponding domains in related proteins"". 
Numbers on the leji detail position of motifs, and Genbank sequence identifiers are listed für each 
protein (right). Conserved residues are highlighted in grey; '. ': any residue; V: YTWLIV 4A; 
'': STQNF, DRKH; 'b': KREQWFYLMI. B) RNA binding domains of mouse and human Met are 
based on previously defined sequence consensus3=1. Numbers left refer to initiating residue off' 
motif and Genbank sequence identifiers are listed for each protein. '. ': any residue; 





Nuclear localization signals 
Figure 6.2 Diagramatic representation of the Met protein. 
Met is a protein consisting of 1031 amino acids, - 3.7kb. It has three regions which bear strong 
homology to SAF-B, as indicated above (SAF-box, RNA binding motif and a glutamine%arginine 
rich region). Also located in the carboxy terminal are 3 nuclear localization sites. 
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Preliminary studies (performed by Dr. Shane Colley) showed that Met, like Het, down- 
regulated transcriptional activity of the oestrogen receptor in MCF-7 cells. However, 
analysis of a vector constitutively expressing ß-galactosidase (used as a control for 
transfection efficiency), suggested that increasing amounts of Met also resulted in 
decreased transcription of ß-galactosidase. Thus, over-expression of Met appeared to 
cause a generalized inhibition of transcription which might result either in cell toxicity or 
the induction of apoptosis in MCF-7 cells. The experiments described in this chapter 
were performed to further analyse the ability of Met to block transcription, and to 
investigate the possibility that Met might induce apoptosis in breast cancer cells. 
6.2 RESULTS 
6.2.1 Effect of Met on the activity of reporter genes in MCF-7 cells 
All plasmids containing the Het and Met moieties were constructed by Dr. Shane Colley, 
and all sequences were confirmed by sequencing. Full-length murine Met cDNA (3.7 kb), 
amplified by RT-PCR from mouse bone marrow, was cloned into pCR3.1 (Invitrogen) 
(pCR-Met). A BamH I/Eco RV digest of this plasmid was subcloned into Bgl II/Sma I 
digested pEYFP-C1 (Clontech) resulting in an amino-tagged enhanced yellow fluorescent 
protein (EYFP)- Met chimera: pEYFP-Met. 
pMet-HA was constructed as follows. The 3'end of Met cDNA was amplified with the 
HA tag using Pfu DNA polymerase (Promega) and specific primers (5'mid Met 
ATGGAACGCGAACGCTTGGAA and 3'HA-Met: AAAGCGGCCGCTCAAGCGTA 
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GTCTGGGACGTCGTATGGGTATGCAAATCGCCGTGGAGGTCCACT), resulting 
in a -4. lkbp fragment. This fragment was digested with Smal/Notl and the resultant 
397bp fragment isolated, and cloned into similarly digested pCR-Met, to generate pCR- 
Met-HA (pMet-HA). 
pHA-Het was constructed in the following manner. The amino terminus of the IMAGE 
clone 3611151 (GI 989737) was amplified by PCR using Pfu polymerase (Promega) and 
specific primers that coded for the haemaglutinin epitope (5'HA Het 
a aaggatccaaaatggcatacccatacgacgtcccagactacgccatggcggagactctgtcaggcct, 3'mid Het 
gtcgtcacccttcttagcatca). This resulted in a 1.6kb fragment which was digested using 
BamH I/Eco RV and subcloned into IMAGE clone 3611151. The latter was then digested 
with BamH I/Pst I and the insert released was subcloned into a similarly prepared pCR3.1 
to generate pHA-Het (with the HA tag at the amino terminus). 
Initial experiments by Dr. Colley were performed using the EYFP-Met chimera. Once an 
HA-tagged Met plasmid had become available, we decided to repeat the initial 
experiments using the HA tagged construct, which would be more comparable to the 
HA-tagged Het and would also avoid the criticism that the chimera might interfere with 
transcription as a result of toxic effects caused by the EYFP moiety. 
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6.2.1.1 Expression of Het and Met in MCF-7 cells Assessed by Western Blotting 
Fig. 6.3a shows a Western blot of the EYFP-Met chimera, reported to be migrating with 
an apparent molecular weight of 130kDa (Dr. S. Colley, personal communication). This 
blot was performed by Dr. Shane Colley. 
To confirm that HA-tagged Het and Met constructs of the appropriate size were 
expressed, a Western blot was performed. COS-7 cells (5x10) were seeded onto 90mm 
dishes and incubated overnight. The cells were then transfected with 5µg of HA-tagged 
Met or Het and incubated for 24 hours before cell lysates were prepared and Western 
blotting performed. The primary antibody was the anti-HA probe (Santa Cruz) diluted 
1: 1000, and the secondary antibody was anti-rabbit IgG (diluted 1: 10,000). 
Fig. 6.3b shows the expression of HA-tagged proteins migrating with an apparent 
molecular weight of 130kDa. Although the predicted molecular weight of the proteins is 
approximately 90kDa, Het has previously been shown to migrate at an anomalous rate 
with an apparent molecular weight of 130kDa327, probably as result of 25 charged 
domains on the molecule (basic N- and C- termini, and an acidic central amino acid 
sequence 326). It appears that MET migrates in a similarly anomalous manner. 
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Figure 6.3 Expression of Het and Met constructs. 
(a) Detection by Western blotting of pEYFP-Met expressed in MCF-7 cells (experiment 
performed by Dr. Shane Colley), (b): Detection by Western blotting of transfeeted HA-Het and 
Met-HA expressed in MCF-7 cells. 5x106 MCF-7 cells were transfected with 5µg of HA-Hei or 
Met-HA plasmids. Cells were incubated for 24 hours before being lysed and a Western blot 
performed on cell extracts using anti-HA probe (Santa Cruz). Control cells were transfected with 
empty plasmid. 
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6.2.1.2 Does overexpression of Het and Met regulate oestrogen signalling? 
The preliminary experiments performed by Dr. Colley had indicated that both Het and 
Met down-regulate a constitutively active ß-galactosidase reporter, and it was clearly 
important to confirm this fording. Also, these experiments utilized an EYFP-Met 
chimera, so it was important to show that the inhibitory effects on ß-galactosidase 
expression were not due to the EYFP moiety. Hence, the experiment was repeated using 
HA-tagged versions of both Het and Met. Oestrogen signalling was assessed using an 
oestrogen receptor response element linked to a luciferase reporter (pERE-Tk-luc332). 
MCF-7 cells (3x104) were seeded into 48-well plates and transfected with pERE-Tk-luc 
(150ng), pSV-ß-galactosidase (60ng, Promega) and varying amounts of HA-Het or Met- 
HA (50ng, 100ng, or 200ng) using FuGENE 6. A control plasmid, pcDNA3 (Invitrogen), 
was used to balance the amount of DNA used to transfect each well. Following an 
overnight incubation, the cells were serum starved for 6 hours before exposure to 10-8M 
E2 (170-oestradiol) for 18hrs. The cells were lysed and luciferase activity of the lysate 
measured using a Dynex luminometer. Concurrently, a sample of the lysate from each 
well was also assessed for ß-galactosidase activity, which was measured in a Dynex 
microplate reader. 
Fig. 6.4a confirms that both Het and Met decreased the ability of the oestrogen receptor 
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Figure 6.4 Effect of Met and Het on reporter gene activity. 
(a): The effect of Met and Hei on the activation cif the ERE-tk-luc reporter gene by the oestrogen 
receptor. MCF 7 cells were transfected with pERE-Tk-Luc (150ng) and varying amounts of 
Met(M), Het(H) or empty plasmid (Ctrl). The cells were incubated overnight and serum-starved 
for 6 hours before treatment with 10-8M L2 for 18 hours. Next, cells were lysed and luciferase 
activity measured using the Dynex luminometer. This experiment was repeated on 5 separate 
occasions, and a typical experiment is shown here (mean } SI)). Control cells were treated with 
and without E2 and all cells transfected with Het or Met were treated with F, 2. 
(6): The effect of Het(H) and Met(M) on the activity of a constitutively active f-galactosidase 
reporter. MCF- 7 cells were transfeeted with pSL=ß-galaetosidase(IOOng) (under the control of a 
SV40 promoter) and varying amounts of Met or Het, with pcDNA3. I used to bring total DNA 
transfected up to 300ng. The cells were incubated overnight and serum-starved for 24 hours, then 
lysed and fi-galactosidase activity measured. The figure is taken from a typical experiment, which 
was performed 5 times (mean + SD). 
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of control when cells were transfected with 5Ong Het, and 47±14% (SD) of activity of 
control when 5Ong Met was used). 
Both Het and Met also caused a marked dose-dependent decrease in ß-galactosidase 
activity (Fig. 6.4b), however, even though ß-galactosidase is expressed from a plasmid 
(pSV-ß-galactosidase) under the control of a constitutively active SV40 promoter. The 
latter result suggests that Het and Met cause a generalized decrease in gene expression, 
although when ß-galactosidase results are used to `correct' oestrogen reporter results, the 
results from 5 separate experiments (Fig. 6.5) suggest that there may nevertheless be a 
specific effect on oestrogen signalling. It is possible that this effect is artefactual, 
however, resulting from differences in half-life of luciferase (about 3 hrs) and ß- 
galactosidase (over 20 hrs). For this reason, we would predict that if Het and Met block 
transcription, luciferase activity would be expected to decline more rapidly than ß- 
galactosidase, leading to a false conclusion if the former is `corrected' by the latter. 
6.2.1.3 Effect of overexpressing Met on a constitutively active luciferase reporter. 
To confirm our hypothesis that inhibition of oestrogen signalling by Het329 and Met 
(Fig. 6.5) could be explained by differences in half life of luciferase and ß-galactosidase, 
we went on to investigate the effect of overexpressing Met on the activity of a 
constitutively active luciferase reporter. MCF-7 cells (1x104) were seeded into 48-well 
plates and transfected with 60ng pBR-RSV-Luc plasmid, 60ng pSV-ß-galactosidase 
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Figure 6.5 Effect of Het and Met on the transcriptional activity of the estrogen reporter 
after correction of luciferase activity for ß-galactosidase activity. 
The above figure represents data from the mean of 5 experiments (each point represents 
percentage of control without Het or Met). 
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incubation, the cells were serum starved for 24 hours prior to lysis and the luciferase and 
ß-galactosidase activity measured. 
Fig. 6.6 shows that Met causes a dose dependent decrease in the activities of both 
constitutively active reporters. In accordance with our hypothesis, there appears to be a 
greater inhibition of the luciferase reporter (down to 25±2% (SD) with 50ng Met) activity 
compared to the decrease in the ß-galactosidase reporter activity (down to 38±4% (SD) 
with 50ng Met) (Student's t test, p<0.001), probably reflecting the shorter half-life of the 
luciferase enzyme. 
As a consequence of this discrepancy in the half-lives of both reporters, it is difficult to 
draw any firm conclusions regarding possible effects of Met on the activity of the 
oestrogen reporter, but the evidence would suggest that apparent inhibitory effects are 
primarily artefactual. 
6.2.2 Does Over-Expression of Met or Het Induce Apoptosis? 
The above experiments suggested that Met (and Het) have generalized inhibitory effects, 
which could be a result of, or lead to, apoptosis. As the experiments were performed in 
MCF-7 cells, we first investigated the cell cycle profile of this cell line after transfection 
with Met to determine whether the effects on reporter gene activity in the cells 












Figure 6.6 Effect of Met on the transcriptional activity of a constitutively active luciferase 
reporter, compared to its effect on the constitutively active ß-galactosidase reporter. 
MCF-7 cells were co-transfected with both pBR-RSV' Luc (60nß (under the control of a Roi, s 
sarcoma virus promoter) and pSV-ß-galactosidase (60ng), then serum stan'ed. for 24 hours prior 
to assaying for luciferase and fi-galactosidase activity (mean ± SD)(* :p0.01). 
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6.2.2.1 Comparison of Het and Met effects on the Cell Cycle Profile of Breast Cancer 
cells 
Plasmids encoding HA-tagged Het and Met cDNA were used to assess whether these 
proteins altered the cell cycle profile of MCF-7 cells. Transfection efficiencies of MCF-7 
cells are relatively low. Therefore, to allow identification of transfected cells, a plasmid 
encoding enhanced yellow fluorescent protein (pEYFP-C1, Clontech) was co-transfected 
with Het or Met. Using a gate that only accepted fluorescent cells, the cell cycle profile of 
the selected cell population was then analysed. 
MCF-7 cells (3x105) were seeded into each well of a 6-well plate and incubated 
overnight. The cells were co-transfected with pEYFP-C1 and either pcDNA3.1 (empty 
plasmid), HA Het, or Met-HA (1µg of each plasmid). The cells were then incubated 
overnight before serum starvation in SFM for 24 hours. The cells were collected, fixed in 
70% ethanol for 45 min at 4°C, stained with propidium iodide by incubation at 4°C for 1 
hour, and the cell cycle profile analysed by flow cytometry. The method of fixation in 
this instance was modified to a shorter incubation period as EYFP is known to leak out of 
permeabilized cells. 
Fig. 6.7 (top) shows a typical dot plot obtained with MCF-7 cells transfected with EYFP 
and stained with PI (FL1 and FL2 respectively). The gated region (polygon) shows the 
boundaries of the gate set to detect cells exhibiting EYFP fluorescence. Fig. 6.7 (bottom) 
is a histogram depicting the cell cycle profile of the EYFP transfected cell population. 












(top) Dot plot diagram 
showing the gate (black 
polygon) used to isolate 
the cell population of 
interest (EYFP- 
fluorescence) on the flow 
cytometer, which was 
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distribution on the 
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and the cell cycle profile 
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of the fluorescent cells analysed. On the 2 diagrams, the various phases of the cell cycle (preG1, 
G1, G2 and S) are shown. 
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GI, G2 and S) of the cell population is depicted. The histogram shown displays 2 peaks, 
which correspond to cells in G1 (taller peak) and G2 (shorter peak). Cells to the left of 
GI are described as the pre-GI population, while cells in S phase correspond to the 
population between the two peaks. This cell cycle profile is different from those 
previously obtained (See Fig. 2.1) because in order to analyse dual-coloured populations, 
the scales used in the dot plots for acquisition of data had to be on a log scale. In Fig. 2.1, 
being a single-colour analysis, the scale for acquisition of data was linear. 
In cells transfected with Het, the pre-G1 population of MCF7 cells increases from 12±3% 
(SD) (control cells) to 16±4% (SD) (Student's t test, p<0.05), and in cells transfected 
with Met, the preGi population increases to 23±6% (SD) (Student's t test, p<0.05). This 
represents the mean of 6 experiments, each experiment being performed in quadruplicate. 
Moreover, the pre-GI accumulation induced by Met is significantly higher than that 
induced by Het (Student's t test, p<0.001). When all 3 groups (pre-G1 populations from 
control, Het-transfected and Met-transfected cells) are compared by ANOVA, a 
significant difference between all the groups was found (p<0.001). The results from a 
typical experiment are shown in Fig. 6.8. 
6.2.2.2 Use of the EYFP-Met construct to analyse the effect of Met overexpression on the 
Cell Cycle Profile of MCF-7 Breast Cancer cells 
The pEYFP-tagged Met plasmid was used to investigate ability of Met to induce 
apoptosis in greater detail. This construct provided a simple method for analysing the 
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Figure 6.8 Comparison of the effects of Het and Met on the cell cycle profile of MCF-7 cells. 
Cells were co-transfected with pEY1, P-Cl (1µt; ) and either pcDNA3 (YP) (empty plasmid, I, uy) 
Het-HA (YH) (1µg) or HA-Met (YM) (lug). After an overnight incubation, cells were serum 
starved for 24 hours before they were collected and stained with PI for cell cycle analysis. This 
figure represents a typical experiment, of which 5 were performed in quadruplicate(mean ± SD) 
(* = p<: 0.05). 
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transfected population on the flow cytometer, because only transfected cells would 
exhibit EYFP fluorescence, enabling detection by the flow cytometer. Such an analysis is 
otherwise compromised by the fact that only a small proportion of cells are transfected. 
The pEYFP-C1 plasmid (Invitrogen) was used as a control. 
MCF-7 cells (3x105) were seeded into each well of a 6-well plate. The cells were 
transfected with EYFP-C1 or EYFP-Met (l µg of each plasmid) using FuGENE 6 (31l). 
After an incubation of 24 hours, cells were washed and transferred to SFM for a further 
24 hours. The cells were then collected, fixed and stained with propidium iodide before 
analysis by flow cytometry. 
Fig. 6.9 shows that the pre-G1 population of MCF-7 cells increases markedly when cells 
were transfected with Met. From the mean of 4 separate experiments, each experiment 
performed in quadruplicate, the increase was from 10±5% (SD) in control cells 
transfected with pEYFP to 37+10% (SD) in cells transfected with the pEYFP-Met 
(p<0.05). Importantly, the previous experiment (Fig. 6.8) using the HA-tagged proteins 
show that apoptosis induced by EYFP-Met is not due to the EYFP-moiety. 
6.2.2.3 Effect of Met on the Cell Cycle Profile of the mouse fibroblast cell line, MC3TC 
The Met gene was identified by screening a cDNA library of the bone marrow of an 
oestrogen-treated mouse. Thus, before proceeding any further with experiments in human 
cell lines, we wished to confirm that the effect of Met was reproducible in murine cells. 
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Figure 6.9 Effect of EYFP-Met on the cell cycle profile of MCF-7 cells. 
MCF-7 cells were transfected with pEYFP-C1 (Ipg) or pEYFP-Met (lµg. ('ells were serum 
starved for 24 hours before they were collected and stained with PI for cell cycle analysis. This 
experiment was performed 4 times, and a typical experiment is shown (mean ± SD) (* p<- 0.05). 
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We therefore decided to investigate the effect of over-expressing Met on the cell cycle of 
the MC3T3 mouse cell line. MC3T3 cells (a mouse calvarial fibroblast cell line) (3x105) 
were seeded into 6-well plates and transfected with either 1µg of pEYFP-C 1 (empty 
plasmid) or pEYFP-Met using FuGENE 6. The cells were incubated for 24hrs, before 
being transferred to SFM for a further 24hrs. Following serum-starvation, the cells were 
collected, fixed and stained with propidium iodide and the cell cycle analysed by flow 
cytometry. 
Fig. 6.10 shows that in the MC3T3 cells, Met induces a clear increase in the pre-G1 
population from 6+3% (SD) to 21+7% (SD) (Student's t test, p value). Thus we can 
conclude that the apoptotic effect is not due to inter-species differences in proteins. 
6.2.2.4 Effect ofMet overexpression on the cell cycle profile of different cell lines 
To ascertain whether the effect of Met on the cell cycle was limited to specific cancer 
cells, or if it was a universal effect and would affect all cell lines in the same way, we 
used Ros (rat osteosarcoma), HepG2 (human hepatocarcinoma), HeLa (human cervical 
adenocarcinoma) and SF (human fibroblast, primary culture) cell lines. For these 
experiments, 3x105 cells from each line, seeded in 6-well plates, were transfected with 
1µg of pEYFP-C1 or pEYFP-Met as described before. 
From Fig. 6.11, it can be seen that Met induces apoptosis in all of these cell lines, albeit 
to different extents. In Ros cells, the pre-GI population increases from 9±4% (SD) to 
18±6% (SD) (p<0.001). In HepG2 cells the increase is from 4+1% (SD) to 17+3% (SD) 
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Figure 6.10 Change in cell cycle profile of mouse MC3T3 cells following transfection with 
Met. 
MC373 cells were transfected with either pEYI P (control plasmid) or pE, YPP-Met. After an 
overnight incubation, the cells were serum starved for 24 hrs before they were collected, fixed 
and stained with PI, for analysis of the cell cycle profile by. f ow cytometry. This experiment was 
performed 3 times, and a typical experiment is shown (mean ± SD) (* -- p 0.05). 
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Figure 6.11 Effect of EYFP-Met on the cell cycle profile of various cell lines. 
3x105 cells from each of the cell lines shown above were plated out and transfecied with pEYI"'P- 
C1 (1pß or pEYTP-Met (jug). Cells were incubated overnight, followed by serum-starvation for 
24 hours before they were collected and stained with PI for cell cycle analysis. (A) Ros cells, 
(B) = HepG2 cells, (C) -- Hela cells and (D) = SF cells. Figures shown are representative of a 
typical experiment, experiments were performed in quadruplicate and each was repeated 3 
separate times (mean ± SD). 
(B) HepG2 cell line 
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(p<0.001). In the HeLa cell line, it increases from 17±4% (SD) to 33+5% (SD) (p<0.001) 
and in the SF (human fibroblasts) cell line, pre-GI increases from 4+2% (SD) to 17±2% 
(SD) (p< 0.001). The changes in pre-G1 are tabulated in Table 6-1. All statistical 
analyses were performed using the Student's t test. 
In addition to studying changes in the proportion of cells in the pre-GI phase, we went on 
to analyse the data from all cell lines to assess changes in cell cycle profile of the 
viable/intact cell population (i. e. cells in G1, G2 or S phase of the cell cycle). From our 
calculations, there appeared to be a general trend for the G1 population to increase, the 
G2 population to decrease and the S phase cells to remain constant, when cells were 
treated with Met (Table 6-2). However, in all but the HeLa cell line, these changes were 
not statistically significant. 
6.2.2.5 The effect ofMel on the cell cycle profile of breast cancer cells in the presence of 
serum. 
Because the initial aim of these studies was to assess the effect of Met on oestrogen 
signalling, all studies were carried out in serum-free conditions. To determine whether 
Met induced apoptosis only under conditions of stress (i. e. serum starvation) or whether it 
was a more generalized effect, MCF-7 cells (3x105) were seeded onto 6-well plates and 
incubated overnight. The cells were transfected with either 1µg of pEYFP-C 1 or pEYFP- 
Met and incubated overnight. The next day, half of the cells from each group of 
transfected cells were washed and subjected to serum-starvation as in previous 
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Cell Line % EYFP-transfected cell 
population in pre-GI 
% EYFP-Met-transfected 
cell population in pre-G1 
Student t- 
test 
Mean + SD (No. of samples) Mean + SD (No. of samples) 
MCF-7 10 ±5 (15) 37 ± 10 (16) p<0.05 
HeLa 17+3 (11) 33+5 (12) p<0.05 
HepG2 5+3 (16) 24 ± 15 (16) p<0.05 
MC3T3 6+3 (12) 21+7 (12) p<0.05 
Ros 9+4 (12) 18+6 (12) p<0.05 
SF 4+2 (15) 17+2 (14) p<0.05 
Table 6.1 Change in the proportion of cells in the pre-GI population without (EYFP) or 
with (EYFP-Met) the expression of Met. 
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Cell line 
% Viable population % Viable population % Viable 
(transfected 
in GI in G2 population in S 
plasinid) 
Mean I SD Mean + SD Mcan f SD 
HepG2 (YFP) 20+5 74 +5 6+2 
HepG2 (YFP-Met) 22 +4 68+5 11 +4 
HeLa (YFP) 45 + 6* 44+9 11 ±3 
HeLa (YFP-Met) 58+4* 31 +5 11 +l 
MCF-7 (YFP) 58+ 11 34+8 8+3 
MCF-7 (YFP-Met) 63+7 29 ±6 8+2 
MC3T3 (YFP) 40+ 12 49 + 14 11 +3 
MC3T3 (YFP- 
42+3 42+8 16±6 
Met) 
Ros (YFP) 52+15 41+15 6.4+1 
Ros (YFP-Met) 63 + 10 30 + 11 6+2 
SF(YFP) 40+4 52+4 8+4 
SF(YFP-Met) 42+4 50+4 9±4 
Table 6.2 Tabulation of the changes in the cell cycle profile of the viable cell population 
after treatment with Met. 
The difference between the preGi populations of YEP-transfected HeLa cells is signifrcanil}y 
different to that of the YFP-Met transfected cells (* = p<O. 05, Student's t test). 
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experiments. The other half of the transfected cells were left in normal medium 
containing 10%FCS until they were collected and stained with PI for cell cycle analysis. 
Fig. 6.12 shows that in the absence of serum, the proportion of cells transfected with Met 
in the pre-GI phase is 39±4% (SD), while in the presence of serum, 47±7% (SD) of the 
cells are in the pre-GI phase. This is in comparison to a pre-GI population of 9±3% (SD) 
in the control cells transfected with EYFP alone. Thus the ability of Met to induce 
apoptosis in MCF-7 cells is independent of whether or not the cells are stressed by serum 
deprivation. 
6.2.2.6 Does Met cause apoptosis as assessed by Hoechst staining? 
We next proceeded to verify that the increase in pre-GI population detected by flow 
cytometry is due to `classical' apoptosis. HeLa cells have been documented to undergo 
apoptosis under various conditions, which is detectable by Hoechst staining 333,334. Thus 
we examined pEYFP-Met transfected Hela cells by Hoechst staining to confirm that 
apoptosis is induced by Met. 
HeLa cells (2x105) were seeded into 60mm dishes and incubated overnight. The cells 
were transfected, with either 1µg of pEYFP-C1 or pEYFP-Met, and incubated for a 
further 24 hours. The cells were then serum starved for 24 hours before being fixed 
(2%PFA/PBS, 20 min at room temperature) and stained with Hoechst (IOµg/ml, 15min at 
room temperature in the dark). Fluorescent microscopy was performed and 300 
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MCF-7 cells were iransfected with pEYI''P-('/ or J) YI''P-Met (Ipg each) and incubated 
overnight. The following day, cells were eüherwashed and serum-starved for 24 hours (SFM or 
left in normal medium for 24 hours (DMEM). The cells were collected as usual, stained with PI 
and the cell cycle profile analysed by flow cylometry. This experiment was performed in 
quadruplicate, and repeated 3 times. The figure shows a typical experiment (mean ± SD) 
(/)- 0.01, Student's 1 ! es! ). 
173 
pre-G1 G1 G2 M 
pEYFP-Met transfected cells (Fig. 6.13a) correspond to cells with the classical features of 
apoptosis, shown by Hoechst staining (Fig. 6.13b). Cell counts of the pEYFP and 
pEYFP-Met transfected cells (Fig. 6.13c) show an increase in apoptotic index from 3+1% 
(SD) to 20±2% (SD) (p<0.001), consistent with results obtained by cell cycle analysis 
(Fig. 6.11). 
6_3 DISCUSSION 
At the start of this project, all current knowledge regarding the Met protein was from 
work performed by Dr. Shane Colley. A fragment of the Met gene was isolated from the 
bone marrow of oestrogen-treated mice by PCR based subtractive hybridization. A full- 
length virtual cDNA sequence coding for a protein of 1031 amino acids was then 
generated based on this fragment and using homologous EST sequences. A 3.7kb product 
was then amplified and cloned from mouse bone marrow cDNA by RT-PCR, using 
primers designed on the basis of the virtual cDNA sequence. A corresponding virtual 
human Met sequence (91% homologous to the mouse sequence, 98% if conserved 
substitutions are taken into account) was generated using human ESTs335 and consisted of 
1034 amino acids. 
Met was found to share 35% homology with Het over 863 amino acids, with the greatest 
homology occurring in three distinct regions of the peptide (Fig. 6.1). The first of these 
conserved regions is a SAF box, which is located between amino acids 22-56 of the Met 









(c): Hoechst staining in HeLa cells, cell counting 
(b) 
Figure 6.13(a, b& c) The induction of apoptosis in HeLa cells by Met, assessed by Hoechst 
staining. 
HeLa cells were transfected with lug of pEYFP-C1 or pEYFP-Mel. The cells were incubated 
overnight and then transferred to SFM for 24 hours. Next, cells were fixed and stained with 
Hoechst and assessed by fluorescent microscopy. Fig. 6.13(a): EYFP-Met-transfected cells seen 
through filter for EYFP(scale bars: 5um), (b): EYFP-Met-transfected cells seen under filter for 
Hoechst staining. Fig. 6.13(c) shows the change in apoptotic index of HeLa cells after expression 
of Met, assessed by cell counting. This experiment was performed in triplicate, and repeated 3 
times (mean + SD). The results shown are those ofa typical experiment. 
175 
Y YM 
(S/MARs) which are believed to be involved in the regulation of chromatin expression 
and gene expression328,336. The next conserved domain in Met corresponds to an RNA 
binding domain (beginning at residue 382). Such domains are usually about 80 amino 
acids long and contain two well-conserved sub-motifs RPN-1 (octamer) and RPN-2 
(hexamer)331. A similar sequence is also found in Het327, and similar sequences on other 
proteins have been shown to alter pre-mRNA splicing, and hence cellular responses such 
as growth, differentiation and apoptosis337. 
A third motif conserved between the Met and Het proteins which is rich in glutamine 
(26%) and arginine (31%) residues falls between residues 652-740 of Met, and there is 
73% identity between the two. In the Het protein, this sequence has been shown to 
interact with hnRNP D338, and was proposed to be responsible for the effect of Het on the 
transcriptional activity of the oestrogen receptor. Nayler et a1339 demonstrated that the C- 
terminal portion of SAF-B was able to bind the C-terminal domain (CTD) of the large 
subunit of RNA polymerase II. 
The Met sequence has also been shown to contain 3 separate nuclear localization signals, 
beginning at residues 593,726 and 800, all of which are found at the carboxyl end of the 
protein. Using Northen blot analysis, Met has been shown to be present in most tissues of 
the mouse (analysis performed by Dr. Shane Colley in this lab) (Fig. 6.14). 
Like Het, Met appeared in initial experiments to downregulate the transcriptional activity 
of the estrogen receptor. More careful analysis, however, showed that it also causes a 
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down-regulation of the constitutively active ß-galactosidase reporter (Fig. 6.4b). Although 
`correction' of luciferase activity by ß-galactosidase appears to leave a residual inhibitory 
effect of Het and Met on oestrogen signalling, it seems likely that differences in half-life 
of these two proteins are responsible for these changes, raising doubts about the earlier 
reports describing Het as a regulator of oestrogen signalling329. Similar arguments may 
apply to the ability of Het to downregulate Hsp27 transcriptional activity in various cell 
lines325. Experiments described in this thesis clearly show the potential for 
misinterpretation of reporter assays when a constitutively expressed reporter is used to 
control for transfection efficiency of a regulatable reporter340. 
That Met behaves in a similar manner to Het is not entirely unexpected. Het has been 
shown to bind RNA polymerase II (Pol 11)326, so the ability of Met to interfere with 
reporter gene activity could be due to its effect on RNA polymerase II activity. If Met 
does indeed function at the level of the polymerase, it would explain why it has a 
generalized effect on cellular activity, rather than exerting effects on specific gene 
sequences. 
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Figure 6.14 Northern Blot showing expression of Met mRNA in various tissues (BM= bone 
marrow. Experiment performed by Dr. S. Colley). 
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From the experiments described in this chapter, we conclude that Met induces apoptosis, 
not just in the MCF-7 breast cancer cell lines, but also in other cancer (HepG2, HeLa 
cells) and non-cancerous (SF) cell lines (Table 6.1). This effect is also preserved across 
the species barrier (Ros and MC3T3), as established by cell cycle profiling, and 
confirmed by Hoechst staining (Fig. 6.14). In HeLa cells, the remaining viable cell 
population appears to be arrested primarily in the G1 phase, with a corresponding 
decrease in the G2 population. The proportion of cells in the S phase remained 
unchanged (Fig 6.12). Similar changes were noted in the other cell lines, but these were 
not statistically significant (Table 6.2). 
From results shown in Figs. 6.9 and 6.8, apoptosis induced using the EYFP-Met chimera 
(37±10% (SD)) appears to be greater than that detected when HA-tagged Met is used 
(23+6% (SD)). This discrepancy may be due to preferential leakage of EYFP from cells 
(co-transfected with pEYFP and HA-Met) in late apoptosis owing to leaky membranes. 
Leakage of enhanced green fluorescent protein (EGFH) from permeabilized cells is 
known to occur (infomation from Invitrogen website). EYFP is very similar to EGFP 
(created by performing 4 amino acid substitutions to EGFP) in structure and size, and it 
can be expected to behave in a similar manner. In contrast, when cells are transfected 
with the EYFP-Met chimera, owing to the larger size of the product, there is less likely to 
be loss of EYFP. 
Similarly, the extent of apoptosis induced by Met varies depending on the cell line in 
question (Table 6.1). In Ros and HeLa cell lines, Met induces a twofold increase in the 
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amount of apoptosis detected, whereas in the MCF-7 and MC3T3 cell lines, this increase 
is threefold. In the HepG2 and SF cell lines, the increase is fourfold. The difference does 
not appear to be due to interspecies differences as Ros and MC3T3 cell lines are derived 
from rat mouse respectively. The difference in apoptosis detected could be attributed to 
several factors, the first being differences in transfection efficiency. A difference in the 
response of each cell line to serum starvation, leading to changes in cell cycle 
progression, survival signalling, and how these affect the response of the cell to apoptois 
could also be responsible. Another factor that has to be considered is the effect of 
transformation/immortalization on susceptibility to apoptosis. SF fibroblast cells were 
found to be particularly prone to apoptosis. These are primary untransformed cells and 
their reaction to Met is consistent with the hypothesis that the further along the 
transformation pathway a cell has gone, the more resistant it is to apoptosis. This leads on 
to the third possibility that the amount of apoptosis induced is affected by the presence or 
absence of mutations affecting the apoptotic programme, which will vary from cell line to 
cell line. 
Most probably, decreased expression of reporter plasmids is linked to the induction of 
apoptosis by Met and could, for example, result from decreased gene expression or 
mRNA translation, or increased mRNA or protein turnover. Given the similarity between 
Met and Het, together with evidence that Het interacts with RNA polymerase II, it seems 
likely that one consequence of overexpressing Met might be inhibition of mRNA 
synthesis. Whether or not effects on reporter genes are linked to the ability of Met to 
induce apoptosis is unclear. One possible path by which Met could induce apoptosis 
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would be by affecting alternative splicing, since Het has been shown to regulate 
alternative splicing339. Thus, Met may favour the splicing of or induce the transcription of 
pro-apoptotic proteins which result in apoptosis 
Alternative splicing is a rapidly advancing field despite its relative infancy. The 
discovery that various cell proteins and enzymes exist in various isoforms, each 
possessing a unique function, has opened up another avenue by which cells can regulate 
their activities and response to extracellular stimuli341. Studies on key apoptotic 
components confirm that one mechanism of regulation could well be via alternative 
splicing. The best known example of alternative splicing in apoptosis is that of the Bcl-X 
protein. This exists as two isoforms, a long form (Bcl-XL), well known for its anti- 
apoptotic effect, and a short form (Bcl-Xs) which has been shown to be pro-apoptotic3a2 
In the same study, caspase-9 was also shown to have both pro-and anti-apoptotic 
isoforms. One of the earliest caspases to be discovered, caspase-2 (or Ich-1), has a pro- 
apoptotic long form and a short anti-apoptotic form3a3,3aa In addition, alternative splice 
forms for Apaf-1345 and caspase-8346 have also been identified and their apoptotic 
activities investigated. 
In view of these findings, we decided to characterize the Met protein further, by 
investigating its cellular localization, its co-localization with sites of transcription, and 
whether it alters transcription and mRNA processing. 
181 
7 Met Expression and Function 
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7.1 Characterization of Met 
Because of its similarity to HetJSAF-B, in the previous chapter we investigated the 
involvement of Met in oestrogen signalling. In this chapter, we investigate other possible 
similarities between the two proteins, such as cellular localization. Also, because 
Het/SAF-B has been shown to be involved in pre-mRNA processing339, we hypothesized 
that induction of apoptosis by Met might result from altered RNA processing. All 
confocal images were acquired using a Leica TCS-NT confocal laser scanning 
microscope attached to a Leica DM RBE upright epifluorescence microscope with phase- 
contrast. Leica software was used to process the images acquired. 
7 1.1 The cellular distribution of Met 
HeLa cells (1x105) were grown on coverslips in 6-well plates and incubated overnight. 
The cells were transfected with 1µg of either pEYFP-C1 (control plasmid) or pEYFP-Met 
using Fugene6 and incubated for 48 hours to allow for protein expression. The coverslips 
were fixed (2% PFAIPBS, 20min at room temperature) and mounted onto glass slides 
(BDH) and viewed by confocal microscopy to determine the cellular distribution of Met. 
From Fig. 7.1, it can be seen that Met is confined entirely to the nucleus, in a speckled 
distribution similar to that reported for Het/SAF-B. In addition, as with HeVSAF-B 325, it 
is clear that Met is also excluded from the nucleolus. 
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Figure 7.1 Cellular distribution of Met assessed by confocal microscopy. 
HeLa cells were grown on coverslips and transfected with either pEYIT(a) or p/; YI P-Met(h). 
The cells were fixed and mounted onto glass slides and viewed by confocal microscopy. (Scale: 
white bar: 5pm) 
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7.1.2 Comparison of Met localization with other proteins 
7.1.2.1 Does Met co-localize with the SC-35 splicing factor? 
As Met has a speckled distribution in the nucleus, we investigated the possibility that it 
might co-localize with a nuclear protein that displays the `classical' speckled distribution 
within the nucleus, namely a serine/arginine-rich (SR) splicing factor. The SC-35347 
splicing factor is one such protein localized to nuclear speckles. Although initial studies 
with a partial Het/SAF-B sequence did suggest co-localization between the two339, a 
subsequent study showed that Het/SAF-B speckles were distinct from speckles 
containing SC-35327. 
1x105 HeLa cells were grown on coverslips in 6-well plates and incubated overnight. The 
cells were transfected with 1µg pEYFP-Met using Lipofectamine Plus and incubated for 
48 hours to allow for protein expression. The coverslips were fixed (2% PFA/PBS, 20min 
at room temperature) and permeabilized (0.1% Triton X/PBS, 5min, room temperature). 
The cells were then blocked with 1%BSA/PBS for 20min at room temperature. Next, the 
cells were incubated with mouse anti-SC-35 primary antibody (Sigma, 1: 1000 dilution in 
1%BSA/PBS) overnight at 4°C. Following 3 washes with 1%BSA/PBS, the cells were 
incubated with Cy3-conjugated donkey anti-mouse secondary antibody (Jackson 
Immunology) (1: 800 dilution in 1%BSA/PBS) for 1-1.5 hrs at room temperature in the 
dark. After 3 washes with PBS, the coverslips were mounted onto glass slides using 
DAKO fluorescent mounting medium and the slides analysed by confocal microscopy. 
Fig. 7.2 shows that Met does not co-localise with the splicing factor SC-35, but forms 
distinct speckles. 
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Figure 7.2 Distribution of Met compared with that 
of SC-35, an SR protein, assessed by confocal 
microscopy. 
HeLa cells were grown on coverslips and transfected 
with EYFP-Met. The cells were fixed, permeahilized 
and then stained for SC-35. Following detection of the 
primary antibody using a donkey anti-mouse 
secondary antibody, the coverslips were mounted onto 
glass slides and viewed by confocal microscopy. Cells 
transfected with YFP-Met(top), distribution of S(7- 
35(middle), and overlay showing different 
distributions of Met and SC-35(bottom). (Scale: while 
bar: S1um) 
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7.1.2.2 Co-localization ofMet with Het 
We next studied the distribution of Met in comparison to Het. HeLa cells were plated out 
as before and co-transfected with 1µg of both pEYFP-Met and pHA-Het. Following a 48 
hour incubation, the cells were fixed, permeabilized, and blocked before staining for the 
Het protein using an anti-HA mouse monoclonal antibody (Sigma, 1: 5000 dilution) (4°C, 
overnight). The cells were washed 3 times with 1%BSA/PBS and then incubated with the 
secondary antibody (anti-mouse linked to Cy3, Jackson Immunology) (room temperature, 
1-1.5 hrs in the dark). The cells were then washed 3 times in PBS and then mounted onto 
glass slides. 
Fig. 7.3 shows that Met partially co-localizes with Het (white arrows). The co- 
localization is not complete, however, as shown by the presence of some green (Met) 
speckles in locations where Het appears to be absent (broad arrows) suggesting that 
functions of the two proteins may not be identical. 
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Figure 7.3 Co-localization of EYFP-Met with HA- 
Het. 
Hela cells were transfected with pEYFP-Met and HA- 
lfet. The cells were fixed and stained with anti-HA 
antibody before viewing under the confocal 
micro. sccope. The pictures show the distribution of Met 
(top, Het (middle) and an overlay of both images 
('bottom) showing co-localization of Het with Met. (co- 
localization: narrow arrow; lack of co-localisation: 
broad arrows. ). (Scale: white bar. - S/tm) 
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7.1.2.3 Does Met co-localize with the oestrogen receptor (ER)? 
Although our initial experiments did not provide evidence in favour of a role for Met in 
the regulation of oestrogen receptor activity, we could not completely rule out such an 
interaction. In addition, several studies have shown that members of the nuclear hormone 
receptor family form discrete foci within the nucleus after activation by ligand 48,149 The 
question then arises whether these foci, which probably represent sites of gene regulation, 
coincide with Met speckles. Therefore, we decided to compare the distribution of Met 
with the ER. As it is quite difficult to detect endogenous ER, we used a red fluorescent 
protein tagged ER chimera (pRFP-ERa, provided by Donald McDonald). HeLa cells 
were co-transfected with 1µg of both pEYFP-Met and pRFP-ERa. After a 48 hour 
incubation, the cells were exposed to 10$M E2 for 1 hour, then fixed and mounted onto 
glass slides before viewing under the confocal microscope. 
Fig. 7.4 shows that Met (green) does not co-localise at all with ERa (red) in the absence 
of E2. Although it has been reported that E2 results in nuclear relocalisation of ER 349, We 
found that the images were unchanged for cells that had been exposed to E2 (Fig. 7.4d) 
showing that ERa either does not undergo nuclear localization on ligand binding, or else 
this change was very transient. 
7.1.3 Mechanism of Action of Met 
Met and Net induce apoptosis when overexpressed in cells while Net has been shown to 
alter splicing. Since changes in splicing have been linked with the induction of 






Figure 7.4 Distributuion of Met compared with the Oestrogen receptor (ER). 
MCF-7 cells were transfected with pEYFP-Met and pRFP-fina, incubated for 48hrs with or 
without exposure to 10-$M B2 for I hr, prior to fixing and analysis under the confocal 
microscope. (a) shows the distribution of EYFP-Met in MCF- 7 cells, (b) shows the distribution oJ' 
ERa, and (c) shows an overlay of the two images, with different distributions of Met and the LR. 
(d) shows an overlay of Met and ER following treatment with E2. (Scale: white bar: Slum) 
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action might involve altered splicing of caspases. 
7.1.3.1 The presence of Ich-1L and Ich-IS in HeLa cells 
43 Caspase 2 has been shown to have two isofonm which result from alternative splicing' 
The full-length caspase, called Ich-1L, is a 435 amino acid product, while the truncated 
form, Ich-1 s, is only 312 amino acids long. Figure 7.5 shows the isoforms of caspase-2, 
and how they arise following splicing from the two 5' donor splice sites (blue arrows). 
Splicing of the distal site (5'a) results in an mRNA encoding the full-length caspase-2. 
When the proximal site (5'b) is spliced, 61 base pairs of the intron (blue rectangle) are 
included in the mRNA sequence, resulting in the inclusion of an early Stop codon (red 
arrow), and hence translation of a shortened protein. 
The primers used in the reverse transcription - polymerase chain reaction (RT-PCR) are 
those described by Wang et al3a3 The purple triangles indicate the approximate positions 
of the primers. RT-PCR of mRNA is expected to result in two products, corresponding to 
the long and short forms of caspase-2. Owing to inclusion of the additional 61bp of the 
intron, following splicing at the proximal 5'site (5'b) for Ich-ls, the resulting PCR 
product is longer (-295bp) than the PCR product for Ich-IL (the full caspase-2) which 
does not include the additional 61 bases (-234bp). Thus when the products are 
electrophoresed on an agarose gel, the larger product corresponds to Ich-Is, while the 








Figure 7.5 Alternatively spliced forms of Caspase -2 (Ich-1). 
Caspase 2 has two isoforms that arise due to alternative splicing of the 5 splice site. Splicing of 
the proximal site (5' b) results in the inclusion of a 61bp sequence, and places in frame a 
translational stop codon 21 amino acids downstream of the insertion site. This early stop codon 
results in the translation of a shortened protein, the truncated caspase 2 (Ich-IS). Splicing of the 
distal 5'splice site excludes the 61bp sequence and the early termination codon, resulting in the 
full length caspase 2 protein (Ich-IL) (Purple triangles: position of primers, showing how the 
PCR product from Ich-I L is shorter than the product from Ich-1 S)343. 
192 
3x107 HeLa cells were trypsinized, washed in PBS and resuspended in RNAlater 
(Ambion). Total RNA was then extracted from the cells using the RNAeasy Midi Kit 
(Qiagen) and poly(A+) RNA was isolated using the PolyATract Isolation System IV 
(Promega). mRNA was then reverse transcribed and the cDNA obtained subjected to a 
polymerase chain reaction (Access RT-PCR Kit, Promega), using primers for the Ich-1 
gene. These primers are on separate exons, separated by an intronic sequence of 2.8kb in 
genomic DNA, so avoiding the risk of amplifying genomic DNA. 
The primers were: 
Forward: GTT ACC TGC ACA CCG AGT CAC G 
Reverse: GCG TGG TTC TTT CCA TCT TGT TGG TCA 
The following PCR conditions were used: 1mM magnesium sulphate, 50pmol of each 
primer, and 20mM dNTPs. Reverse transcription was performed at 48°C, for 45 min, 
followed by a2 min denaturation at 94°C. The following PCR cycle was used: 40 cycles 
of 94°C for 1 min, 57°C for 1 min and 68°C for 2 min, and a final extension at 68°C for 
10 min. 
The products of the PCR reaction were electrophoresed on a 2% TAE agarose gel. Fig. 
7.6 shows a band migrating at -295bp and a weaker band at -234bp, corresponding to 
Ich-ls and Ich-1L respectively. 
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4 295bp (Ich-is) 
4 234bp (Ich-1L) 
Figure 7.6 RT-PCR of HeLa mRNA to demonstrate presence of the mRNA for Ich-Is 
(295bp) and Ich-1L (234bp). 
mRNA from HeLa cells was extracted and RT-PCR using primers specific for Ich-1 was 
performed (The control (Ctrl) was performed using a water blank). 
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7.1.3.2 Effect ofMet on alternative splicing ofpro-caspase2 
We next investigated the possibility that overexpression of Met in HeLa cells might result 
in a change in the amounts of the alternative spliced forms of Ich-1L and Ich- I Is 
3x106 cells were seeded in 100mm dishes and transfected with either 4µg of pcDNA3 (P) 
or pMet-HA (M) using Lipofectamine Plus reagent. The cells were incubated for 48 
hours and RNA extracted with the RNAeasy Kit (Qiagen). mRNA was isolated as before. 
The mRNA was then reverse transcribed and PCR performed using the Access RT-PCR 
kit (Promega), with the same conditions as described previously. 
Fig. 7.7 shows the cDNA products from RT-PCR of mRNA extracted from HeLa cells 
transfected with either pcDNA3 (P) or pMet-HA (M). In cells transfected with Met, the 
amount of PCR product for both the long and short forms of caspase-2 appears to be 
increased compared to the cells transfected with the empty plasmid. RT-PCR for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) from the mRNA samples was 
subsequently performed as a control to assess consistency of mRNA extraction between 
the 6 samples. The primers used for PCR of GAPDH were as follows: 
Forward primer: AAGGCTGAGAACGGGAAGCTTGTCATCAAT (exon 3, bp241-270) 
Reverse primer: TTCCCGTCTAGCTCAGGGATGACCTTGCCC (exon 7, bp 740-711) 




Figure 7.7 cDNA products from RT-PCR assessing the effect of overexpressing Met on the 
relative abundance of the alternatively spliced forms of the Ich-1 (caspase 2) gene. 
HeLa cells were transfected with pcDNA3 (empty plasmid, pcDNA) or pMet-HA plasmid (Met) 
and incubated for 48hrs. 3 separate transfections with each plasmid were performed and the RNA 
extracted separately. mRNA was then isolated and RT-PCR using specific primers was 
performed The product from the Ich-1S is 295bp, and the product from the Ich-IL isoform is 
234bp. (M. " markers) 
S00bp 
Figure 7.8 cDNA products from RT-PCR of GAPDH mRNA in the above samples. 
mRNA from the above samples was suhjected to RT-PCR using primers specific to GAPDH. The 
. 
fragment from GAPDH PCR is about 500bp in size. (M. - markers) 
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from Met transfected cells in comparison to that from the control cells transfected with 
empty plasmid (pcDNA3). Similar results were obtained in two additional experiments 
(not shown) implying that total mRNA was extracted more efficiently from Met 
transfected cells. 
The results shown in Fig. 7.7 do not show an obvious change in the ratio of Ich-1L to Ich- 
's, but it is difficult to quantify bands visually. To obtain a quantitative measure of the 
ratio of long to short isoforms of Ich-1, the above PCR assay was repeated using a 
fluorescent moiety on the 5'end of the forward primer, and the fluorescence of the 
products of the PCR reaction was measured using an ABI Prism 310 Genetic Analyzer 
(analysis performed by Ms Sarah Groves, Dept of Pathology and Microbiology, 
University of Bristol). 
As shown in Fig. 7.9, there is no change in the ratio of the long to short forms of the 
caspase-2 PCR products in cells transfected with Met. 
7.1.3.3 Measurement of mRNA synthesis using [3H] uridine incorporation. 
Given that Met had an inhibitory effect on reporter gene activity, we decided to 
investigate whether this could be due to an inhibition of mRNA transcription. Therefore, 
we measured incorporation of uridine into RNA. 
HeLa cells (1.5x105) were seeded into 60mm dishes, and transfected with either 21Lg of 







Figure 7.9 Ratio of the PCR products of Ich-! 1, to Ich-1s following transfection with Met. 
HeLa cells were transfected with either pcDNA3 (empty plasmid) or pMet-HA (Ipg each). 
Following a 48 hr incubation, cells were lysed and mRNA extracted. RT-PCR of'the mRNA, using 
fluorescent labeled primers, was performed and the products of the reaction analysed on an AB! 
Prism 310 Genetic Analyser (analysis performed by Dr. S. Groves). This figure is the mean of 
three separate experiments (showing the mean and standard deviation). 
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20jCi/dish for lhr, after which the cells (from medium, 1xPBS wash and following 
trypsinization) were collected, lysed and RNA extracted using the RNeasy Mini Kit. 
mRNA was then isolated using the Promega PolyTract A+ mRNA Isolation Kit and 
radioactivity measured using the 1400 DSA Liquid Scintillation Counter. As shown in 
Fig. 7.10, Met-transfected cells show a marked inhibition of mRNA synthesis (down to 
47%±14(SD)) compared to pcDNA transfected cells, (p<0.005). 
7.1.3.4 Measurement of total RNA transcription using [3H] uridine incorporation. 
To determine whether overall RNA synthesis was affected by Met, HeLa cells (3x104) 
were seeded in 96-well plates and incubated overnight. The cells were transfected with 
0.1µg of either pcDNA3 (empty plasmid) or pMet-HA using Lipofectamine Plus 
(Invitrogen), and incubated for a further 48 hours. Following this, cells were exposed to 
[3H] uridine (lttCi/well) for 1 hour. The cells were then lysed and transferred to Printed 













Figure 7.10 Effect of Met on mRNA synthesis in HeLa cells, assessed by uridine 
incorporation. 
HeLa cells were transfected with 2, ug of either pcDNA3 (empty plasmid) or pMet-HA, and 
incubated for 48hrs. The cells were exposed to /3H/ uridine (20R('i dish) for Ihr, hebre cells 
were collected and RNA extracted. The mRNA fraction was isolated from this, and the 
radioactivity measured in the 1400 DSA Liquid Scintillation Counter (Wallas). phis figure is the 
mean of three separate experiments (showing the mean and standard deviation). 
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Fig. 7.11 shows that there is no significant difference (p= 0.67) in the overall rate of RNA 
synthesis following overexpression of Met in HeLa cells. 
7_2 DISCUSSION 
Using confocal microscopy, we were able to ascertain that Met was confined to the 
nucleus in a speckled fashion (Fig. 7.1), in a distribution that was similar, but not 
identical to that of Het (Fig. 7.3). This implies that while Met may be involved in some of 
the same processes as Het, this is not the sum of its actions, and thus Met is likely to have 
some unique functions. Methodological considerations, however, meant that we cannot 
be entirely sure that the small differences in location reflect true differences in the 
distribution of these proteins. It is possible that differences in expression result from the 
use of different vectors (Het in PCR 3.1 and Met in pEYFP-Cl), though both are driven 
by the same promoter (CMV). It is also possible that the EFYP moiety itself affects 
distribution, perhaps resulting in some degradation of the chimera at specific sites. 
Finally, incomplete co-localization could arise due to a difference in fluorescent 
intensities of EYFP and Cy3 since a certain degree of photo-bleaching was observed with 
Cy3. It was also noted that Met was excluded from the nucleoli of the cell, the main site 
of ribosomal RNA synthesis, processing and maturation351, which leads us to infer that 
Met does not have any direct activity on ribosomal RNA synthesis, a view that was 
strengthened by our results from [3H] incorporation showing that Met inhibited mRNA 













Figure 7.11 Effect of Met on transcription of total RNA in HeLa cells, assessed by uridine 
incorporation. 
HeLa cells were transfected with 0.1 pg of either pcDNA3 (empty plasmid) or pMe! -HA, and 
incubated for 48hrs. The cells were exposed to 13HJruridine (l pCi, well) for Ihr before cells lysed 
harvested, and radioactivity measured. This figure is the mean of three separate experiments 
(showing the mean and standard deviation. 
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The studies described in the previous chapter did not support a role for Met in regulation 
of ER signalling, but had not completely ruled out such a function. Moreover, earlier 
studies on nuclear hormone receptors demonstrated that ER could be induced to assume a 
speckled pattern in the nucleus after ligand activation349, so we decided to determine 
whether Met and the ERa co-localised in the nucleus. The complete absence of any 
overlap in distribution of the two proteins is compatible with our earlier conclusion that 
Met does not interact directly with the ER, but does not rule out an indirect interaction 
(Fig. 7.4). However, unlike a previous study349, we did not observe E2-induced speckling 
of ERa. The most probable reason was that we were looking at the distribution of 
overexpressed ERa, while the previous study had analysed distribution of endogenous 
ERa using labelled autoantibodies. 
In recent years, it has been accepted that the nucleus is organized into distinct structural 
components, called `nuclear bodies'. These include nucleoli, Cajal (coiled) bodies, 
promyelocytic leukaemia bodies and speckles352'353. Most of these structures have been 
implicated in RNA metabolism354 Nuclear speckles have been found to contain high 
concentrations of pre-mRNA splicing factors, such as SC-35, and correspond to 
interchromatin granules originally observed via the electron microscope355. Whilst the 
function of these speckles is still undefined, it is clear from the available evidence that 
they are involved with the storage and/or assembly of components of the splicing 
machinery356-35s The speckled nuclear distribution of Met therefore suggested that Met 
may be involved in mRNA transcription or processing and we were interested to compare 
its distribution with other proteins localized to speckles that are known to be involved in 
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mRNA splicing. One of these is SC-35, a splicing factor that is involved in mRNA 
processing359. From our studies, it is apparent that Met does not co-localize with SC-35 at 
all (Fig 7.2). Weighardt et a1.327 made a similar observation when studying possible co- 
localization of SC-35 and Het/SAF-B/HAP. In this initial study, Weighardt et al. had 
described a 917 amino acid protein that was a member of the hnRNP family, as co- 
immunoprecipitation studies using the anti-HAP antibodies also brought down 
ribonucleoprotein complexes327. In this and a later paper, they also demonstrated the re- 
localization of HAP/SAF-B into a distinctive punctate pattern that did not coincide with 
coiled bodies or speckles following heat shock. Incidentally, they had performed co- 
localisation studies of HAP/SAF-B with splicing factor SC-35 in HeLa cells without heat 
shock, and also found no co-localisation between the two proteins3n, 
360. As Met appears 
to have a similar distribution, we propose that Met, together with Het/SAF-B, may reside 
in a previously unidentified nuclear domain, but this will require further investigation. 
Studies on uridine incorporation show that Met must exert a profound effect on mRNA 
synthesis. These experiments were performed on cells transfected with a plasmid 
expressing Met, so that inhibition of mRNA by -50% when cells are transfected with an 
efficiency of about 80% suggests an almost complete cessation of mRNA synthesis in 
cells overexpressing Met. Given that Met down-regulates both cellular transcriptional 
activity and induces apoptosis, we wished to identify the initiating event for these 
processes. It is possible that either Met induces apoptosis which then results in decreased 
transcriptional activity or that Met inhibits transcriptional activity which then results in 
apoptosis. The former seems more likely because apoptosis has been associated with 
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decreased mRNA levels361"363, probably due to degradation of RNA polymerase II, 
required for transcription of mRNA, by caspases3M. The latter posibility seems less likely 
because generalized inhibition of transcription by itself does not invariably result in 
apoptosis36s The presence of a SAF box and RNA binding domains within Met suggest 
that Met is involved in mRNA processing, and one way it could induce apoptosis at this 
level would be to alter splicing of proteins involved in apoptosis. 
Several studies have shown that various pro-apoptotic proteins, particularly caspases, 
have alternative splice forms 342 346 3cß, 367, and the expression of one over the other can tip 
the cell into apoptosis, or favour cell survival344'345,368Moreover, Valcarcel et al have 
recently shown that the apoptosis-promoting factor T-cell restricted intracellular antigen 
(TIA)-1369 is able to regulate splicing of the human Fas mRNA by strengthening the 
recognition signal of a particular splice site in the gene370, thus promoting apoptosis, and 
we speculated that Met may promote apoptosis via a similar mechanism. 
Thus, we decided to investigate the possibility that Met may affect the splicing and 
hence, change the ratio of caspase-2 (Ich-1) isoforms, which have been shown to have 
opposite functions343 The long form (Ich-1L) induces apoptosis, while the shorter form 
(Ich-1 s) blocks apoptosis. Various studies have shown, and we also confirmed (Fig. 7.6), 
that HeLa cells express both isoforms of Ich-1343,367 This, together with the fact that 
HeLa cells transfect relatively efficiently, made them the cell line of choice to assess 
whether overexpression of Met affected the ratio at which the long form of Ich-1 was 
expressed compared to the shorter form. 
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If our hypothesis were true, we would expect a relative increase in the amount of the long 
form of Ich-1, associated with either a decrease, or no change, in the amount of Ich-Is 
expressed. Unexpectedly, RT-PCR appeared to show an increased amount of mRNA for 
both Ich-1L and Ich-Is (Fig. 7.7). A similar change was observed using primers for 
GAPDH (Fig. 7.8) as an internal control, however. Similar results were obtained in three 
separate assays, suggesting that mRNA from Met transfected cells is more efficiently 
recovered, perhaps due to physical interaction between Met and mRNA preventing 
degradation, or increased efficiency of mRNA extraction from cells undergoing 
apoptosis. This was reflected in the results of the RT-PCR reactions using fluorescent 
primers (Fig. 7.9) which allowed us to quantify the relative amounts of Ich-IL and Ich-Is. 
Thus, regardless of the apparent increase in the amount of mRNA extracted from Met 
transfected cells, the proportion of Ich-1L to Ich-ls remains unchanged, and is not 
affected by Met. The question arises whether Met is involved in alternative splicing at all. 
The factors that point to a possible role are the presence of a serine/arginine (SR) rich 
domain (characteristic of a group of splicing factors called SR proteins, such as SC- 
35)347.371, and the RNA recognition motifs that are found in proteins known to affect 
alternative splicing (e. g. hnRNP Al and hnRNP D (Fig. 6.1)). Splicing of pre-mRNA 
occurs in a large ribonucleoprotein complex, termed the spliceosome. This consists of 5 
small nuclear ribonucleoproteins (snRNPs) and between fifty to a hundred polypeptides, 
some of which are splicing factors. The complex functions not only to identify splice 
sites, but also to position the pre-mRNA transcript into a configuration suitable for 
efficient excision of introns and ligation of remaining exons, to produce mature 
mRNA372. Whilst the `core' members of the spliceosome are the snRNPs, they are 
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facilitated in their function by various SR proteins, such as SC-35 and U2 auxiliary factor 
(U2AF)372. Indeed, it is the RNA recognition motifs (RRMs) of SR proteins that are 
responsible for binding of RNA and substrate spec city372.373. Thus it is possible that the 
RNA binding sites on Met do not recognize the splice sites of caspase-2 and thus, Met is 
unable to affect splicing of this protein. A construct that has been used by many groups to 
assess the ability of a protein to affect alternative splicing is the EIA minigene374-379. A 
partial sequence of Het/SAF-B (corresponding to the C-terminal portion of human SAF- 
B) has been shown to affect splicing of the EIA minigene339, but the properties of this 
fragment differ from those of the full length protein because Nayler et al found that the 
Het/SAF-B fragment co-localized with the splicing factor SC-35 whereas later studies 
with the full length protein found that SAF-B did not co-localize with SC-3532'. 
Nevertheless, it would clearly be interesting to test the ability of Met to affect splicing of 
the E1A minigene. 
There are a number of questions raised. Is Met a specific trigger for apoptosis in cells, 
and is there a mechanism by which cells could be stimulated to produce Met? If so, can 
Met production be initiated by known death ligands / stimuli? Alternatively, is the 
cellular concentration of Met so critical that a small change disrupts cellular metabolism 
so severely as to result in apoptosis? 
Thus, it would be interesting to assess the effect of Met on caspase activation, 
cytochrome c release, as well ratios of the bcl-2 protein family. At the same time, it 
would be interesting to assess gene activation and repression using microarrays, targeted 
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initially at genes that are important in cell survival and in apoptosis. Another avenue to 
pursue would be to assess whether Met affects the splicing of other proteins involved in 
apoptosis that are known to have alternative splice forms such as caspase-9342, caspase- 
8346 and Bcl-x380. 
In summary, the Met protein is located entirely within the nucleus, but is excluded from 
the nucleoli, which are concerned mainly with the synthesis, processing and maturation 
of ribosomal components351'3s1 Functionally, this is corroborated by the results of uridine 
incorporation, where Met overexpression profoundly inhibits mRNA synthesis but has 
very little effect on overall RNA transcription rate (Fig. 7.1 1), which represents primarily 
ribosomal RNA synthesis. Within the nucleus, Met is distributed in a punctate fashion, 
reminiscent of, but distinct from, other nuclear bodies such as speckles, although it has a 
very similar distribution to Het/SAF-B. Overexpression of Met has been shown to induce 
apoptosis, but the mechanism is still unclear. We investigated the possibility that Met 
may alter the alternative splicing of proteins involved in apoptosis, but analysis of 
alternatively spliced forms of caspase-2 did not show any relative change in the amounts 
of each transcript. 
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8 Final Conclusion 
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The development of tumours is due to the immortalization of cells, linked to various 
adaptations they undergo in order to bypass normal cellular mechanisms that would 
otherwise implement programmed cell death in response to DNA damage or lack of 
growth factors. 
We proposed that, in breast cancer cells, one possible survival pathway is provided by 
activation of the Jak2-STATS pathway, by factors such as prolactin382. In other 
mammalian cell lines, STAT5 has been implicated in tumourigenesis243, zaa as well as cell 
survival245,2a6. In addition, in recent years, there has been increasing evidence to support 
the idea that prolactin may have a role in breast cancer to an extent that was not 
previously appreciated217,219,3s3,384 
In Chapter 3, we showed that247'385 prolactin did exert a protective effect in T47-D cells 
exposed to ceramide. This conclusion is complicated by two factors, however: (a) a 
protective effect was found using some assays, but not others, and (b) we failed to detect 
certain apoptotic markers such as annexin staining and accumulation of preG1 cells. In 
addition to ceramide, we tried a variety of other cytotoxic/apoptotic agents (gamma 
irradiation, progesterone, taxol etc., results not shown), but were unable to detect any 
change in the preG1 population or any increase in Annexin V binding, suggesting that 
these cells are unusually resistant to apoptosis, perhaps because they lack functional 
p53176. Further experiments involving the T47-D cells were also complicated by the 
limited degree of protection afforded by prolactin, making any assessment of changes / 
decreases in the protective effect difficult to quantify. 
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We decided, therefore, to use alternative approaches to dissect out the pathways that may 
be involved in the protective effects of prolactin. First we attempted to create a model of 
apoptosis in which the role of the Jak/STAT pathway could be investigated more readily. 
To this end, we attempted to create a stable cell line from human leukaemic CEM-C7 
cells. We chose these cells because they apoptose readily when exposed to 
glucocorticoids. Also, prolactin had already been established as a survival factor in 
glucocorticoid-induced apoptosis of the Nb2 rat lymphoma cell line 
386,387. Thus, we 
wished to translate this model into a human cell line in which we could more precisely 
assess the role of STAT5 in regulating apoptosis. 
CEM-C7 cells were shown to possess the components of the Jak2-STATS pathway, but 
we were unable to establish a stable line expressing the prolactin receptor, despite the fact 
that clones were isolated that appeared to have incorporated the prolactin receptor cDNA 
into their genome. Although this project may have provided some insight into the role of 
the Jak/STAT pathway in mediating the protective effects of prolactin, in retrospect, the 
information it may have provided might have been of limited value for understanding 
breast cancer. 
Next we attempted to create stable breast cell lines in which the survival effect of 
prolactin might be augmented. A clone of MCF-7 cells with stably incorporated STAT5b 
showed no obvious change in response to prolactin, but a clone of T47-D cells 
overexpressing STAT5b provided quite unexpected results. Rather than the enhanced 
protective response to prolactin we predicted, these cells exhibited a decreased 
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proliferative response to prolactin stimulation, and enhanced susceptibility to ceramide 
cytotoxicity following prolactin exposure. Had additional time been available, it would 
have been interesting to create stable cell lines expressing the STAT5a transcription 
factor, which could be responsible for the protective effects of prolactin. 
The last part of the study focused on work that had begun in our laboratory on a newly 
identified gene, which was originally thought to be involved in down-regulation of 
oestrogen signalling. Preliminary experiments by Dr. Colley appeared to support this 
finding, but subsequent studies raised doubts because it appeared that Met might be 
acting as a general inhibitor of transcription. We confirmed that Met exerts generalized 
inhibitory effects, and showed that constitutively active reporter genes used to control for 
transfection efficiency may lead to incorrect conclusions when they are used 
inappropriately. We then went on to show that Met has a punctuate distribution in the 
nucleus which is distinct from nuclear speckles, and overexpression of Met in a variety of 
cell types results in apoptosis. 
The results raise a number of questions. Is Met a specific trigger for apoptosis in cells, 
and is there a mechanism by which cells could be stimulated to produce Met? If so, can 
Met production be initiated by known death ligands/stimuli? Alternatively, is the cellular 
concentration of Met so critical that a small change disrupts cellular metabolism so 
severely that apoptosis ensues? Thus, it would be interesting to assess caspase activation, 
cytochrome c release, and changes in ratios of the bcl-2 protein family in response to 
overexpression of this protein. At the same time, it would be interesting to assess gene 
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activation and repression using microarrays, targeted initially at genes that are important 
in cell survival and in apoptosis. Another avenue to pursue would be to assess whether 
Met affects the splicing of other proteins involved in apoptosis that are known to have 
alternative splice forms such as caspase-9342, caspase-8346 and bcl-x380. 
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Appendix 
Ovine prolactin was purchased from Sigma. All tissue culture reagents and media were 
purchased from Sigma Corp., and tissue culture plastics (Nunc) were purchased from 
Fisher Scientific. Recombinant human prolactin was a kind gift from Vincent Goffin. All 
chemicals were purchased from Sigma Corp., unless otherwise stated. 
The HA-tagged Stat5a and Stat5b plasmids were a kind gift from Corinne M. Silva 
(University of Virginia). The pRK5-Jak-2 plasmid was kindly provided by Dr. J. Ihle (St 
Jude's Children's Hospital). pEYFP-Met, HA-Met plasmids were all constructed by Dr. 
Shane Colley. 
All primers were purchased from Invitrogen. 
Chemicals and Reagents 
1. Acrylamide/bisacrylamide solution (37.5: 1) 
2. N-acetyl-D-sphingosine (C2- ceramide) 
3.170-Estradiol 
4. Adenosine 5'-triphospate, sodium salt (ATP) 
5. Agarose, Type VII: Low Gelling Temperature 
6. Bovine Serum Albumin, Fraction V 
Biochemistry Stores, University of 
Bristol 
Sigma, Poole, Dorset, UK 
Sigma, Poole, Dorset, UK 
Sigma, Poole, Dorset, UK 
Sigma, Poole, Dorset, UK 
Sigma, Poole, Dorset, UK 
7. Charcoal / Dextran stripped Fetal Bovine Serum Perbio 
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8. Chlorophenol red-ß-D-galactopyranoside (CRPG) Sigma, Poole, Dorset, UK 
9. Co-enzyme A, sodium salt Sigma, Poole, Dorset, UK 
10. Dexamethasone (9a-fluoro-l6a-methylprednisolone) Sigma, Poole, Dorset, UK 
11. DL-Dithiothreitol (DTT) Sigma, Poole, Dorset, UK 
12. Fetal Bovine Serum First Link, UK 
13. Geneticin, G418 sulphate Gibco-BRL, Paisley, UK 
14. Hoechst 33258 Sigma, Poole, Dorset, UK 
15. Kanamycin Sigma, Poole, Dorset, UK 
16. LE Agarose, Seakem FMC Bioproducts 
17. L-glutamine Sigma, Poole, Dorset, UK 
18. Luciferin, sodium salt Promega, UK 
19. Neutral Red Sigma, Poole, Dorset, UK 
20. Optiphase `HISAFE' 3 Wallac 
21. Protein A-agarose beads. CN Biosciences, UK 
22. RNase A Sigma, Poole, Dorset, UK 
23. RNasesZap Ambion, Uk 
Solutions and Buffers 
1.4% paraformaldehyde (PFA): Solution made by dissolving PFA in PBS - heating to 
70°C, with stirring. 1M NaOH solution added slowly till PFA has dissolved completely. 
Stored in working aliquots at -20°C. Solutions can be stored at 4°C for 2 weeks. 
2. Antibiotic Stock solutions: All stored in aliquots at -20°C after filter sterilization. 
Ampicillin: l 00mg/ml in dH2O 
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Kanamycin: 30mg/ml in dH2O 
3. apo-Transferrin: 5mg/ml stored at -20°C in lml aliquots. 
4. ATP solution: 200mM ATP, stored in working aliquots, -20°C. 
5. Bovine serum albumin (BSA): 100mg/ml, stored at -20°C in 1 ml aliquots. 
6. Cell freezing solution: 10% DMSO, 20% FCS in the medium of growth. Mixture is 
made up just before use, filtered and chilled before cells are resuspended in it. 
7. Ceramide stock solution: 20mM in ethanol, Stored at -20°C. 
8. CPRG Assay Reagent: To be prepared just before use. 
4 plates 5 plates 6 plates 
CPRG Buffer 21m1 21m1 26m1 
ß-Mercaptoethanol 74µl 74µl 92µl 
CPRG Solution 2.8m1 2.8m1 3.5ml 
9. CPRG Buffer: 60mM Na2HPO4.7H20,40mM NaH2PO4110mM KC1,1mM 
MgSO4.7H20. pH to 7.3, filter and store at room temperature. Before use, add 50mM ß- 
Mercaptoethanol. 
10. CPRG solution: 62.5ml H2O with 250mg CPRG. Aliquot into light-tight tubes and 
store at -20°C 
11. CoEnzyme A solution: 135mM solution in dHZO, stored in working aliquots at -20°C. 
12. DMEM: supplemented with 10% FCS, 2mM L-glutamine. 
13. DNA loading buffer: 30% glycerol, 0.25% bromophenol blue. 
14. DTT solution: 1M solution, stored in working aliquots, -20°C, in the dark. 
15. G418 solution: 200mg/ml in dH20, filter sterilized and stored in aliquots at -20°C. 
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16. Hoechst Dye: 100pg/ml, stored in working aliquots at -20°C. 
17. Krishnan's reagent: 0.05mg/mi PI, 0.1% sodium citrate, 0.02mg/ml ribonuclease A, 
0.3% NP-40 (Igepal), pH 8.3. The solution is made up in 100ml of dHZO, and stored at 
4°C. 
18. L-glutamine solution: 200mM stock, stored at -20°C, in 5 ml aliquots. 
19. Luciferin Solution: 10mM, dissolve in Luciferase Assay Reagent and store in 
working aliquots at -80°C, in the dark. 
20. Luciferase Assay Buffer (lx): 20 mM tricine, 0.1 mM EDTA, 1.07 mM 
(MgCO3)4Mg(OH)2.5H20,2.67 mM MgSO4.7H20, pH to 7.8, filter and store at room 
temperature. 
21. Luciferase Assay Reagent: Prepare just before use, protect from light. 
for: l oml 20m1 50m1 
1X Luciferase assay 9.5m1 19m1 47.5m1 
buffer 
200mM ATP 26.61l 53.21il 133µI 
1M DTT 333µl 666µl 1.665m1 
135mM CoA 20µ1 400 1O00 
10mM luciferin 5000 imi 2.5m1 
22. Luria Bertani (LB) Broth: Yeast extract Sg/L, Bacto-tryptone lOg/L, NaCl lOg/L. 
Aliquoted and autoclaved immediately. For LB agar, l5g/L of bacteriological agar added 
to LB broth before autoclaving. 
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23. Lysis Buffer A (lx) for Luciferase Assay and ß-Gal Assay: 25mM Tris Phosphate, 
2mM CDTA, 10% Glycerol, 0.5% Triton X-100, made up as a 5x solution and stored at 
room temperature. 2nM DTT added just before use. 
24. Lysis Buffer B: 0.05M Tris HCI, pH 8.0; O. IM EDTA; 0.5% SDS 
25. Neutral red solution: 3.3g/1 in PBS, stored at 4°C in the dark 
26. PMSF solution: 200mM in methanol, stored at 4°C. 
27. Prolactin stock: Lyophilized solid is suspended in 10mM Tris HCl (pH 8), allowed to 
rehydrate for 10min on ice. Solution then centrifuged at 10,000rpm for 10 min at 4°C, 
and supernatant aliquoted and stored at -80°C. 
28. Propidium iodide stock solution: 1 mg/ml in dH2O; 0.1% sodium azide, stored at 4°C 
in the dark. 
29. Protein Loading Buffer (SSB): 4.8ml dH2O, 1.2m1 0.5M Tris HCl (pH 6.8), lml 
glycerol, 2m1 10%(w/v) SDS, 0.5m1 0.1 %(w/v) bromophenol blue. Stored at room 
temperature. Just before use, add ß-mercapthoenthanol (final concentration 5% (v/v)). 
30. Recipe for 2xDMEM / 2xRPMI: 
2x DMEM (I Omis) 2x RPMI (I Omis) 
7.5% NaHCO3 0.986m1 0.534m1 
L-glutamine (200mM) 0.2m1 0.2ml 
Fetal Calf Serum 2m1 2ml 
1 Ox DMEM/RPMI 2m1 2m1 
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dH2O 4.814m1 5.066m1 
31. Recipe for SDS-Page Gel: 
8% Separating Gel 4% Stacking Gel 
AcrylamideBis (30% Protogel) 21.4 mis 5.4 m1s 
Tris HC1,1.5M, pH 8.8 20 mis -- 
Tris HC1,0.5M, pH 6.8 -- 10 mis 
10% (w/v) SDS 0.8 mis 0.4 mis 
Water 37.8 mis 24 m1s 
10% Ammonium persulphate 0.8 mis 0.4 mis 
TEMED 27µl 20µ1 
32. RNase A solution : 10mg/ml, stored in working aliquots at -20°C. 
33. Running Buffer (5x): 15g Tris Base, 72g Glycine and 5g SDS in 1L dH2O. Stored at 
room temperature. 
34. Serum free DMEM: DMEM, 2mM L-glutamine. Stored at 4°C. 
35. Serum Free Medium (SFM): DMEM/F12,10µg/m1 apo-Transferyin, 0.01%BSA and 
2mM L-glutamine. 
36. Standard Lysis Buffer (SLB): 10mM Tris HCI, pH 7.6; 5mM EDTA (disodium salt);. 
50MM NaCl; 30mM Na pyrophosphate; 50mM NaF; 100µM sodium orthovanadate, 1% 
Triton X-100. Store at 4°C. On day of lysis, the buffer is supplemented with 1 mM PMSF, 
2.5pg/ml aprotinin, 2.5µg/ml leupeptin and 50pg/ml Pepstatin A. 
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37. TAE (50x): 242g Tris HCI, 57.1 ml glacial acetic acid and 100m1 0.5M EDTA (pH 
8), in 1L of dH2O. Stored at room temperature. 
38. TBS-Tween (10x): 100mM Tris HCI, pH 8.0; 1.5M NaCl; 0.5% Tween. Stored at 
room temperature. 
39. TE buffer: 10mM Tris-Cl, pH 8.0; 1 mM EDTA. Stored at room temperature. 
40. Transfer Buffer: 3g SDS, 87g glycine, 17.4g Tris Base; dissolved in dH20, with the 
addition of 600m1 methanol, before bringing final volume to 3L with dH2O. Stored at 
room temperature. 
Laboratory Equipment 
1. Avanti 30 centrifuge 
2. Capacitance Extender Plus 
3. CellQuest software 
Beckman, Fullerton, CA 
BioRad, Hemel Hempstead, UK 
Becton Dickinson, Oxford, UK 
4. Clifton heating block and stirrer 
5. Cell Counter Model Dn 
6. Consort E844 electrophoresis powerpack 
7. Coverslips (22mmx22mm) 
8. EPS 600 electrophoresis powerpack 
9. FACS Calibur 
10. Gene Pulser II 
11. Gene quart spectrophotometer 
12. Glass Slides 
13. Grant heating block 
Jencons-PLS, Leighton Buzzard, UK 
Coulter, UK 
Jencons-PLS, Leighton Buzzard, UK 
BDH 
Pharmacia, Little Chalfont, UK 
Becton Dickinson, Oxford, UK 
BioRad, Hemel Hempstead, UK 
Pharmacia, Little Chalfont, UK 
BDH 
Jencons-PLS, Leighton Buzzard, UK 
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14. Grant waterbath Jencons-PLS, Leighton Buzzard, UK 
15. GraphPad Prism Software GraphPad Prism CA 
16. Hettich zentrifugen Rotanta 46R Jencons-PLS, Leighton Buzzard, UK 
17. Leica TCS-NT confocal laser scanning microscope Leica 
18. Leica DM RBE upright epifluorescence microscope Leica 
19. Leica Confocal Software Leica 
20. LKB EPS 500/400 electrophoresis powerpack Pharmacia, Little Chalfont, UK 
21. Meltilex A (melt-on scintillator sheets, 73x109mm) Wallac 
22. Microcentaur tabletop microcentrifuge 
23. Microcentrifuge tubes 
24. Microfluor-Microtitre Plates 
Jencons-PLS, Leighton Buzzard, UK 
Appleton Woods, Selly Oak, UK 
Dynex Technologies, UK 
25. Micromax RF 
26. Microsoft Word Software 
27. Midi horizontal electrophoresis unit 
28. Mini-plus horizontal electrophoresis unit 
29. MLX microtiter plate luminometer 
Thermo Life Sciences, Basingstoke, UK 
Microsoft 
Jencons-PLS, Leighton Buzzard, UK 
Jencons-PLS, Leighton Buzzard, UK 
Dynex Technologies, Ashford, UK 
30. Plasticware Fisher, Loughborough, UK 
31. Plugged 2Oµ1,200µl and 1000}tl tips Anachem, UK 
32. Printed Filtermat A(glass fibre filter 90x120mm) Wallac 
33. Protean II xi cell Western Blot tank BioRad, Hemel Hempstead, UK 
34. RLX ß-microplate reader 
35. Stuart Scientific Platform Shaker STR6 
36. Trans-blot SD, semidry transfer cell 
Dynex Technologies, Ashford, UK 
Prior Lab Supplies, UK 
BioRad, Hemel Hempstead, UK 
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37. Techne Genius Thermocycler Jencons-PLS, Leighton Buzzard, UK 
38. TOMTEC Harvester 96 Mach 3 Receptor Technologies, Ltd. 
Banbury, UK 
39. Ultracentrifuge Beckman, Fullerton, CA 
40.1450 MicroBeta Liquid Scintillation and Luminescence Counter Wallac 
41.1450 MicroBeta Windows Workstation Version 3.2 Wallac 
42.1400 DSA Liquid Scintillation Counter Wallac 
43.1400 DSA version 2.5 (software) Wallac 
Kits: 
1. Access RT-PCR System 
2. ApoAlert® Annexin-V-FITC Kit 
3. Enhanced Chemiluminescence Kit 
4. HiSpeed Plasmid Purification Kits 
5. Po1yA+Tract (mRNA) Isolation System IV 
6. Protein Microdetermination Kit 
7. QlAprep Miniprep Kit 
8. QIAquick Gel Extraction Kit 
9. RNAeasy Midi/Maxi Kit 
10. Top10 Competant E. Coli 
11. XTT Cell Proliferation Kit II 
Promega, 











Enzymes, Vectors and Antibodies: 
1. ANTI-FLAGG M2 monoclonal antibody, FITC-conjugate Sigma 
2. ANTI-FLAGS M2 monoclonal antibody Sigma 
3. EZviewTM red ANTI-FLAGS M2 affinity gel Sigma 
4. Monoclonal Anti-HA, clone HA 7 Sigma 
5. Anti-HA probe, rabbit polyclonal Autogen BioClear 
6. Monoclonal anti-splicing factor, SC-35 Sigma 
7. Anti-Stat5b, C-17, rabbit polyclonal Autogen Bioclear 
8. Donkey anti-mouse, Cy3-linked Jackson Immunology (Stratech 
Scientific, Soham, Cambs, UK) 
9. FuGENE 6 Roche 
10. Goat anti-rabbit, HRP-linked Amersham 
11. Lipofectaminelm reagent Invitrogen 
12. Plus"' reagent Invitrogen 
13. pEGFP-N1 vector Clontech, Basingstoke, UK 
14. pEYFP-C1 vector Clontech, Basingstoke, UK 
15. Sheep anti-mouse, HRP-linked Amersham 
16. Taq polymerase Gibco 
17. Molecular Weight Markers VII / VIII Roche 
18. Full range RAINBOW (molecular weight markers) Amershanm 
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